Food & Function. Vol 01, No 01, October 2010

View Online Food & Function Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10...

Author: Williamson | G etal (eds)

140 downloads 1033 Views 8MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form

DOWNLOAD PDF

View Online

Food & Function Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10.1039/C0FO90001J

Linking the chemistry and physics of food with health and nutrition www.rsc.org/foodfunction

Volume 1 | Number 1 | October 2010 | Pages 1–132

ISSN 2042-6496

REVIEW Min-Hsiung Pan, Ching-Shu Lai and Chi-Tang Ho Anti-inflammatory activity of natural dietary flavonoids

PAPER Hau Yin Chung, Zhen Yu Chen et al. Hypocholesterolemic activity of onion is mediated by enhancing excretion of fecal sterols in hamsters

2042-6496(2010)1:1;1-D

View Online

Food & Function Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10.1039/C0FO90002H


ISSN 2042-6496

Volume 1 | Number 1 | October 2010 | Pages 1–132

PAPER Gina Borges, William Mullen and Alan Crozier Comparison of the polyphenolic composition and antioxidant activity of European commercial fruit juices

REVIEW David Julian McClements and Yan Li Review of in vitro digestion models for rapid screening of emulsion-based systems

View Online

Food & Function Linking the chemistry and physics of food with health and nutrition www.rsc.org/foodfunction RSC Publishing is a not-for-profit publisher and a division of the Royal Society of Chemistry. Any surplus made is used to support charitable activities aimed at advancing the chemical sciences. Full details are available from www.rsc.org

IN THIS ISSUE Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10.1039/C0FO90003F

ISSN 2042-6496 CODEN FFOUAI 1(1) 1–132 (2010) Cover See Min-Hsiung Pan, Ching-Shu Lai and Chi-Tang Ho, pp. 15–31. Flavonoids are widely present in the average diet in such foods as fruits and vegetables. Numerous studies have indicated that flavonoids act through a variety of mechanisms to prevent and attenuate inflammatory responses and serve as potential antiinflammatory agents. Image reproduced by permission of Min-Hsiung Pan and Chi-Tang Ho from Food Funct., 2010, 1, 15.

Inside cover See Gina Borges, William Mullen and Alan Crozier, pp. 73–83. Pomegranates contain a myriad of bioactive ellagitannins and anthocyanins. Research shows that in pomegranate juices and drinks sold in Europe, there are large variations in these phytochemicals. Image of ‘‘Wonderful’’ variety pomegranates courtesy of POM Wonderful and reproduced by permission of Alan Crozier from Food Funct., 2010, 1, 73.

EDITORIALS 11 Welcome to the first issue of Food & Function Gary Williamson, Editor-in-chief, and Sarah Ruthven, Managing editor, introduce the inaugural issue of Food & Function.

12 Meet the Food & Function Editorial Board The Food & Function Editorial Board members introduce themselves.

This journal is ª The Royal Society of Chemistry 2010

Food Funct., 2010, 1, 3–10 | 3

View Online

EDITORIAL STAFF Editor Sarah Ruthven Deputy editor Kathleen Too


Senior publishing editor Elinor Richards

Food & Function provides a dedicated venue for research relating to the chemical and physical properties of food components and their nutritional and health benefits in humans.

Development editor Anna Simpson Publishing editors Mary Badcock, David Barden, Emma Eley, David Parker, Charles Quigg, Michael Townsend

Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10.1039/C0FO90003F

Food & Function

Publishing assistants Anna Anderson, Jackie Cockrill Publisher Emma Wilson For queries about submitted articles please contact Elinor Richards, Senior publishing editor, in the first instance. E-mail [email protected]

EDITORIAL BOARD Editor-in-Chief Professor Gary Williamson, University of Leeds, UK Associate Editors Cesar Fraga, University of Buenos Aires, Argentina & University of California, Davis, USA Steven Feng Chen, The University of Hong Kong, China

For pre-submission queries please contact Sarah Ruthven, Editor. E-mail [email protected] Food & Function (print: ISSN 2042-6496; electronic: ISSN 2042-650X) is published 12 times a year by the Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, UK CB4 0WF. All orders, with cheques made payable to the Royal Society of Chemistry, should be sent to RSC Distribution Services, c/o Portland Customer Services, Commerce Way, Colchester, Essex, UK CO2 8HP. Tel +44 (0)1206 226050; E-mail [email protected] 2010 Annual (print + electronic) subscription price: £1200; US$2232. 2010 Annual (electronic) subscription price: £1080; US$2008. Customers in Canada will be subject to a surcharge to cover GST. Customers in the EU subscribing to the electronic version only will be charged VAT. If you take an institutional subscription to any RSC journal you are entitled to free, site-wide web access to that journal. You can arrange access via Internet Protocol (IP) address at www.rsc.org/ip. Customers should make payments by cheque in sterling payable on a UK clearing bank or in US dollars payable on a US clearing bank. Periodicals postage paid at Rahway, NJ, USA and at additional mailing offices. Airfreight and mailing in the USA by Mercury Airfreight International Ltd., 365 Blair Road, Avenel, NJ 07001, USA. US Postmaster: send address changes to Food & Function, c/o Mercury Airfreight International Ltd., 365 Blair Road, Avenel, NJ 07001. All despatches outside the UK by Consolidated Airfreight. Advertisement sales: Tel +44 (0) 1223 432246; Fax +44 (0) 1223 426017; E-mail [email protected] For marketing opportunities relating to this journal, contact [email protected]

Members Aedin Cassidy, University of East Anglia, UK Kevin Croft, University of Western Australia, Australia Eric Decker, University of Massachusetts, USA Alejandro Marangoni, University of Guelph, Canada

Reinhard Miller, Max Planck Institute of Colloids & Interfaces, Germany Paul Moughan, Riddet Institute, Massey University, New Zealand Johan Ubbink, Food Concept & Physical Design, Switzerland Fons Voragen, Wageningen, The Netherlands

ADVISORY BOARD Hitoshi Ashida, Kobe University, Japan Junshi Chen, Chinese Centre of Disease Control & Prevention, China E. Allen Foegeding, North Carolina State University, USA Vincenzo Fogliano, University of Napoli Federico II, Italy Mike Gidley, University of Queensland, Australia Chi-Tang Ho, Rutgers University, USA Richard Hurrell, ETH Zurich, Switzerland Peter Lillford, University of York, UK Rui Hai Liu, Cornell University, USA

Julian McClements, University of Massachusetts, USA John A. Milner, National Cancer Institute, National Institutes of Health, USA Brent Murray, University of Leeds, UK Patricia Oteiza, University of California at Davis, USA Augustin Scalbert, INRA, France Helmut Sies, University of Dusseldorf, Germany Leif Skibsted, University of Copenhagen, Denmark

David Stuart, The Hershey Company, USA Arthur Tatham, University of Wales Institute, Cardiff, UK Junji Terao, University of Tokushima, Japan George van Aken, NIZO Food Research, The Netherlands Erik van der Linden, TI Food & Nutrition, The Netherlands Jose Vina, University of Valencia, Spain Peter Wood, Agriculture and Agri-Food Canada, Canada

INFORMATION FOR AUTHORS Full details on how to submit material for publication in Food & Function are given in the Instructions for Authors (available from http://www.rsc.org/authors). Submissions should be made via the journal’s homepage: http://www.rsc.org/foodfunction. Authors may reproduce/republish portions of their published contribution without seeking permission from the RSC, provided that any such republication is accompanied by an acknowledgement in the form: (Original Citation)–Reproduced by permission of The Royal Society of Chemistry. This journal is © The Royal Society of Chemistry 2010. Apart from fair dealing for the purposes of research or private study for non-commercial purposes, or criticism or review, as permitted under the Copyright, Designs and

Patents Act 1988 and the Copyright and Related Rights Regulation 2003, this publication may only be reproduced, stored or transmitted, in any form or by any means, with the prior permission in writing of the Publishers or in the case of reprographic reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. US copyright law is applicable to users in the USA. The Royal Society of Chemistry takes reasonable care in the preparation of this publication but does not accept liability for the consequences of any errors or omissions. ∞ The paper used in this publication meets the  requirements of ANSI/NISO Z39.48–1992 (Permanence of Paper). Royal Society of Chemistry: Registered Charity No. 207890.

View Online

REVIEWS 15 Anti-inflammatory activity of natural dietary flavonoids Min-Hsiung Pan,* Ching-Shu Lai and Chi-Tang Ho*


Flavonoids may have beneficial properties for various chronic inflammations.

32 Review of in vitro digestion models for rapid screening of emulsion-based systems David Julian McClements* and Yan Li In vitro digestion methods can be used to rapidly screen the ability of different factors to alter the rate and extent of lipid digestion in emulsion-based foods and delivery systems.

60 Combining nutrition, food science and engineering in developing solutions to Inflammatory bowel diseases – omega-3 polyunsaturated fatty acids as an example Lynnette R. Ferguson,* Bronwen G. Smith and Bryony J. James Nutrition, food science and engineering link in developing the evidence base for long chain omega-3 polyunsaturated fatty acids in Inflammatory bowel diseases.

PAPERS 73 Comparison of the polyphenolic composition and antioxidant activity of European commercial fruit juices Gina Borges, William Mullen and Alan Crozier* This paper reports on the use of antioxidant assays and HPLCPDA-MS and fluorescence detection to assess the anthocyanin, ellagitannin and ellagic acid content of pomegranate juices and pomegranate juice blends sold in Europe.


Food Funct., 2010, 1, 3–10 | 5

Garlic and Other Alliums The Lore and the Science

This unique book, with a foreword by Nobel Laureate E. J. Corey, outlines the extensive history and the fascinating past and present uses of these plants. The author has carefully sorted out fact from fiction based upon detailed scrutiny of historic documents as well as numerous laboratories studies.

Garlic and Other Alliums

The Lore and the Science


Eric Block

Readers will be entertained and educated as they learn about early cultivation of garlic and other alliums while being introduced to their remarkable chemistry and biochemistry, much of which prominently features the element sulfur. They will learn how alliums have been portrayed and used in literature, poetry and the arts and how alliums are featured in the world’s oldest cookbook.

Garlic and Other Alliums

The Lore and the Science

Written by Eric Block, Carla Rizzo Delray Distinguished Professor of Chemistry at the University at Albany, State University of New York, well known for his discoveries elucidating the natural product chemistry of the Allium species, Garlic and Other Alliums will make fascinating reading for both scientists and non-scientists alike.

Eric Block

Foreword by E. J. Corey Block

“This is a fascinating book written by an authority on the chemistry of the edible alliums, which include garlic, onions, leeks and chives.” Jim Hanson, Chemistry World, February 2010.

Garlic and Other Alliums_dust jacket.indd 4

03/07/2009 10:54:31

Title: Garlic and Other Alliums Subtitle: The Lore and the Science Author: Eric Block ISBN: 9781849731805 Publication Date: Nov 2009 Format: Paperback Price: £24.99/U.S. $42.00

“This book by Eric Block is a synthesis of his four decades of distinguished work with alliums. His account of this everincreasing knowledge is accessible and will even entertain readers without a deep knowledge of chemistry.” Meriel Jones, Chemistry & Industry, February 2010 “Dr. Block’s book may be the definitive word on the alliums for the moment, but as it and he make clear, there are new flavors to look forward to.” Harold McGee, The New York Times, June 2010

www.rsc.org/books Registered Charity Number 207890

View Online

PAPERS 84 Hypocholesterolemic activity of onion is mediated by enhancing excretion of fecal sterols in hamsters Lei Guan, Hau Yin Chung,* Yalun Su, Rui Jiao, Cheng Peng and Zhen Yu Chen*


Dietary onion enhances the conversion of cholesterol into bile acid in liver.

90 Suppression of breast xenograft growth and progression in nude mice: implications for the use of orally administered sphingolipids as chemopreventive agents against breast cancer Kirk W. Simon, Larry Tait, Fred Miller, Chun Cao, Kevin P. Davy, Tanya LeRoith and Eva M. Schmelz* Dietary sphingomyelin suppressed progression of breast cancer xenografts in nude mice by reducing proliferation, angiogenesis and reversing aberrant protein expression.

99 Consumption of polyphenolic-rich beverages (mostly pomegranate and black currant juices) by healthy subjects for a short term increased serum antioxidant status, and the serum’s ability to attenuate macrophage cholesterol accumulation Mira Rosenblat, Nina Volkova, Judith Attias, Riad Mahamid and Michael Aviram* Polyphenolic-rich juices with impressive in vitro antioxidant properties, also demonstrate antioxidant effects in vivo when analyzed for short term consumption.

110 Mediterranean diet improves dyslipidemia and biomarkers in chronic renal failure patients Khedidja Mekki,* Nassima Bouzidi-bekada, Abbou Kaddous and Malika Bouchenak Nutritional advice based on a Mediterranean diet reduces dyslipidemia, and protects against lipid peroxidation and inflammation in chronic renal failure patients.


Food Funct., 2010, 1, 3–10 | 7

View Online

PAPERS 116 Effects of dietary consumption of cranberry powder on metabolic parameters in growing rats fed high fructose diets Ramesh C. Khanal, Theodore J. Rogers, Samuel E. Wilkes, Luke R. Howard and Ronald L. Prior*


Cranberry powder attenuates markers of metabolic syndrome in a high fructose fed rat model.

124 Dealcoholized red wine reverse vascular remodeling in an experimental model of metabolic syndrome: role of NAD(P)H oxidase and eNOS activity Marcela Alejandra Vazquez-Prieto, Nicol as Federico Renna, Carina Lembo, Emiliano Ra ul Diez and Roberto Miguel Miatello* Red wine reduced oxidative stress, improved vascular function and remodeling in a model of metabolic syndrome. The antioxidant properties of polyphenols could be responsible for these beneficial effects.

8 | Food Funct., 2010, 1, 3–10



First in its class “I attribute this success to the quality of the authors that the editor and editorial board have been able to recruit…” Professor Jonathan Sessler, The University of Texas, USA

Chemical Society Reviews (Chem Soc Rev) publishes the largest number of chemical review articles, making it first in its class for chemical scientists*. With an impact factor of 20.086* and the leading immediacy index for a chemical reviews journal at 5.314, this impressive result underlines the continuing success of the journal. Chem Soc Rev supplies high quality and highly cited articles, covering topical areas of interest across the chemical sciences. Published monthly, it includes themed issues reviewing new research areas, and edited by a specialist guest editor.

*2009 Journal Citation Reports® ( Thomson Reuters 2010 )

Find out more... www.rsc.org/chemsocrev/firstclass Registered Charity Number 207890

View Online

Top science …free institutional access Number 1 | 2009

Chemical Science Volume 1 | Number 1 | 2010

Chemical Science

Volume X | Number x | 2010

www.rsc.org/chemicalscience

Food & Function Linking the chemistry and physics of food with health and nutrition www.rsc.org/foodfunction

Volume 1 | Number 1 | Autumn 2010 | Pages 001–200

Food & Function

ISSN 2041-6520

Pages 1–140


Pages 0000–0000

ISSN 2042-6496

New for 2010 Chemical Science - a new journal presenting findings of exceptional significance from across the chemical sciences. www.rsc.org/chemicalscience

Food & Function - linking the chemistry and physics of food with health and nutrition. www.rsc.org/foodfunction

MedChemComm - focusing on medicinal chemistry research, including new studies related to

biologically-active chemical or biochemical entities that can act as pharmacological agents with therapeutic potential or relevance. www.rsc.org/medchemcomm

Polymer Chemistry - publishing advances in polymer chemistry covering all aspects of synthetic and biological macromolecules, and related emerging areas. www.rsc.org/polymers

New for 2009 Analytical Methods - highlights new and improved methods for the practical application of analytical science. This monthly journal will communicate research in the advancement of analytical techniques for use by the wider scientific community. www.rsc.org/methods

Integrative Biology - focusing on quantitative multi-scale biology using enabling technologies and tools to exploit the convergence of biology with physics, chemistry, engineering, imaging and informatics. www.rsc.org/ibiology

Metallomics - covering the research fields related to metals in biological, environmental and clinical systems. www.rsc.org/metallomics

Nanoscale - publishing experimental and theoretical work across the breadth of nanoscience and nanotechnology. www.rsc.org/nanoscale

Free institutional access, managed by IP address, is available on all these titles. For more details, and to register, visit www.rsc.org/free_access_registration

www.rsc.org/journals Registered Charity Number 207890

View Online

EDITORIAL

www.rsc.org/foodfunction | Food & Function

Welcome to the first issue of Food & Function

Downloaded on 21 October 2010 Published on 04 October 2010 on http://pubs.rsc.org | doi:10.1039/C005532H

DOI: 10.1039/c005532h We are delighted to introduce the inaugural issue of Food & Function. This new timely journal from RSC Publishing will provide a much needed platform devoted to bringing together research which links the chemistry and physics of food with health and nutrition. Monthly issues of Food and Function will publish communications and full papers reporting primary research as well as in-depth reviews focusing on the interaction of food components with the human body, including the influence of the physical properties and structure of food, the chemistry of food components, the biochemical and physiological actions and the nutrition and health aspects of food.

Submissions to Food & Function are handled fairly, quickly and efficiently by our Associate editors, Steven Feng Chen from the University of Hong Kong, and Cesar Fraga from the University of Buenos Aires and UC Davis. The journal is supported by international Editorial and Advisory Boards, and we would like to thank these board members for their support of Food & Function. The members of the Editorial Board are Aedin Cassidy, Kevin Croft, Eric Decker, Alejandro Marangoni, Reinhard Miller, Paul Moughan, Johan Ubbink and Fons

Voragen, and more details about our Editorial Board members can be found in the ‘Meet the Food & Function Editorial Board’ article is this first issue. The journal is backed by a dedicated team of RSC Publishing editors. RSC Publishing has a strong heritage and reputation for publishing science of the very best quality and has a great track record for new journal launches. We are confident that Food & Function will be a high quality publication. You will see that this inaugural issue of Food & Function contains papers that represent the full scope of the journal. Especial thanks must be given to the authors and referees for their support of Food & Function at this early stage. Finally, it is important to note that papers published in issues this year and in 2011 will be free to access, and will therefore have maximum visibility and be widely promoted. We encourage you to sign up to the Food & Function newsletter – Food for Thought. This quarterly newsletter will keep you up to date with all the latest news about the journal. For details

Gary Williamson; Editor-in-chief

Sarah Ruthven; Managing editor

of how to sign up to the newsletter, and register for free access to Food & Function, please visit the journal platform at: www.rsc.org/foodfunction. We hope you enjoy reading the papers in this first issue of Food & Function and will consider submitting some of your research to the journal. Details of how to submit an article to Food & Function are available on our platform. We welcome any comments you have about the journal and invite you to contact us at [email protected]. Gary Williamson, Editor-in-chief Sarah Ruthven, Managing editor


Food Funct., 2010, 1, 11–11 | 11

View Online

EDITORIAL


Meet the Food & Function Editorial Board

Downloaded on 21 October 2010 Published on 24 September 2010 on http://pubs.rsc.org | doi:10.1039/C005531J

DOI: 10.1039/c005531j

vice-president of the Oxygen Club of California. His original research interests in free radical and antioxidants in biological systems were the foundation for his current activities centered on the health effects of plant constituents. Professor Fraga has earned numerous prizes and awards and is one of the most cited scientists in phytonutrients and human health.

Professor Gary Williamson; Editor-in-Chief

Professor Steven Feng Chen; Associate Editor

Professor Gary Williamson is Professor of Functional Food at the University of Leeds, UK, in the School of Food Science and Nutrition. His research interests are in nutritional and food biochemistry. He has over 270 refereed scientific publications, and is one of the most highly cited authors in agricultural sciences according to ISI. Currently, he is also a Visiting Professor of Food Safety at University of Surrey, UK, and Honorary Chair at Harbin Medical University, China. Prior to joining the University of Leeds in 2007, Gary was the Head of Nutrient Bioavailability at Nestle Research Centre, Lausanne, Switzerland, and before that Head of Phytochemicals at the Institute of Food Research, Norwich, UK. In addition to his full-time professorship at the Univeristy of Leeds, Gary is also a Scientific Advisor to the nutrient bioavailability group at Nestle Ltd, specialising in polyphenols.

Supervisor Award, HKU Outstanding Young Researcher Award, and CIFST Outstanding Researcher in Food Science and Technology Award. He is a highly cited scientist (top 1%) in agricultural sciences, and is an elected Fellow of American Institute for Medical and Biological Engineering.

Professor Steven Feng Chen is Professor of Food and Nutritional Science at the University of Hong Kong in the School of Biological Sciences. His research interests are primarily in the areas of functional foods and food biotechnology. He is particularly interested in the development of functional foods and nutraceuticals from plants and algae. He has edited 4 books, filed 6 patents, and published over 200 papers in refereed journals. He has received several prestigious awards such as HKU Outstanding Research Student

Professor Cesar Fraga received his doctoral degree in Biological Chemistry from the University of Buenos Aires in 1985. In 1990 he was appointed Professor of Physical Chemistry at the School of Pharmacy and Biochemistry, University of Buenos Aires, and Researcher at the National Council for Scientific Research Argentina (CONICET), positions that he still holds today. From 2004 Professor Fraga has also had a position of Research Professor at the Department of Nutrition, University of California, Davis. He is

12 | Food Funct., 2010, 1, 12–14

Professor Cesar Fraga; Associate Editor

Professor Aedin Cassidy, Editorial Board member

Professor Aedin Cassidy is Professor of Diet and Health at the Medical School, University of East Anglia, Norwich, UK. Her research interests are in nutritional biochemistry with a specific interest in food bioactives and cardiovascular disease prevention. She received her PhD from Cambridge University in 1991 where she conducted some of the first studies to elucidate the biological effects of phytochemicals in humans. Prior to joining UEA, Aedin was Head of Molecular Nutrition and Women’s Health at Unilever Research and previously was Reader in Nutritional Biochemistry at the University of Surrey, UK. She was awarded the Nutrition Society Medal in 1999 and in 2008 an award for ‘Outstanding Contribution to Research’ in Tokyo, Japan, for her contribution to the isoflavone research field. Professor Kevin Croft is a Professorial Fellow of the School of Medicine and Pharmacology at the University of Western Australia. He also holds the



View Online

Professor Kevin Croft, Editorial Board member

following positions: Chair, the Animal Ethics Committee, Royal Perth Hospital; Member of the Board of Postgraduate Studies, University of Western Australia; Director of Research, School of Medicine and Pharmacology, UWA; and was President of the Australasian Society for Free Radical Research, 2006–2007. Kevin’s major research interests are bioactive polyphenols in the diet, the absorption and metabolism of dietary polyphenols, impact on cardiovascular risk factors, human intervention trials, animal models of atherosclerosis, mechanism of vascular protection by polyphenols, lipid metabolism and the role of arachidonic acid metabolism by CYP450 and the role in cardiovascular disease. He has published over 200 peer reviewed papers.

the Food Science Section of the Department of Animal Sciences at the University of Kentucky from 1988 to 1993 after which he joined the Department of Food Science at the University of Massachusetts, Amherst as an Associate Professor in Food Chemistry. He was named the Fergus Clydesdale Endowed Chair from 2002–2007. Professor Decker has been actively conducting research to characterize mechanisms by which lipids oxidize in heterogeneous food systems. His lab has worked extensively in the development of antioxidant technologies for food systems. As part of this research program, he has developed patented technologies to maximize the concentrations and stability of bioactive lipids such as omega-3 fatty acids allowing them to be incorporated into foods at nutritionally significant levels. In addition, Professor Decker has actively collaborated with other scientists to investigate the role of antioxidants, lipids and lipid oxidation products in the molecular basis of disease. Professor Decker has published over 250 peer reviewed journal articles, reviews, and book chapters. He has also organized symposia and workshops on antioxidants, bioactive lipids, lipid oxidation and functional foods.

a Canada Research Chair (2001, renewed in 2006), two Distinguished Researcher Awards from the Ontario Innovation Trust (2002), a Career Award from the Canadian Foundation for Innovation (2002), an E.W.R. Steacie Memorial Fellowship (2002), given to the top 6 Canadian scientists from all disciplines, and the T.L. Mounts Award from AOCS in 2004. Professor Marangoni is a past chair of the Natural Sciences and Engineering Research Council of Canada’s Plant Biology and Food Science Grant Selection Committee and a member of NSERC’s E.W.R. Steacie Memorial Fellowship selection committee. Professor Marangoni has co-founded two high-technology food companies and is the co-recipient of the 2008 Guelph Partners of Innovation ‘‘Innovator of the year’’ award for his discovery of a zero trans, low saturate shortening alternative which could revolutionize the baking industry.

Dr Reinhard Miller; Editorial Board member

Professor Alejandro Marangoni, Editorial Board member

Professor Eric Decker; Editorial Board member

Professor Eric Decker received his B.S. degree in biology from Penn State University in 1982, his M.S. from the Department of Food Science and Human Nutrition, Washington State University, in 1985 and his Ph.D. from the Department of Food Science at the University of Massachusetts, Amherst in 1988 where he was a USDA National Needs Fellow. Professor Decker was an Assistant Professor in

Professor Alejandro Marangoni is a professor and Canada Research Chair in Food and Soft Materials Science at the University of Guelph. His work concentrates on the physical properties of foods, particularly fat crystallization and structure. He has published over 200 refereed research article and four books. He is the recipient of many awards including a 1999 Premier’s Research Excellence Award, the first Young Scientist Award form the American Oil Chemists’ Society (2000),


Dr Reinhard Miller is group leader at the Max Planck Institute of Colloids and Interfaces in Potsdam, Germany. He studied Mathematics in Rostock and Colloid Chemistry in Dresden. His scientific interests are focused on dynamics of interfacial layers containing proteins, surfactants and other food relevant compounds. Dr Miller edited the book series ‘‘Studies in Interface Science’’ (24 volumes) and is now editor of the ‘‘Progress in Colloid Interface Science’’ series. He has published about 400 papers in refereed journals. At present he is President Elect of the European Colloid and Interface Society. Professor Paul J. Moughan holds the position of Distinguished Professor at Food Funct., 2010, 1, 12–14 | 13


View Online

Professor Paul J. Moughan, Editorial Board member

Massey University, New Zealand, and is Director of the Riddet Institute. The Riddet Institute, a New Zealand government funded Centre of Research Excellence (CoRE), is a partnership between the University of Otago, Auckland University and Massey University and two New Zealand Crown Research Institutes, Plant and Food Research and AgResearch, and is dedicated to research and postgraduate education in the area of food science and human nutrition. He was formerly foundation head of the Institute of Food, Nutrition and Human Health at Massey University, Director of the university’s Mongastric Research Centre and Foundation Scientific Director of the Fonterra-funded Milk and Health Research Centre. Professor Moughan was appointed to the foundation chair in monogastric biology at Massey University in 1993 and his research has encompassed the fields of

14 | Food Funct., 2010, 1, 12–14

human and animal nutrition, food chemistry, functional foods, mammalian growth biology and digestive physiology. He has published in excess of 300 scientific works. In 1995 he was awarded Doctor of Science and in 1997 was awarded a Personal Chair at Massey University and was elected a Fellow of the Royal Society of New Zealand. He has received several prestigious international awards for his work and is an adviser to the international food and feedstuffs industries. He is a non-executive Director of the Gardiner Foundation, Melbourne, Australia.

Netherlands). After stays as visiting scientist at the University of Bristol (UK) and Moscow State University (Russia), he joined industry. Initially as Senior Scientist at corporate research at Givaudan (Switzerland), in 1999 he switched to the Nestle Research Center in Lausanne (Switzerland) where he was active as R&D specialist, coordinator for Delivery Systems and Scientific Expert Materials Science. His current research interests include food sustainability, the physics of glassy carbohydrates, the statistical mechanics of biopolymer complexes, and the biophysics of stabilization and delivery of fragile bioactive compounds.

Dr Johan Ubbink; Editorial Board member

Dr Johan Ubbink is Senior Consultant at Food Concept & Physical Design, a strategy and technology company focusing on the development of sustainable foods. Trained as an experimental physical chemist at the University of Leiden (The Netherlands), he obtained his Ph.D. in the field of DNA biophysics at Delft University of Technology (The

Professor Fons Voragen, Editorial Board member

Professor Fons Voragen is a Professor in the Laboratory of Food Chemistry of Wageningen University. His research expertise is in the areas of cereal products, enzymes, polysaccharides and proteins. He has published over 300 papers in refereed journals.


View Online

REVIEW


Anti-inflammatory activity of natural dietary flavonoids Min-Hsiung Pan,*a Ching-Shu Laia and Chi-Tang Ho*b

Downloaded on 21 October 2010 Published on 13 September 2010 on http://pubs.rsc.org | doi:10.1039/C0FO00103A

Received 30th July 2010, Accepted 12th August 2010 DOI: 10.1039/c0fo00103a Over the past few decades, inflammation has been recognized as a major risk factor for various human diseases. Acute inflammation is short-term, self-limiting and it’s easy for host defenses to return the body to homeostasis. Chronic inflammatory responses are predispose to a pathological progression of chronic illnesses characterized by infiltration of inflammatory cells, excessive production of cytokines, dysregulation of cellular signaling and loss of barrier function. Targeting reduction of chronic inflammation is a beneficial strategy to combat several human diseases. Flavonoids are widely present in the average diet in such foods as fruits and vegetables, and have been demonstrated to exhibit a broad spectrum of biological activities for human health including an anti-inflammatory property. Numerous studies have proposed that flavonoids act through a variety mechanisms to prevent and attenuate inflammatory responses and serve as possible cardioprotective, neuroprotective and chemopreventive agents. In this review, we summarize current knowledge and underlying mechanisms on anti-inflammatory activities of flavonoids and their implicated effects in the development of various chronic inflammatory diseases.

Introduction Inflammation is a normal biological process in response to tissue injury, microbial pathogen infection and chemical irritation. This biological process also involves the innate and adaptive immune systems. At a damaged site, inflammation is initiated by migration of immune cells from blood vessels and release of mediators, followed by recruitment of inflammatory cells and release of reactive oxygen species (ROS), reactive nitrogen species (RNS) and proinflammatory cytokines to eliminate foreign pathogens, resolving infection and repairing injured tissues.1,2 Thus, the main function of inflammation is beneficial for a host’s defense. In general, normal inflammation is rapid and self-limiting, but aberrant resolution and prolonged inflammation causes various chronic disorders.3 Chronic inflammation can inflict more serious damage to a host tissue than bacterial infection. Diverse ROS and RNS such as O2 (superoxide anion), OH (hydroxyl radical), H2O2 (hydrogen peroxide), nitric oxide (NO), and 1O2 (singlet oxygen) generated by inflammatory cells injure cellular biomolecules including nucleic acids, proteins and lipids, causing cellular and tissue damage, which in turn augments the state of inflammation.4 These also trigger a series of signaling molecules, inflammatory gene expression and activation of enzymes involved in chronic inflammation. Inflammatory chemicals produced by inflamed and immune cells also attack normal tissues surrounding the infected tissue, causing oxidative damage and extensive tissue inflammation.1,4

a Department of Seafood Science, National Kaohsiung Marine University, No.142, Haijhuan Rd., Nanzih District, Kaohsiung, 81143, Taiwan. E-mail: [email protected]; Fax: (+886)-7-361-1261; Tel: (+886)-7-361-7141 Ext 3623 b Department of Food Science, Rutgers University, 65 Dudley Road, New Brunswick, New Jersey, 08901-8520, USA. E-mail: [email protected]. edu; Fax: +1-732-932-6776


Studies show that chronic inflammation is linked to a wide range of progressive diseases, including cancer, neurological disease, metabolic disorder and cardiovascular disease.3,4 Numbers of studies suggest elimination of chronic inflammation as a major way to prevent various chronic diseases.1,3 Epidemiological studies provide convincing evidence that natural dietary compounds that humans consume as food possess many biological activities. Among these natural bioactive compounds, flavonoids are widely recognized for their biological and pharmacological effects, including antiviral, anti-carcinogenic, antioxidant, antimicrobial, anti-inflammatory, anti-angiogenic and anti-thrombogenic properties.1,5 Epidemiologic studies indicate that the incidence of chronic disease and cancer is inversely correlated with the consumption of fruits and vegetables rich in flavonoids,5,6 and this is attributed to their possible anti-inflammatory activities. This review forcuses on the molecular basis of the anti-inflammatory potential of flavonoids, with special emphasis on their effect on molecular mechanisms and signaling pathways involved in inflammation, as agents in reducing or eliminating different chronic inflammation-associated human diseases.

The role of inflammation in human disease Inflammation is a complicated process, driven by preexisting conditions (infection or injury) or genetic changes, that results in triggering signaling cascades, activation of transcription factors, gene expression, increased of levels of inflammatory enzymes, and release of various oxidants and proinflammatory molecules in immune or inflammatory cells.2 In this condition, excessive oxidants and inflammatory mediators have a harmful effect on normal tissue, including toxicity, loss of barrier function, abnormal cell proliferation, inhibiting normal function of tissues and organs, and finally leading to systemic disorders.1,2 Over the past few decades, many studies reveal that chronic inflammation is a critical component in many human diseases and conditions, Food Funct., 2010, 1, 15–31 | 15


View Online

Fig. 1 Chronic inflammation is linked to human diseases.

including obesity, cardiovascular diseases, neurodegenerative diseases, diabetes, aging, and cancers2,4 (Fig. 1). Cardiovascular diseases Cardiovascular disease (CVD) is becoming the leading cause of death in the world. Chronic inflammation, such as atherosclerosis, coronary diseases, cerebrovascular disorder, heart failure and cardiomyopathy is common in CVD.7 In the past, researchers suggested a number of traditional risk factors implicated in the pathogenesis of CVD including age, hypertension, dyslipidemia, hypercholesterolemia, glucose tolerance and metabolic symptoms. However, recent studies focus on the relationship between endothelial dysfunction and inflammatory condition.7,8 Vascular endothelium is very important in regulation of vascular homeostasis, and inhibition of leukocyte adhesion and platelet aggregation by release of mediators such as nitric oxide (NO).8 Increase of NO production, damage of endothelial cells, increase of oxidative stress and an enhanced proinflammatory state lead to the alteration of vascular integrity, the reduction of vasodilator capacity and the appearance of endothelial dysfunction. Atherosclerosis is a chronic inflammatory disease and a major cause of CVD. Recent studies demonstrate that vascular inflammation is the earliest event in the development of atherosclerosis.7,9 The process involves stimulation of cholesterol, oxidized low-density-lipoprotein (ox-LDL) and oxidative free radicals, which initiate activation of vascular endothelial cells and enhance their adhesive property with monocytes by expression of adhesion molecules selectins, vascular cell adhesion molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1).10 Once monocytes firmly attach on the surface of endothelium, they transmigrate into the arterial intima and differentiate to macrophages. This transmigration is triggered by chemoattractant molecules 16 | Food Funct., 2010, 1, 15–31

such as monocyte chemoattractant protein-1 (MCP-1), proinflammatory cytokines (TNF-a and ILs) as well as growth factors (PDGF and TGF-b) produced by activated T cells and macrophage.11 Among these, studies indicate that MCP-1 is important for recruitment of monocytes into intima. Differentiated macrophages that expresse scavenger receptors become foam cells via uptake of ox-LDL generated in the intima resulting in formation of fatty streaks.12 The molecules secreted by monocytes, macrophages and arterial cells maintain an inflammatory response within the artery and promote proliferation and migration of vascular smooth muscle cells.9,11 Proliferative smooth muscle cells release fibrogenic mediators and build a dense extracellular matrix around foam cells and monocytes, finally causingfatty streaks to progress into fibrous plaque.13 In pathogenesis and progression of atherosclerosis, chronic inflammation is involved in every stage that is characterized by infiltration of monocytes/macrophages and production of proinflammatory cytokines9,11 (Fig. 2). Hence, the modulation or regulation of the interaction between endothelial and inflammatory cells and the transformation of macrophages to foam cells could be the basis for the beneficial effects that prevent or slow down the progression of this disease. This diversity of cytokine expression and function might also lead to the identification of selective therapeutic targets for the prevention and treatment of atherosclerosis.10,11 Moreover, clinical research shows that elevated levels of systemic inflammatory molecules including IL-6, ICAM-1, P-selectin, E-selectin and C-reactive protein (CRP), are classic acute-phase markers occurring in patients with coronary disease, and, therefore that might be a predictor of cardiovascular risk.14,15 Different treatments of atherosclerosis are associated with reduction of these inflammatory markers, providing a new target for blockage or therapy of atherosclerosis by inhibition of inflammation.9,16 This journal is ª The Royal Society of Chemistry 2010

View Online


Neurological disorders

Fig. 2 Induction of inflammatory responses by ox-LDL in development of atherosclerosis. Stimulated ox-LDL increases chemoattractant concentration and induces monocyte transmigrating into intima then transforming to macrophage. Differentiated macrophage that specific to uptake ox-LDL becomes foam cell and leads to the formation of fatty streak in intima.

Many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, amyotrophic lateral sclerosis and other nervous system pathologies are associated with inflammatory injury (Fig. 3). This complex inflammatory process involves different cellular components in the central nervous system, such as microglial cells, astrocytes, ependymal cells, macrophages and mast cells.17 Microglial cells are macrophages in the brain and the central nervous system that are the first response to a neuronal injury.18 In the case of Alzheimer’s disease, a cleavage product of amyloid precursor protein (APP), an integral membrane protein, and the aggregation of amyloid b peptides (Ab1-42 and Ab1-40) trigger activation of microglials and astrocytes, following activation of transcription factors such as nuclear factor-kappa B (NF-kB) and activator protein (AP)-1 that induce production of ROS and various proinflammatory mediators including NO, PGE2, ILs and TNF-a.17,18 These proinflammatory cytokines and ROS produced by activated microglial and astrocytes may cause neuronal damage or neurotoxicity resulting in apoptosis and necrosis.17 Moreover, proinflammatory mediators released from microglials and astrocytes can activate each other to amplify inflammatory signals to neurons. Parkinson’s disease is a neurodegenerative disorder in the central nervous system with a pathology similar to Alzheimer’s disease. Aggregation and accumulation of a-synuclein protein of Lewy bodies and loss of dopaminergic neurons are major neuropathological alterations in Parkinson’s disease.19 Lewy bodies and

Fig. 3 Neuroinflammation in Alzheimer’s disease. During the development of Alzheimer’s disease, b amyloid peptide is produced by cleavage of amyloid precursor protein (APP), aggregates and accumulates as b amyloid plaques. Both aggregates and plaques cause neurotoxicity or activation of microglia through up-regulating NF-kB and AP-1 transcription factors, which in turn release ROS and pro-inflammatory cytokines such as NO, PGE2, IL-1, IL-6, and TNF-a that damage cholinergic neuron. These pro-inflammatory cytokines also directly activate astrocytes that also produce cytokines to amplify inflammatory signals and result in neuroinflammation and neurodegeneration. Flavonoids act through avoiding b amyloid induced-neuron injury and death, modulation of pro-inflammatory cytokines and ROS production as well as inhibiting the activation of microglia and astrocyte as neuroprotective mechanisms.


Food Funct., 2010, 1, 15–31 | 17


View Online

intracellular and/or extracellular a-synuclein protein aggregates released from neurons lead to the activation of microglial cells,20,21 resulting in the activation of transcription factor NF-kB, gene expression of iNOS, COX-2 and NAPDH oxidase, and production of inflammatory mediators.22 Proinflammatory cytokines such as TNF-a and ILs derived from activated microglial cells also trigger activation of astrocytes. Studies show that released factors from activated microglials and astrocytes have a combinational effect in promoting neurotoxicity.17,22 In neurodegenerative diseases, the activation of immune cells such as microglials and astrocytes is a critical step in neuropathology. Oxidative stress is also important in neurodegenerative diseases, both in Alzheimer’s disease and Parkinson’s disease.17,18,22 Several therapeutic approaches that target inflammatory responses demonstrate the ability to interfere with activation of transcription factor and inhibit function of inflammatory enzymes and production of ROS.23,24 Obesity Obesity, resulting from excessive fat sorted in adipose tissue is a highly prevalent condition that is related to many metabolic disorders throughout the world. Numerous studies indicate the high risk of obesity in the development of cardiovascular disease, type 2 diabetes, hypertension, fatty liver disease and cancer.25 It is now clear that the function of adipose tissue is not only as fat storage, but also as a major endocrine and secretary organ that produces adipokines such as leptin and adiponectin.26 Leptin is an important hormone in the regulation of energy expenditure and caloric intake for maintaining energy balance.27 Clinical and animal studies show that leptin deficiency results in body weight increase and a high risk for the development of type 2 diabetes.27,28

In recent years, many studies document that obesity is significantly associated with a chronic low-grade inflammation29 (Fig. 4). The first connection between obesity and inflammation is evidenced by the release of TNF-a from adipocytes. As the lipid content increases in adipose tissue, adipocytes synthesize TNF-a and several cytokines (IL-1b and IL-6) that change the number and size of cells, influencing lipoprotein lipase and increasing the inflammatory state.30 TNF-a also induces insulin resistance by downregulation of insulin receptor phosphorylation, decrease of glucose uptake and expression of GLUT4 transporter.29,31 Another important inflammatory feature in adipose tissue is recruitment of immune and inflammatory cells such as neutrophils, eosinophils and macrophages.32 Studies in both mice and humans show that while in an obese state, macrophage infiltration is increased in adipose tissue.32 Large adipocytes secret chemotactic signals, such as monocyte chemoattractant protein-1 (MCP-1), to trigger infiltration of macrophages, that then leads to the creation of a chronic, lowgrade inflammation in obesity.32,33 Increased levels of acute phase protein CRP are found in many obese individuals,34 and circulating CRP concentrations are related to the development of cardiovascular disease,14 indicating the association of obesity and cardiovascular disease. Some lines of evidence also suggest that obesity is linked to fat storage in the liver that can lead to the development of fatty liver diseases.25 It is suggested that IL-6 derived from adipocytes may drive the production of CRP in the liver.35 Overexpression of MCP-1 in adipose tissue leads to increase of hepatic triglyceride content.33 In addition, elevated levels of circulating TNF-a in an obese state is often associated with an increase in insulin resistance.31,36 These observations emphasize the correlation among obesity, inflammation and metabolic disorders.

Fig. 4 Obesity in the induction of inflammation. Adipose tissue of visceral obesity induced chronic low-grade inflammation through macrophage infiltration by MCP-1 and secretion of pro-inflammatory factors. However, obesity may cause the high risk in development of several diseases.

18 | Food Funct., 2010, 1, 15–31


View Online


Metabolic disorders Extensive research reveals that inflammation is a characteristic feature of metabolic disorders, including fatty liver disease, type 2 diabetes, chronic kidney disease and heart disease (Fig. 5). Inflammatory responses are considered to be a critical stage of metabolic dysfunction characterized by abnormal proinflammatory cytokine production, increased acute phase protein and activation of inflammatory signaling pathways.37 In addition, obesity correlates with an increase in inflammatory conditions and metabolic syndromes.29 Type 2 diabetes is the most prevalent and serious metabolic disease caused by insulin resistance derived from pancreatic beta cell dysfunction. Both experimental and clinical studies demonstrate that several inflammatory cytokines are closely related to pathogenesis of insulin resistance.38 Increased levels of IL-1b in plasma are shown to have detrimental effects on the function of IL-1 receptor antagonist proteins (IL-1ra) that promote beta cell destruction and alter insulin sensitivity.39 Moreover, IL-6 acts on activation of tyrosine phosphatase and interferes with the interaction between insulin receptor and suppressor of cytokine signaling (SOCS) proteins that result in insulin resistance.40 In patients with chronic kidney disease, elevated levels of serum acute phase proteins such as C reactive protein (CRP), TNF-a and ILs are associated with an increase in chronic inflammatory states and insulin resistance.41 In addition to insulin resistance and Type 2 diabetes, an elevated concentration of CRP and

various cytokines also occur in chronic heart failure with fluid overload and cardiovascular disease.34,41 Non-alcoholic fatty liver disease (NAFLD) is a common liver disorder associated with obesity and insulin resistance that results from abnormal adipokine and cytokine production.42 In liver tissue, these mediators, such as leptin, TNF-a and ILs decrease insulin signaling to hepatocytes by the activation of several signaling molecules and kinases. This results in hepatic insulin resistance, hyperglycemia and fatty liver development caused by increased fatty acid uptake and VLDL production.37,42 Hepatic insulin resistance also stimulates the production of CRP and cytokines that promote atherosclerosis by the inhibition of NO production, an increase in the adhesion property in endothelial cells, and increasing macrophage uptake ox-LDL.40 This information indicates that hepatic insulin resistance is related to the induction of metabolic syndromes and the acceleration of cardiovascular disease progression.

Bone, muscular and skeletal diseases Rheumatoid arthritis is an autoimmune disease that causes joint destruction and functional disability, often characterized by chronic inflammatory responses primarily affecting the synovium of diarthrodial joints (Fig. 6). Besides infections and genetic factors, rheumatoid arthritis is indicated in the interaction between immune cells, such as T cells, B cells, macrophages,

Fig. 5 Proinflammatory cytokines in insulin resistance and metabolic disorders. Insulin synthesized and secreted from b cells in pancreas acts as normal function in different organs and tissues, includes reducing glucose production and output in liver, facilitating glucose uptake in skeletal muscle, and decreasing lipolysis in adipose tissue. Excessive pro-inflammatory cytokines (CRP, IL-1, IL-6, and TNF-a) cause dysfunction of b cell or recruit of inflammatory cells (monocytes and macrophages) that affect both insulin secretion and insulin action, promote pathogenesis of insulin resistance and subsequently reducing insulin-dependent signalling. This local insulin resistance also contributes to its target tissues such as increase concentration of glucose and fatty acids in skeletal muscle, liver and adipose tissue that lead to various metabolic disorders. Flavonoids act through interfering with proinflammatory cytokines-induced b cells dysfunction and cell death, decreasing cytokines production, up-regulation of insulin-dependent signaling and improving glucose uptake in different cell types.


Food Funct., 2010, 1, 15–31 | 19


View Online

Fig. 6 Mechanisms of inflammation-associated pathogenesis in rheumatoid arthritis and osteoporosis. In inflamed rheumatoid synovium and bone tissue, pro-inflammatory cytokines produced by recruited inflammatory cells (macrophages, T cells and B cells), endothelial cells and synovial fibroblasts are central to the inflammatory process in rheumatoid arthritis and osteoporosis. This pathological process also involves in innate and adaptive immunity responses. These pro-inflammatory cytokines result in activation of synovial fibroblasts and produce proteases that lead to tissue destruction. In addition, cytokines-trigger activation and differentiation of osteoclasts are important in bone loss. Flavonoids act through reducing recruitment of inflammatory cells, cytokines production, MMPs expression, and activation or differentiation of osteoclasts.

dendritic cells and fibroblasts and as such plays an important role in the pathogenesis of this disease.43 In patients with rheumatoid arthritis, large numbers of activated T cells are present in inflamed joints. Recruited T cells develop a lymphoid structure in synovium with B cells, macrophages and fibroblast-like synoviocytes that create a complex network between cells through secreting various cytokines, such as TNF-a, IL-1 and IL-6.44 Among these cell types in synovium, fibroblast-like synoviocytes is known to produce prostaglandins and proteases that destroy bone and cartilage.45 Moreover, activated B cells and macrophage continuously secrete IL-1 and TNF-a that maintain the synovial fibroblast in an inflamed state.44,45 Enrichment of these immune cells and derived-proinflammatory cytokines in synovium causes varying degrees of joint destruction and also extraarticular organ involvement. Osteoporosis is also a chronic inflammation condition that is characterized by the loss of bone density (Fig. 6). Studies identify proinflammatory cytokines TNF-a, IL-1 and IL-6 as important mediators of bone resorption through increased expression of 20 | Food Funct., 2010, 1, 15–31

receptor activator of NF-kB (RANK), activation and differentiation of osteoclast, and decreased osteoblast survival.46 Despite several in vitro and in vivo studies indicating that proinflammatory cytokines contribute to osteoporosis, and increased levels of IL-1b, IL-6 and TNF-a in whole blood culture from patients with osteoporosis, the mechanism involved in bone loss is still unclear. In addition, recent studies also reveal that elevated systemic CRP is associated with poor bone health.46,47 Chronic inflammatory diseases A continued chronic inflammatory state in different organs and tissues leads to a various chronic inflammatory diseases such as chronic obstructive pulmonary disease (COPD), psoriasis, rheumatoid arthritis, chronic pancreatitis and inflammatory bowel disease (IBD) all of which are frequently associated with infiltration of immune and inflammatory cells. For example, inflammatory bowel disease leads to ulcerative colitis (UC) and Crohn’s disease (CD), based on clinical features and This journal is ª The Royal Society of Chemistry 2010


View Online

Fig. 7 Underlying mechanisms in inflammatory bowel disease. As bacteria infection or environmental factors that cause colonic endothelium damage result in recruitment of inflammatory and immune cells from bloodstream. Accumulated inflammatory cells produce pro-inflammatory mediators that trigger proliferation and activation of T cells, lead to differentiate to Th1 and Th2 cells that result in amplification of inflammatory cascade and cause tissue injury. Flavonoids act through decreasing inflammatory cytokines production, reducing recruitment of inflammatory cells and modulation of differentiation and proliferation of T cells.

histopathology, which result from abnormal regulation of the immune system in the intestine.48 In IBD, damage of epithelium in the colon increases recruitment of immune cells such as activated T lymphocytes and leucocytes that are mediated by the expression of adhesion molecules.49 This is thought to be a key step of inflammatory process involved in IBD (Fig. 7). A number of studies indicate that an increased level of proinflammatory cytokines is important for pathogenesis of IBD.48 In general, epithelial cells, paneth cells, enterocytes and immune cells of colon form a complex barrier by the expression of cytokines, chemokines and metabolite from microbes or hosts in order to fight pathogens and to maintain intestinal homeostasis. Also, an alteration of the immune system toward luminal antigens is thought to play a crucial role in pathogenesis in IBD.48 In an immune response, T helper (Th) cells recognize selfantigens (from food consumption or intestinal bacteria) that present from lymphocytes and phagocytes, and then start to produce cytokines. As the specific-antigen occurs, it enhances production of various cytokines in colonic epithelium that promote CD4 and CD8 cells which then differentiate to Th1 and Th2 cells. These two Th cells produce a dramatic amount of proinflammatory cytokines that affect colon mucosa and intestinal cells.50 Studies show that Crohn’s disease is mediated by Th1 cells that are characterized by the production of IL-1, IL-6, interferon-g (IFN-g) and TNF-a, whereas ulcerative colitis is This journal is ª The Royal Society of Chemistry 2010

thought to be a Th2 cell mediated response by the secretion of IL-4, IL-5 and IL-10.48,50 Overexpression of these proinflammatory cytokines is found in the intestinal mucosa from IBD patients and is related to the alteration of intestinal homeostasis and results in an abnormal inflammatory response in the intestinal mucosa. Indeed, increased proinflammatory cytokines in colon mucosa are also linked to the enhanced expression of antiapoptotic molecules, leading to apoptotic resistance and promotion of accumulation of T cells.48,50

Cancers Several lines of evidence indicate that cancer development in humans is a multistep and long-term process which requires six properties, including limitless replication potential, evasion of apoptosis, self-sufficiency in growth signals, insensitivity to antigrowth signals, sustained angiogenesis, and tissue invasion and metastasis.51 Since Virchow observed in 18th century, that cancers frequently occur at sites of chronic irritation, much research confirms the concept that chronic inflammation is a critical component of tumor promotion and progression, including colorectal, gastric, pancreatic, pulmonary, cystic, hepatocellular, ovarian, skin and esophageal cancers.4,52 In view of inflammation involved in different cancers, increasing Food Funct., 2010, 1, 15–31 | 21


View Online

evidence suggests that inflammation should be the seventh hallmarker in cancer development.53 The pathological mechanism of inflammation involved in tumorigenesis is very complicated.54 In tissue injury or inflammatory stimulation, inflammatory cells are recruited and production of pro-inflammatory cytokines and diverse ROS and RNS that induce genetic change which enhances malignant transformation and proliferation of initiated cells. Subsequently, as tumor tissue forms, inflammation continues to promote development of cancer by creating an inflammatory microenvironment, which consists of stromal cells, inflammatory cells and the extracellular matrix from surrounding tissues. The inflammatory and immuosuppressive cytokines and chemokines secreted from these cells not only promotes proliferation, angiogenesis, invasion and metastasis but also suppresses the host’s immune system and facilitates tumor growth and development54,55 (Fig. 8). There are many key molecules that link inflammation and cancer, including transcription factors, signal transducers and activators of transcription 3 (STAT3), nuclear factor-kB (NFkB), nuclear factor of activated T-cells (NFAT), activator protein-1 (AP-1), CCAAT enhancer binding protein (C/EBP), cAMP response element binding protein/p300 (CBP/p300),

activator transcription factor (ATF), downstream genes iNOS, COX-2, interleukin-6 (IL-6), IL-1b, tumor necrosis factor-R (TNF-R), 5-lipoxygenase (5-LOX), hypoxia inducible factor-1a (HIF-1a), and vascular endothelial growth factor (VEGF), resulting in inflammation and tumorigenesis.54,56 Besides the above, inflammatory signaling is regulated by upstream kinases, such as NFkB-inducing kinase (NIK), IkB kinase (PKC), mitogen-activated protein kinase (MAPK), phosphoinositide-3 kinase (PI3K)/Akt and protein kinase C (PKC), also important in inflammation linked tumorigenesis. These critical molecules can be considered important in the modulation of an inflammatory response, and thus could block or prevent inflammationassociated carcinogenesis.54,56

Chemoprevention: inflammation as potential target The term ‘‘chemoprevention’’ was coined by Sporn in the mid1970s and is defined as the use of a chemical substance of either natural or synthetic origin to prevent, hamper, arrest, or reverse a disease.57 It is suggested that inflammation is a multifaceted and complicated process implicated in infiltration and activation of various immune and inflammatory cells, cytokine production, signal transduction and molecular mechanism that results in

Fig. 8 Role of inflammation in cancer development. Chronic inflammation is a critical component of tumor promotion and progression, including colorectal, gastric, pancreas, lung, bladder, hepatocellular, ovary, skin and esophageal cancers. In colonic tumorigenesis, inflammatory stimulation, inflammatory cells are recruited and production of pro-inflammatory cytokines and diverse ROS and RNS that induction of genetic change, enhanced malignant transformation and proliferation of initiated cells. Subsequently, as tumor tissue formation, inflammation also promotes development of cancer by creating an inflammatory microenvironment. The inflammatory and immuosuppressive cytokines and chemokines secreted from these cells not only promote proliferation, angiogenesis, invasion and metastasis but also suppress the host’s immune system and facilitates tumor growth and development.

22 | Food Funct., 2010, 1, 15–31



View Online

a widespread physiological state in organ and tissue. There are many clinical drugs and dietary natural compounds that are demonstrated to be able to exert protective action by different mechanisms, on a number of pathological aspects through targeting interference with chronic inflammatory response. For example, anti-inflammatory drugs, including nonsteroidal antiinflammatory drugs (NSAID), are found to have some neuroprotective effects.58 Resveratrol and curcumin are found to prevent cell damage and death through their antioxidative activities that reveal potential neuroprotective activities.59,60 Anti-a4 integrin monoclonal antibody acts by disrupting adhesion and migration of immune cells that attenuate cytokine release in Crohn’s disease individuals.61 Using monoclonal antibodies against B cells function, TNF-a and IL-6 signaling are beneficial for autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease.62 In patients with type 2 diabetes, treatment with an IL-1 receptor antagonist may restore the function of pancreatic b cells and improve insulinresistance.39 Kinase Inhibitors such as SB203580, a p38 MAPK inhibitor, are found to decrease IL-1b production and reduce rheumatoid arthritis in mice.63 Oral intake of tyrosine kinase inhibitor showed a reduction of inflammatory markers and improved quality in rheumatoid arthritis and psoriasis patients.62 In an in vivo study, PPARg agonist reduced the expression of proinflammatory cytokines that then decreased immune complex deposition and renal inflammation, and lowered atherosclerotic lesions.64 PPARg agonist also lowered plasma glucose and serum CRP and TNF-a, and increased the production of adiponectin in adipose tissue, thus improving insulin resistance in humans with type 2 diabetes.62 The relationship between inflammation and cancer is established.54,55 Numerous evidence demonstrates that inflammatory pathways are critical targets in cancer treatment and prevention.65 Many natural bioactive compounds are reported to interfere with the initiation, promotion/progression, and invasion/metastasis of cancer through the control of intracellular signaling cascades as the process of inflammation progresses. These bioactive compounds include flavonoids, flavonolignans, isothiocyanates, proanthocyanidins, terpenoids, and other polyphenolic compounds.1,56 These bioactive compounds act by avoiding the causes of tissue damage, inhibiting signaling pathways and the activation of transcription factors, inhibiting oxidant-generating enzymes and mediators of inflammation, scavenging reactive oxygen and nitrogen species generated by inflammatory cells, and modulating angiogenesis and metastasis.

Flavonoids: new approach in chronic inflammatory diseases Flavonoids are plant secondary metabolites that are ubiquitous in fruits, vegetables, nuts, seeds and plants. These polyphenolic compounds are a subgroup of chemically related polyphenols that possess a basic 15-carbon skeleton and can be represented as C6-C3-C6, consisting of two benzene rings (C6) joined by a linear three carbon chain (C3).1 Based on the differences in the structure of the aglycones C ring, flavonoids can be classified into seven groups: flavones, flavanones, flavonols, flavanonols, isoflavones, flavanols (catechins) and anthocyanidins (Table 1). The structural variation of flavonoids may come from various This journal is ª The Royal Society of Chemistry 2010

patterns of substitution through enzymatic reactions including hydroxylation, methoxylation, sulfonation, acylation, prenylation, or glycosylation. Flavonoids are most frequently present as conjugates in glycosides and polymers that are water soluble and degraded to variable extents in the digestive system.66 There are also a wide variety of types of naturally occurring flavonoids—at least 2000. Some of them exhibit a broad spectrum of pharmacological properties such as antioxidant, free radical-scavenging, anti-inflammatory, anti-carcinogenic, antiviral, anti-bacterial, anti-thrombogenic and anti-atherogenic activities. It is reported that human intake of all flavonoids is a few hundred milligrams to 650 mg per day in our diet.66 Significant scientific evidence shows that flavonoids have many beneficial health effects for human beings. Many studies show that flavonoid intake improves health and fights off chronic diseases.67 Among the biological properties of flavonoids, antiinflammatory activity is attracting growing interest in managing chronic inflammatory diseases. The biochemical and molecular mechanisms, as well as the signaling pathways, of flavonoids implicated in chronic inflammatory diseases are described below. Flavones Apigenin, a flavonoid present in parsley and celery (Fig. 9), is found to inhibit HIF-1a and VEGF expression by blocking PI3K/Akt signaling or LPS-induced pro-inflammatory cytokines expression by inactivating NF-kB through the suppression of p65 phosphorylation.1 Lupus is autoimmune disease, characterized by production of autoantibodies to attack nuclear antigens and immune complex deposition in organs.68 In an in vivo study, apigenin decreased response of Th1 and Th17 cells to major lupus autoantigen, and subsequently suppressed the ability of lupus B cells to produce pathogenic autoantibodies that limit the inflammatory state in SFN-1 mice. Apigenin also downregulated the expression of COX-2 and cellular FLICE-like inhibitory protein (c-FLIP) in immune cells as well as causing activated immune cells to undergo apoptosis, thus suppressing inflammation in lupus.69 In the pathogenesis of rheumatoid arthritis, it is reported that inflammatory cytokines produced by fibroblastlike synoviocytes are involved in joint destruction. Apigenin is known to induce ROS production and cause apoptosis through oxidative stress-activated ERK1/2 pathway in fibroblast-like synoviocytes.70 Moreover, intake of apigenin also showed immunomodulating effects triggered by TNF-a in a mouse model of rheumatoid arthritis.71 Luteolin is prevalent in thyme and also exists in beets, brussels sprouts, cabbage and cauliflower, and is shown to possess great antioxidative activity. It is known that the activation of microglia and cytokine production is important in neurodegenerative diseases. Treatment with luteolin strongly suppressed IFNginduced CD40 expression and the production of TNF-a and IL-6 through downregulated phosphorylation of STAT-1 in microglia.72 Also, luteolin significantly inhibited LPS-induced activation of microglia by inhibiting JNK phosphorylation and activation of AP-1, increasing dopamine uptake and decreasing excessive TNF-a, NO and superoxide production in microglia,73,74 suggesting the neuroprotective effect of luteolin against brain injury. In addition, luteolin was found to regulate MAPK and NF-kB signaling that inhibits TNF-a induced IL-8 Food Funct., 2010, 1, 15–31 | 23

View Online

Table 1 Backbone structures of the different classes of flavonoids


Groups

Structure

Examples

Flavones

Apigenin, luteolin, tangeretin, nobiletin, 5-hydroxy3,6,7,8,30 ,40 hexamethoxyflavone

Flavonols

Kaempferol, myricetin, quercetin, isorhamnetin

Flavanols

Catechin, gallocatechin, epicatechin, epigallocatechin-3gallate

Flavanones

Naringenin, hesperetin, eriodictyol

Isoflavones

Daidzein, genistein, glycitein

Anthocyanidins

Cyanidin, delphinidin, pelargonidin

production, which is an important inflammatory cytokine involved in maintaining the inflammatory state in inflammatory bowel diseases.75 Luteolin also decreases TNF-a, IL-1 and MCP1 gene expression and increases adiponectin and leptin levels through the enhancement of transcriptional activity of PPARg in 3T3-L1 adipocytes that might improve obesity-driven insulin resistance.76 Citrus peel is a rich source of polymethoxyflavones, such as tangeretin and nobiletin, and exhibits a broad spectrum of biological activities, including modulation of inflammatory-derived cancer development.77 It is shown that tangeretin suppresses IL1b-induced COX-2 expression through inhibiting activation of MAPK and Akt.1 In an in vivo study, nobiletin was found to lower levels of eotaxin, a potent eosinophil chemoattractant cytokine 24 | Food Funct., 2010, 1, 15–31

that relieves the infiltration of eosinophils and airway inflammation in asthmatic rats.78 It is suggested that the inhibition of foam cells forming macrophage and ox-LDL uptake is one of the targets for atherosclerosis. Nobiletin inhibited macrophage foam-cell formation through reducing metabolism of b-VLDL, is primarily taken up by macrophages via the LDL receptor in cultured murine J774A.1 macrophages.79 Several studies demonstrate that nobiletin can improve arthritic diseases as evidenced by decreasing proinflammatory cytokine production in human synovial cells and downregulating gene expression of MMPs in human synovial fibroblasts,80 as well as in collagen-induced arthritic (CIA) mice.81 Nobiletin can also inhibit leukocyte infiltration, protein expression of iNOS and COX-2 as well as tumorigenesis in mouse skin.1 In our previous studies, we reported that a metabolite of nobiletin This journal is ª The Royal Society of Chemistry 2010


View Online

Fig. 9 Representative natural flavonoids and their dietary sources. (A) flavones, (B) flavonols, (C) flavanols, (D) flavanones, (F) isoflavones, (G) anthocyanidins.


Food Funct., 2010, 1, 15–31 | 25

View Online


(30 ,40 -didemethylnobiletin) and 5-hydroxy-3,6,7,8,30 ,40 -hexamethoxyflavone, a hydroxylated PMF in citrus peel, inhibited 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced skin inflammation and tumor promotion by suppressing MAPK and PI3K/Akt signaling pathways.82,83 Recently, two new flavones isolated from Cirsium japonicum DC, pectolinarin and 5,7-dihydroxy-6,40 -dimethoxyflavone were found to reduce high-carbohydrate/high-fat diet-induced diabetes in rat through decreasing plasma glucose and increasing adiponectin levels that may improve glucose and lipid homeostasis.84 Flavonols Quercetin, an ubiquitous plant secondary metabolite, is found abundant in onions, broccoli, apples, grapes, wine, tea, and leafy green vegetables, is well known as a potent antioxidant and antiinflammatory agent. Recently, it was shown to possess good antiatherosclerotic activity. In human umbilical vein endothelial cells (HUVECs), quercetin treatment strongly attenuated the inflammation-induced upregulated expression of VCAM-1, ICAM-1 and monocyte chemoattractant protein-1 (MCP-1), which may contribute to its interference with the interaction between monocytes and vascular endothelial cells during the early stages of atherosclerosis.85 Oral feeding of quercetin (64-mg/kg body weight daily) significantly inhibited atherosclerotic lesion size in the aortic sinus and thoracic aorta through reducing superoxide production, improving endothelial NO synthase (eNOS) function and decreasing plasma-sP-selectin levels in the apolipoprotein E (ApoE)(-/-) gene-knockout mouse.86 Quercetin also decreased circulating inflammatory markers, including IFNg, IL-1a and IL-4 in high fat diet animal models and therefore may improve inflammation or obesity-associated disorder.87 In addition, consumption of quercetin is found to decrease systolic blood pressure and plasma oxidised LDL in obese subjects (aged 25–65 years) without affecting liver and kidney functions.88 When rats were fed a diet of rutin, a quercetin glycoside, there was markedly attenuated dextran sulfate sodium (DSS) induced gene expression of IL-1b and IL-6 in colonic mucosa and decreased intestinal colitis.89 Quercetin was found to inhibit 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis of rats possibly through downregulation of TNF-a-induced NF-kB activation.90 Kaempferol, another flavonol-type flavonoid present in broccoli, tea and various vegetables, is considered to improve osteoporosis. For example, treatment with kaempferol stimulated differentiation and mineralization of murine pre-osteoblastic cell lines that may contribute to the prevention of bone loss.91 In the pathology of osteoporosis, proinflammatory cytokines TNF-a is important for bone disruption and osteoclastogenic cytokine production. Kaempferol was reported to antagonize TNF-ainduced p65 translocation and production of IL-6 and MCP-1as well as RANKL-triggered osteoclast precursor cell differentiation. These data indicate that kaempferol exerted a profound anti-osteoclastogenic effect.92 Advanced glycation end products (AGE) are oxidative products formed from nonenzymatic reaction of reducing sugars with free amino groups of proteins. AGE is reported to be involved in diabetic complications and various age/inflammation-related chronic diseases through generation of 26 | Food Funct., 2010, 1, 15–31

ROS and activation of inflammatory signaling cascades.93 Studies show that supplementation of kaempferol in mice reduced AGE-induced activation of NADPH oxidase and proinflammatory gene expression through modulating the NFkB signaling cascade.94 When aged Sprague-Dawley rats were fed with a diet containing kaempferol, the activation of T cell was inhibited and COX-2, iNOS and MCP-1 gene expressions of kidney through modulation of NIK/IKK and MAPK signalings were reduced possibly reducing kidney disease.95 In addition, both kaempferol and quercetin could significantly improve insulin-stimulated glucose uptake in mature 3T3-L1 adipocytes by acting as agonists of PPARg that may exert a beneficial effect on hyperglycemia and insulin resistance.96 Flavanols Tea is a popular beverage worldwide. It is produced from the leaves of Camellia sinensis. There are more than 300 different kinds of tea made by different manufacturing processes. Among these, green tea has attracted attention for its health benefits contributed by catechin compounds including epigallocatechin3-gallate (EGCG), epigallocatechin (EGC), epicatechin-3-gallate (ECG), and epicatechin (EC). Numerous studies demonstrate the potential of green tea in iron-chelating, radical-scavenging, antiinflammatory and brain-permeable activities thus preventing cardiovascular, chronic and neurodegenerative diseases.97,98 In vivo study shows that pretreatment with ()-catechin protected dopaminergic neurons in the substantia nigra against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced toxicity through modulation of the phosphorylation of c-Jun Nterminal kinase (JNK) and GSK-3b.99 Pretreatment with epicatechin also attenuated ox-LDL induced neurotoxicity in mouse-derived striatal neurons.100 EGCG is the most abundant polyphenolic compound in green tea. EGCG is found to inhibit LPS-induced microglial activation, NO and TNF-a production as well as subsequent neuronal injury both in the human dopaminergic cell line SH-SY5Y and in primary rat mesencephalic culture, suggesting the neuroprotective activity of EGCG may be inhibition of microglial activation.101 Neuronal damage and death caused by excessive NO is one of the pathological mechanisms in neurodegeneration. EGCG was found to inhibit NO-induced PC12 cell death by scavenging ROS.102 Obesity is a low-grade inflammatory state and is predisposed to an increased incidence of diabetes and CVD. A number line of evidence shows that EGCG possesses excellent activity against obesity-associated pathogenesis and metabolic disorders. In high fat diet-induced obesity animal models, supplementation with dietary EGCG reduced body weight gain and body fat, plasma cholesterol and MCP-1 levels, and decreased lipid accumulation in hepatocytes as well as attenuated insulin resistance.103 In addition, feeding EGCG improved high fat diet-induced nonalcoholic steatohepatitis in mice by decreasing triglyceride and cholesterol levels, lipid peroxidation, and expression of a-smooth muscle actin (a-SMA) in liver tissue. The liver protective effect of EGCG in mice on obesitywas further evidenced by expressions of insulin receptor substrate-1 (IRS-1) and phosphorylated IRS-1 (pIRS-1), and decreasing TNF-a and NF-kB signaling in liver tissues thus improving nonalcoholic steatohepatitis and insulin This journal is ª The Royal Society of Chemistry 2010


View Online

resistance.104 Treatment with EGCG on regulatory T cells from obese individuals significantly enhanced the function of regulatory T cells by the production of anti-inflammatory cytokine IL10.105 Moreover, EGCG is reported to inhibit TNF-a stimulated activation of activator protein-1 (AP-1) and secretion of MCP-1 porcine aortic endothelial cells that work against vascular endothelial inflammation and atherosclerosis.106 EGCG also protects against bone, muscular and skeletal diseases. In synoviocytes and chondrocytes, upregulation of MAPK is critical for proinflammatory cytokine-induced signaling that causes production of several mediators of cartilage damage in an arthritic joint. EGCG was reported to modulate IL-1b-induced activation of MAPKs and DNA binding activity of AP-1 in osteoarthritis chondrocytes.107 Synovial fibroblasts produce metalloproteinases (MMPs) induced by proinflammatory cytokine TNF-a, which are involved in destroying cartilage and bone in Rheumatoid arthritis. Treatment with EGCG suppresses TNF-a-induced production of MMP-1 and MMP-3 through downregulating phosphorylation of MAPKs, such as ERK1/2, p38, JNK and the activation of AP-1 transcription factor in RA synovial fibroblasts.108 Furthermore, EGCG suppresses osteoclast differentiation through downregulating expression of nuclear factor activated T cells c1 (NFATc1) and reduces histologic scores in experimental arthritis in mice that may improve osteoporosis and rheumatoid arthritis.109 Flavanones Much of the activity of flavanones from citrus peels appears to have an impact on vascular endothelial cells that reveal protective effect against atherosclerosis and cardiovascular diseases. In high cholesterol-fed New Zealand white rabbits, diet supplemented with naringenin were shown to reduce gene expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and MCP-1 in endothelial cells. Plasma lipoprotein levels, total cholesterol, triglyceride, and high-density lipoprotein (HDL) were also decreased by naringenin feeding.110,111 These findings suggest that naringenin can prevent hypercholesterolemia caused fatty liver and acts on interfering immune cells and vascular endothelial cells as well as macrophage infiltration against atherosclerosis. Naringin is shown to inhibit TNF-a-induced expression of MMP-9 in vascular smooth muscle cells (VSMC) through modulation of the PI3K/AKT/mTOR/p70S6K pathway and suppression of the transcriptional activity of AP-1 and NF-kB.112 Emerging studies demonstrate that obesity is a major risk factor for atherosclerosis and cardiovascular disease. Adiponectin secreted from adipocytes was found to suppress atherogenesis by inhibiting monocyte adhesion, reducing macrophage uptake ox-LDL and suppressing the accumulation of ox-LDL in vascular wall.113 Studies show that naringin and hesperetin, other flavanones found in large quantity in citrus peel, enhanced adiponectin transcription in differentiated 3T3-L1 adipocytes through activation of PPARg.114 Naringin is also reported to inhibit high fat diet-induced atherosclerosis and normalize hyperinsulinemia and obesity in low-density lipoprotein receptor-null mice.115 Cytokines promote proliferation and migration of vascular smooth muscle cells and play an important role in atherosclerosis. Hesperetin is found to inhibit platelet-derived growth This journal is ª The Royal Society of Chemistry 2010

factor (PDGF)-BB induced proliferation of primary cultured rat aortic vascular smooth muscle cells through regulation of Akt and MAPKs signaling that results in cell cycle arrest.116 Moreover, hesperetin also increased NO releases from human umbilical vein endothelial cells through up-regulation eNOS expression that may improve function of vascular endothelial cells.117 In addition to the anti-atherosclerosis effect, studies also demonstrate the protective activity of naringin and hesperetin against neuroinflammatory injury. Both naringin and hesperetin attenuated LPS/IFNg-induced TNF-a production through glial cells, while naringin showed a greater effect as evidenced by inhibition of iNOS expression by modulation of p38 MAPK and STAT-1 signaling.118 Isoflavonoids The health benefits of isoflavonoids from soybeans was recognized in recent years, especially about its anti-atherosclerotic functions. Consumption of soy-based diets is associated with a lower risk of cardiovascular disease in humans and reduced atherosclerosis in several experimental animals.119 These effects are related to their antioxidant, anti-inflammatory and antithrombogenic properties through inhibition of endothelial and inflammatory cell activation and reduction in recruitment of leukocytes, as well as foam cell formation. Genistein, the major isoflavone abundantly present in soybean, is known for its role in the regulation of vascular function and protection against atherosclerosis.120 Treatment with genistein markedly inhibited TNF-a-induced cell adhesion molecule CD62E and CD106 expression and subsequent monocyte adhesion in HUVECs and human brain microvascular endothelial cells.121 Genistein also decreased the interaction between monocyte and endothelial cells through the activation of PPARg that inhibits of monocyte adhesion in culture cells and animals.122,123 In an in vitro study, genistein inhibited LPS-induced MCP-1 secretion from macrophages that contribute to reduced monocyte migration.124 In vivo administration of genistein inhibits LPS-induced expression of iNOS and nitrotyrosine protein in vascular tissue that prevents hypotension and vascular alterations.125 Genistein is also known to have a potential effect on rheumatoid arthritis, diabetes, metabolic disorders, neurodegenerative diseases and chronic colitis by modulation of inflammatory response. For instance, genistein inhibits production of proinflammatory molecules NO, IL-1b, and HC gp-39, known as markers of cartilage catabolism in LPS-stimulated human chondrocytes.126 In a collagen-induced rheumatoid arthritis rat, genistein modulated Th1-predominant immune response by suppressing the secretion of IFNg and increasing IL-4 production that balances the inflammatory state.127 NAFLD is an obesity-related fatty liver disease caused by proinflammatory cytokine TNF-a and ILs and leads to the dysfunction of hepatocytes and increase fatty acid uptake. Genistein is reported to reduce high fat diet-induced steatohepatitis through decreasing plasma TNF-a levels and improved liver function in rat.128 Supplementation with genistein and daidzein also decreases mRNA levels of TNF-a, IL-1b and MCP-1 in plasma and liver tissue in obese Zucker rats, suggesting a preventive effect of dietary genistein on steatohepatitis through its anti-inflammatory activity.129 Furthermore, intake of high-dose isoflavones Food Funct., 2010, 1, 15–31 | 27


View Online

(genistein, daidzein, and glycitein) significantly reduced serum TNF-a and increased adiponectin levels in women, indicating that isoflavonids could regulate inflammatory conditions and improve metabolic parameters.130 In addition, genistein attenuated LPS-induced loss of dopamine uptake in rat mesencephalic neuron-glia cultures through reducing microglia activation and production of NO and TNFa131 may protect dopaminergic neuron injury-caused pathogenesis of Parkinson’s disease. In Alzheimer’s disease, accumulation of astrocytes at sites of Ab deposition is the earliest neuropathological changes that initiate the inflammatory response. Treatment with genistein reduced Ab-induced production of inflammatory mediator iNOS, COX-2, TNF-a and IL-1b in astrocytes, possibly through activation of PPARs.132 Also, oral treatment with genistein reduced TNBS-induced chronic colitis by inhibiting expression of COX-2 mRNA and protein as well as the myeloperoxidase (MPO) activity in rat colon that exerts beneficial anti-inflammatory effects against inflammatory bowel disease.133 Genistein is a well-known tyrosine kinase inhibitor. In an in vitro study, genistein was found to prevent IL-1b/IFNginduced expression of COX-2 and iNOS as well as produce PGE2 and NO in human islets that may improve insulin resistance and prevent pathogenesis of diabetes.134 Anthocyanidins Anthocyanidins are common plant pigments that give the red and blue colors in some fruits and vegetables such as blueberries and grapes. Epidemiological investigations and animal experiments indicate that anthocyanins may contribute to chemopreventive activities of various chronic inflammatory diseases.135,136 Anthocyanins-rich berries were demonstrated to possess a broad spectrum of biological properties, including antioxidant, cadioprotective, neuroprotective, anti-inflammatory and anticancer.137 In an animal study, cyanidin was reported to reduce PGE2 levels in paw tissues and TNF-a levels in serum in adjuvant-induced arthritis.138 Damage and apoptosis of vascular endothelial cells is frequently observed in atheromatous plaques and contributes to pathology of atherosclerosis. It has been shown that cyanidin inhibited TNF-a-induced endothelial cell apoptosis, elevated expression of eNOS and thioredoxin may improve vascular endothelial cell function and vasculopathy.139 VEGF is known as a major pro-angiogenic and pro-atherosclerotic factor. Both cyanidin and delphinidin, other major anthocyanidins present in pigmented fruits and vegetables, inhibit PDGF-induced VEGF expression through down-regulation of p38 MAPK and JNK signalings in vascular smooth muscle cells.140 Delphinidin also shows protective effects against cardiovascular disease. It is suggested that proliferation of vascular endothelial cells is important in the pathogenesis of atherosclerosis.141 Delphinidin treatment inhibits serum and VEGFinduced bovine aortic endothelial cell proliferation through modulation of ERK and also results in cell cycle arrest.142 Also, delphinidin increased eNOS expression by mediating the MAP kinase pathway, thus preventing bovine aortic endothelial cell apoptosis.143 In addition, delphinidin was found to fight against ox-LDL-induced damage in HUVECs and regulate apoptotic molecule expression.144 These studies suggest delphinidin may be 28 | Food Funct., 2010, 1, 15–31

important in preventing both plaque development and atherosclerosis. Proanthocyanidines and theaflavins Proanthocyanidins (PAs), also called condensed tannins, are ubiquitous and present as the second most abundant group of natural phenolics after lignin. Oligomers and polymers of proanthocyanidins are widely found in the plant kingdom in fruits, cereals, berries, beans, nuts, cocoa and wine. The abundance of proanthocyanidins in plants makes them an important part of the human diet and are reported to exhibit a wide range of biological effects.145 A recent study demonstrated that dietary grape seed proanthocyanidins (GSPs) is effective against ultraviolet (UV) radiation-induced skin tumor in mice. Dietary GSPs inhibited UVB-induced infiltration of proinflammatory leukocytes and the levels of myeloperoxidase, cyclooxygenase-2 (COX-2), prostaglandin (PG) E(2), cyclin D1 and proliferating cell nuclear antigen (PCNA) in the skin and skin tumors.146 PAs are shown to mediate several anti-inflammatory mechanisms involved in the development of cardiovascular disease by modulation of monocytes adhesion in the inflammatory process of atherosclerosis.145 PAs also exhibit in vivo hepatoprotective and anti-fibrogenic effects against dimethylnitrosamine-induced liver injury.147 Theaflavins, a mixture of theaflavin (TF-1), theaflavin-3gallate (TF-2a), theaflavin-30 -gallate (TF-2b), and theaflavin3,30 -digallate (TF-3) are the major components of black tea. We previously reported that TF-3 exerts its anti-inflammatory and cancer chemopreventive actions by suppressing the activation of NFkB through inhibition of IKK activity.148 We also found that epicatechins in green tea and theaflavins in black tea are able to reduce the concentration of methylglyoxal in physiological phosphate buffer conditions.149 Among these black tea components, TF-3 is generally considered to be the more effective component for a protective effect against inflammatory processes.150

Conclusion Chronic inflammation is linked to numerous human diseases. Increasingly epidemiological and experimental studies demonstrate that modulation of inflammatory response by natural phytochemicals plays an important role in the prevention, mitigation, and treatment of many chronic inflammatory diseases. Flavonoids are a group of natural compounds widely present in vegetables, fruits and edible plants that possess potent biological activities. Dietary intake of flavonoids is suggested to prevent and lower the risk of chronic diseases. In this review, we discussed the possible mechanisms by which flavonoids play a role in the regulation of the inflammatory processes associated with atherosclerosis (cardiovascular disease), neurodegenerative diseases, obesity, metabolic disorders, bone, muscular and skeletal diseases, and chronic inflammatory diseases, as well as cancers. The anti-inflammatory activity of flavonoids is seen through several mechanisms involving the modulation of inflammatory signaling, reduction of inflammatory molecule production, diminishing recruitment and activation of inflammatory cells, regulation of cellular function and their This journal is ª The Royal Society of Chemistry 2010

View Online

antioxidative property. Regarding the safety, ability and the antiinflammatory effects of flavonoids, they are likely to have a potential role in preventive and therapeutic roles in chronic inflammatory conditions. However, additional, extensive research of flavonoids in strengthening the network of inflammatory response needs to be studied in the future.


Abbreviations Ab AGE AP-1 ApoE APP a-SMA ATF CBP/p300 CD C/EBP c-FLIP CIA COPD COX-2 CRP CVD DSS EC ECG EGC EGCG ERK1/2 eNOS GLUT4 GSK-3b HC gp-39 HDL HIF-1a H2O2 HUVEC ICAM-1 IL IL-1ra IBD IFN-g IKK iNOS IRS-1 JNK 5-LOX LPS MAPK MCP-1 MMP MPO MPTP mTOR NADPH oxidase

amyloid b peptide advanced glycation end products activator protein-1 apolipoprotein E amyloid precursor protein a-smooth muscle actin activator transcription factor cAMP response element binding protein/p300 Crohn’s disease CCAAT enhancer binding protein cellular FLICE-like inhibitory protein collagen-induced arthritic chronic obstructive pulmonary disease cyclooxygenase-2 c-active protein cardiovascular disease dextran sulfate sodium epicatechin epicatechin-3-gallate epigallocatechin epigallocatechin-3-gallate external signal regulated kinase 1/2 endothelial NO synthase glucose transporter type 4 glycogen synthase kinase 3b human cartilage glycoprotein-39 high-density lipoprotein hypoxia inducible factor-1a hydrogen peroxide human umbilical vein endothelial cell intercellular adhesion molecule-1 Interleukin IL-1 receptor antagonist protein inflammatory bowel disease interferon-g IkB kinase inducible nitric oxide synthase insulin receptor substrate-1 c-Jun N-terminal kinase 5-lipoxygenase lipopolysaccharides mitogen-activated protein kinase monocyte chemoattractant protein-1 matrix metalloproteinase myeloperoxidase 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mammalian target of rapamycin nicotinamide adenine dinucleotide phosphateoxidase


NAFLD NF-ATc1 NF-kB NFAT NIK NO NSAID 1O2 O2 OH ox-LDL p70S6K PDGF PGE2 PI3K pIRS-1 PKC PPARg RA RANKL ROS SOCS STAT TGF-b Th cell TNBS TNF-a TPA UC VCAM-1 VEGF VLDL VSMC

non-alcoholic fatty liver disease nuclear factor of activated T cells c1 nuclear factor-kappa B nuclear factor of activated T-cells NF-kB-inducing kinase nitric oxide nonsteroidal anti-inflammatory drugs singlet oxygen superoxide anion hydroxyl radical oxidized low-density-lipoprotein p70 ribosomal S6 kinase platelet-derived growth factor prostaglandin E2 phosphoinositide-3 kinase phosphorylated IRS-1 protein kinase C peroxisome proliferator-activated receptor g rheumatoid arthritis receptor activator for nuclear factor kB ligand reactive oxygen species suppressor of cytokine signaling signal transducers and activators of transcription transforming growth factor-b T helper cell 2,4,6-trinitrobenzene sulfonic acid tumor necrosis factor-a 12-O-tetradecanoyl-phorbol-13-acetate ulcerative colitis vascular cell adhension molecule-1 vascular endothelial growth factor very-low-density lipoprotein vascular smooth muscle cells

References 1 M. H. Pan, C. S. Lai, S. Dushenkov and C. T. Ho, J. Agric. Food Chem., 2009, 57, 4467. 2 R. Medzhitov, Nature, 2008, 454, 428. 3 P. C. Calder, R. Albers, J. M. Antoine, S. Blum, R. Bourdet-Sicard, G. A. Ferns, G. Folkerts, P. S. Friedmann, G. S. Frost, F. Guarner, M. Lovik, S. Macfarlane, P. D. Meyer, L. M’Rabet, M. Serafini, E. W. van, L. J. van, D. W. Vas, S. Vidry, B. M. WinklhoferRoob and J. Zhao, Br.J.Nutr, 2009, 101(Suppl. 1), S1. 4 P. Libby, Nutr. Rev., 2007, 65, S140. 5 A. Garcia-Lafuente, E. Guillamon, A. Villares, M. A. Rostagno and J. A. Martinez, Inflammation Res., 2009, 58, 537. 6 L. I. Mennen, D. Sapinho, B. A. de, N. Arnault, S. Bertrais, P. Galan and S. Hercberg, J. Nutr., 2004, 134, 923. 7 P. M. Ridker and J. D. Silvertown, J. Periodontol., 2008, 79, 1544. 8 Y. Higashi, K. Noma, M. Yoshizumi and Y. Kihara, Circ. J., 2009, 73, 411. 9 P. Libby, Y. Okamoto, V. Z. Rocha and E. Folco, Circ. J., 2010, 74, 213. 10 J. Mestas and K. Ley, Trends Cardiovasc. Med., 2008, 18, 228. 11 E. A. Liehn, A. Zernecke, O. Postea and C. Weber, Arch. Physiol. Biochem., 2006, 112, 229. 12 K. J. Moore and M. W. Freeman, Arterioscler., Thromb., Vasc. Biol., 2006, 26, 1702. 13 R. L. Wilensky and D. Hamamdzic, Curr. Opin. Cardiol., 2007, 22, 545.

Food Funct., 2010, 1, 15–31 | 29


View Online

14 E. S. Nakou, E. N. Liberopoulos, H. J. Milionis and M. S. Elisaf, Curr. Vasc. Pharmacol., 2008, 6, 258. 15 G. J. Blake and P. M. Ridker, J. Intern. Med., 2002, 252, 283. 16 R. Klingenberg and G. K. Hansson, Eur. Heart J., 2009, 30, 2838. 17 C. K. Glass, K. Saijo, B. Winner, M. C. Marchetto and F. H. Gage, Cell, 2010, 140, 918. 18 S. T. Dheen, C. Kaur and E. A. Ling, Curr. Med. Chem., 2007, 14, 1189. 19 M. G. Tansey and M. S. Goldberg, Neurobiol. Dis., 2010, 37, 510. 20 R. E. Mrak and W. S. Griffin, J. Neuropathol. Exp. Neurol., 2007, 66, 683. 21 H. Braak, M. Sastre and T. K. Del, Acta Neuropathol., 2007, 114, 231. 22 R. L. Miller, M. James-Kracke, G. Y. Sun and A. Y. Sun, Neurochem. Res., 2009, 34, 55. 23 A. P. Kulkarni, L. A. Kellaway, D. K. Lahiri and G. J. Kotwal, Ann. N. Y. Acad. Sci., 2004, 1035, 147. 24 C. Infante-Duarte, S. Waiczies, J. Wuerfel and F. Zipp, J. Mol. Med., 2008, 86, 975. 25 G. Reaven, F. Abbasi and T. McLaughlin, Recent Prog.Horm.Res., 2004, 59, 207. 26 A. Fortuno, A. Rodriguez, J. Gomez-Ambrosi, G. Fruhbeck and J. Diez, J. Physiol Biochem., 2003, 59, 51. 27 J. M. Friedman and J. L. Halaas, Nature, 1998, 395, 763. 28 V. R. Drel, N. Mashtalir, O. Ilnytska, J. Shin, F. Li, V. V. Lyzogubov and I. G. Obrosova, Diabetes, 2006, 55, 3335. 29 S. Mehta and J. A. Farmer, Curr. Atheroscler. Rep., 2007, 9, 134. 30 G. S. Hotamisligil, N. S. Shargill and B. M. Spiegelman, Science, 1993, 259, 87. 31 T. Tzanavari, P. Giannogonas and K. P. Karalis, Current Directions in Autoimmunity, 2010, 11, 145. 32 J. G. Neels and J. M. Olefsky, J. Clin. Invest., 2005, 116, 33. 33 H. Kanda, S. Tateya, Y. Tamori, K. Kotani, K. Hiasa, R. Kitazawa, S. Kitazawa, H. Miyachi, S. Maeda, K. Egashira and M. Kasuga, J. Clin. Invest., 2006, 116, 1494. 34 H. Florez, S. Castillo-Florez, A. Mendez, P. Casanova-Romero, C. Larreal-Urdaneta, D. Lee and R. Goldberg, Diabetes Res. Clin. Pract., 2006, 71, 92. 35 M. Bluher, Exp. Clin. Endocrinol. Diabetes, 2009, 117, 241. 36 K. T. Uysal, S. M. Wiesbrock and G. S. Hotamisligil, Endocrinology, 1998, 139, 4832. 37 G. S. Hotamisligil, Nature, 2006, 444, 860. 38 S. E. Kahn, Diabetologia, 2003, 46, 3. 39 S. Malozowski and J. T. Sahlroot, N. Engl. J. Med., 2007, 357, 302. 40 R. Meshkani and K. Adeli, Clin. Biochem., 2009, 42, 1331. 41 W. W. Cheung, K. H. Paik and R. H. Mak, Pediatr. Nephrol., 2010, 25, 711. 42 R. Anty, P. Gual, P. M. Huet, Y. L. Marchand-Brustel and A. Tran, Gastroenterol.Clin.Biol., 2007, 31, 1127. 43 R. Scrivo, F. M. Di, A. Spadaro and G. Valesini, Ann. N. Y. Acad. Sci., 2007, 1108, 312. 44 A. Manzo, M. Bombardieri, F. Humby and C. Pitzalis, Immunol. Rev., 2010, 233, 267. 45 B. Bartok and G. S. Firestein, Immunol. Rev., 2010, 233, 233. 46 G. R. Mundy, Nutr. Rev., 2007, 65, S147. 47 R. R. McLean, Curr.Osteoporos.Rep., 2009, 7, 134. 48 M. G. Neuman, Translational Research, 2007, 149, 173. 49 G. Monteleone and F. Caprioli, Clin. Sci., 2010, 118, 707. 50 B. Singh, S. Read, C. Asseman, V. Malmstrom, C. Mottet, L. A. Stephens, R. Stepankova, H. Tlaskalova and F. Powrie, Immunol. Rev., 2001, 182, 190. 51 D. Hanahan and R. A. Weinberg, Cell, 2000, 100, 57. 52 F. Balkwill and A. Mantovani, Lancet, 2001, 357, 539. 53 F. Colotta, P. Allavena, A. Sica, C. Garlanda and A. Mantovani, Carcinogenesis, 2009, 30, 1073. 54 A. Mantovani, P. Allavena, A. Sica and F. Balkwill, Nature, 2008, 454, 436. 55 L. M. Coussens and Z. Werb, Nature, 2002, 420, 860. 56 M. H. Pan and C. T. Ho, Chem. Soc. Rev., 2008, 37, 2558. 57 M. B. Sporn, N. M. Dunlop, D. L. Newton and J. M. Smith, Fed.Proc., 1976, 35, 1332. 58 M. Hirohata, K. Ono and M. Yamada, Curr. Pharm. Des., 2008, 14, 3280. 59 V. Vingtdeux, U. Dreses-Werringloer, H. Zhao, P. Davies and P. Marambaud, BMC Neurosci., 2008, 9(suppl 2), S6.

30 | Food Funct., 2010, 1, 15–31

60 B. Ray and D. K. Lahiri, Curr. Opin. Pharmacol., 2009, 9, 434. 61 A. G. van, S. Vermeire and P. Rutgeerts, Minerva Gastroenterol.Dietol., 2007, 53, 249. 62 C. A. Dinarello, Cell, 2010, 140, 935. 63 K. K. Brown, S. A. Heitmeyer, E. B. Hookfin, L. Hsieh, M. Buchalova, Y. O. Taiwo and M. J. Janusz, Journal of Inflammation, 2008, 5, 22. 64 W. Zhao, S. G. Thacker, J. B. Hodgin, H. Zhang, J. H. Wang, J. L. Park, A. Randolph, E. C. Somers, S. Pennathur, M. Kretzler, F. C. Brosius, III and M. J. Kaplan, J. Immunol., 2009, 183, 2729. 65 B. B. Aggarwal, R. V. Vijayalekshmi and B. Sung, Clin. Cancer Res., 2009, 15, 425. 66 R. H. Liu, J.Nutr., 2004, 134, 3479S. 67 P. Knekt, J. Kumpulainen, R. Jarvinen, H. Rissanen, M. Heliovaara, A. Reunanen, T. Hakulinen and A. Aromaa, Am.J.Clin.Nutr., 2002, 76, 560. 68 J. C. Oates, Autoimmunity, 2010, 43, 56. 69 H. K. Kang, D. Ecklund, M. Liu and S. K. Datta, Arthritis Res. Ther., 2009, 11, R59. 70 G. C. Shin, C. Kim, J. M. Lee, W. S. Cho, S. G. Lee, M. Jeong, J. Cho and K. Lee, Chem.-Biol. Interact., 2009, 182, 29. 71 Y. Kumazawa, K. Kawaguchi and H. Takimoto, Curr. Pharm. Des., 2006, 12, 4271. 72 K. Rezai-Zadeh, J. Ehrhart, Y. Bai, P. R. Sanberg, P. Bickford, J. Tan and R. D. Shytle, J.Neuroinflammation., 2008, 5, 41. 73 S. Jang, K. W. Kelley and R. W. Johnson, Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 7534. 74 H. Q. Chen, Z. Y. Jin, X. J. Wang, X. M. Xu, L. Deng and J. W. Zhao, Neurosci. Lett., 2008, 448, 175. 75 J. A. Kim, D. K. Kim, O. H. Kang, Y. A. Choi, H. J. Park, S. C. Choi, T. H. Kim, K. J. Yun, Y. H. Nah and Y. M. Lee, Int. Immunopharmacol., 2005, 5, 209. 76 L. Ding, D. Jin and X. Chen, J.Nutr.Biochem., 2009. 77 S. Li, M. H. Pan, C. Y. Lo, D. Tan, Y. Wang, F. Shahidi and C. T. Ho, Journal of Functional Foods, 2009, 1, 2. 78 Y. Q. Wu, C. H. Zhou, J. Tao and S. N. Li, Life Sci., 2006, 78, 2689. 79 S. C. Whitman, E. M. Kurowska, J. A. Manthey and A. Daugherty, Atherosclerosis, 2005, 178, 25. 80 N. Lin, T. Sato, Y. Takayama, Y. Mimaki, Y. Sashida, M. Yano and A. Ito, Biochem. Pharmacol., 2003, 65, 2065. 81 K. Imada, N. Lin, C. Liu, A. Lu, W. Chen, M. Yano, T. Sato and A. Ito, Biochem. Biophys. Res. Commun., 2008, 373, 181. 82 C. S. Lai, S. Li, C. Y. Chai, C. Y. Lo, S. Dushenkov, C. T. Ho, M. H. Pan and Y. J. Wang, Carcinogenesis, 2008, 29, 2415. 83 C. S. Lai, S. Li, C. Y. Chai, C. Y. Lo, C. T. Ho, Y. J. Wang and M. H. Pan, Carcinogenesis, 2007, 28, 2581. 84 Z. Liao, X. Chen and M. Wu, Arch. Pharmacal Res., 2010, 33, 353. 85 S. Tribolo, F. Lodi, C. Connor, S. Suri, V. G. Wilson, M. A. Taylor, P. W. Needs, P. A. Kroon and D. A. Hughes, Atherosclerosis, 2008, 197, 50. 86 W. M. Loke, J. M. Proudfoot, J. M. Hodgson, A. J. McKinley, N. Hime, M. Magat, R. Stocker and K. D. Croft, Arterioscler., Thromb., Vasc. Biol., 2010, 30, 749. 87 L. K. Stewart, J. L. Soileau, D. Ribnicky, Z. Q. Wang, I. Raskin, A. Poulev, M. Majewski, W. T. Cefalu and T. W. Gettys, Metab., Clin. Exp., 2008, 57, S39. 88 S. Egert, A. Bosy-Westphal, J. Seiberl, C. Kurbitz, U. Settler, S. Plachta-Danielzik, A. E. Wagner, J. Frank, J. Schrezenmeir, G. Rimbach, S. Wolffram and M. J. Muller, Br. J. Nutr., 2009, 102, 1065. 89 K. H. Kwon, A. Murakami, T. Tanaka and H. Ohigashi, Biochem. Pharmacol., 2005, 69, 395. 90 H. Kim, H. Kong, B. Choi, Y. Yang, Y. Kim, M. J. Lim, L. Neckers and Y. Jung, Pharm. Res., 2005, 22, 1499. 91 M. Miyake, N. Arai, S. Ushio, K. Iwaki, M. Ikeda and M. Kurimoto, Biosci., Biotechnol., Biochem., 2003, 67, 1199. 92 J. L. Pang, D. A. Ricupero, S. Huang, N. Fatma, D. P. Singh, J. R. Romero and N. Chattopadhyay, Biochem. Pharmacol., 2006, 71, 818. 93 S. F. Yan, R. Ramasamy and A. M. Schmidt, Nat.Clin.Pract.Endocrinol.Metab, 2008, 4, 285. 94 J. M. Kim, E. K. Lee, D. H. Kim, B. P. Yu and H. Y. Chung, Age, 2010, 32, 197.



View Online

95 M. J. Park, E. K. Lee, H. S. Heo, M. S. Kim, B. Sung, M. K. Kim, J. Lee, N. D. Kim, S. Anton, J. S. Choi, B. P. Yu and H. Y. Chung, J. Med. Food, 2009, 12, 351. 96 X. K. Fang, J. Gao and D. N. Zhu, Life Sci., 2008, 82, 615. 97 O. Weinreb, S. Mandel, T. Amit and M. B. Youdim, J. Nutr. Biochem., 2004, 15, 506. 98 P. V. Babu and D. Liu, Curr. Med. Chem., 2008, 15, 1840. 99 H. Ruan, Y. Yang, X. Zhu, X. Wang and R. Chen, Neurosci. Lett., 2009, 450, 152. 100 H. Schroeter, J. P. Spencer, C. Rice-Evans and R. J. Williams, Biochem. J., 2001, 358, 547. 101 R. Li, Y. G. Huang, D. Fang and W. D. Le, J. Neurosci. Res., 2004, 78, 723. 102 J. Y. Jung, C. R. Han, Y. J. Jeong, H. J. Kim, H. S. Lim, K. H. Lee, H. O. Park, W. M. Oh, S. H. Kim and W. J. Kim, Neurosci. Lett., 2007, 411, 222. 103 M. Bose, J. D. Lambert, J. Ju, K. R. Reuhl, S. A. Shapses and C. S. Yang, J.Nutr., 2008, 138, 1677. 104 T. Ueno, T. Torimura, T. Nakamura, R. Sivakumar, H. Nakayama, S. Otabe, X. Yuan, K. Yamada, O. Hashimoto, K. Inoue, H. Koga and M. Sata, Int.J.Mol.Med., 2009, 24, 17. 105 J. M. Yun, I. Jialal and S. Devaraj, Br. J. Nutr., 2010, 103, 1771. 106 Y. Zheng, M. Toborek and B. Hennig, Metabolism, 2010. 107 R. Singh, S. Ahmed, C. J. Malemud, V. M. Goldberg and T. M. Haqqi, J. Orthop. Res., 2003, 21, 102. 108 H. J. Yun, W. H. Yoo, M. K. Han, Y. R. Lee, J. S. Kim and S. I. Lee, Rheumatol. Int., 2008, 29, 23. 109 A. Morinobu, W. Biao, S. Tanaka, M. Horiuchi, L. Jun, G. Tsuji, Y. Sakai, M. Kurosaka and S. Kumagai, Arthritis Rheum., 2008, 58, 2012. 110 C. H. Lee, T. S. Jeong, Y. K. Choi, B. H. Hyun, G. T. Oh, E. H. Kim, J. R. Kim, J. I. Han and S. H. Bok, Biochem. Biophys. Res. Commun., 2001, 284, 681. 111 S. C. Choe, H. S. Kim, T. S. Jeong, S. H. Bok and Y. B. Park, J. Cardiovasc. Pharmacol., 2001, 38, 947. 112 E. J. Lee, D. I. Kim, W. J. Kim and S. K. Moon, Mol. Nutr. Food Res., 2009, 53, 1582. 113 H. Ekmekci and O. B. Ekmekci, Clin.Appl.Thromb.Hemost., 2006, 12, 163. 114 L. Liu, S. Shan, K. Zhang, Z. Q. Ning, X. P. Lu and Y. Y. Cheng, Phytother. Res., 2008, 22, 1400. 115 E. E. Mulvihill, J. M. Assini, B. G. Sutherland, A. S. DiMattia, M. Khami, J. B. Koppes, C. G. Sawyez, S. C. Whitman and M. W. Huff, Arterioscler., Thromb., Vasc. Biol., 2010, 30, 742. 116 Y. R. Jin, X. H. Han, Y. H. Zhang, J. J. Lee, Y. Lim, T. J. Kim, H. S. Yoo and Y. P. Yun, J. Cell. Biochem., 2008, 104, 1. 117 L. Liu, D. M. Xu and Y. Y. Cheng, J. Agric. Food Chem., 2008, 56, 824. 118 K. Vafeiadou, D. Vauzour, H. Y. Lee, A. Rodriguez-Mateos, R. J. Williams and J. P. Spencer, Arch. Biochem. Biophys., 2009, 484, 100. 119 S. Nagarajan, J. Nutr. Biochem., 2010, 21, 255. 120 H. Si and D. Liu, Curr. Med. Chem., 2007, 14, 2581. 121 Y. W. Lee and W. H. Lee, J. Nutr. Biochem., 2008, 19, 819. 122 B. K. Chacko, R. T. Chandler, T. L. D’Alessandro, A. Mundhekar, N. K. Khoo, N. Botting, S. Barnes and R. P. Patel, J.Nutr., 2007, 137, 351. 123 S. Kim, H. J. Shin, S. Y. Kim, J. H. Kim, Y. S. Lee, D. H. Kim and M. O. Lee, Mol. Cell. Endocrinol., 2004, 220, 51.


124 S. Nagarajan, R. L. Burris, B. W. Stewart, J. E. Wilkerson and T. M. Badger, J.Nutr., 2008, 138, 332. 125 A. Bermejo, A. Zarzuelo and J. Duarte, J. Cardiovasc. Pharmacol., 2003, 42, 329. 126 S. Hooshmand, d. Y. Soung, E. A. Lucas, S. V. Madihally, C. W. Levenson and B. H. Arjmandi, J. Nutr. Biochem., 2007, 18, 609. 127 J. Wang, Q. Zhang, S. Jin, D. He, S. Zhao and S. Liu, Maturitas, 2008, 59, 405. 128 M. Yalniz, I. H. Bahcecioglu, N. Kuzu, O. K. Poyrazoglu, O. Bulmus, S. Celebi, B. Ustundag, I. H. Ozercan and K. Sahin, J. Gastroenterol. Hepatol., 2007, 22, 2009. 129 O. A. Gudbrandsen, H. Wergedahl and R. K. Berge, Nutrition, 2009, 25, 574. 130 C. Charles, J. Yuskavage, O. Carlson, M. John, A. S. Tagalicud, M. Maggio, D. C. Muller, J. Egan and S. Basaria, Menopause, 2009, 16, 395. 131 X. Wang, S. Chen, G. Ma, M. Ye and G. Lu, NeuroReport, 2005, 16, 267. 132 S. L. Valles, P. Dolz-Gaiton, J. Gambini, C. Borras, A. Lloret, F. V. Pallardo and J. Vina, Brain Res., 2010, 1312, 138. 133 J. Seibel, A. F. Molzberger, T. Hertrampf, U. LaudenbachLeschowski and P. Diel, Eur. J. Nutr., 2009, 48, 213. 134 J. A. Corbett, G. Kwon, M. H. Marino, C. P. Rodi, P. M. Sullivan, J. Turk and M. L. McDaniel, Am.J.Physiol, 1996, 270, C1581. 135 D. X. Hou, M. Fujii, N. Terahara and M. Yoshimoto, J. Biomed. Biotechnol., 2004, 2004, 321. 136 W. R. Leifert and M. Y. Abeywardena, Nutr. Res., 2008, 28, 729. 137 S. Zafra-Stone, T. Yasmin, M. Bagchi, A. Chatterjee, J. A. Vinson and D. Bagchi, Mol. Nutr. Food Res., 2007, 51, 675. 138 Y. H. He, C. Xiao, Y. S. Wang, L. H. Zhao, H. Y. Zhao, Y. Tong, J. Zhou, H. W. Jia, C. Lu, X. M. Li and A. P. Lu, Zhongguo Zhong.Yao Za Zhi., 2005, 30, 1602. 139 J. W. Xu, K. Ikeda and Y. Yamori, Atherosclerosis, 2007, 193, 299. 140 M. H. Oak, J. E. Bedoui, S. V. Madeira, K. Chalupsky and V. B. Schini-Kerth, Br. J. Pharmacol., 2006, 149, 283. 141 J. C. Choy, D. J. Granville, D. W. Hunt and B. M. McManus, J. Mol. Cell. Cardiol., 2001, 33, 1673. 142 S. Martin, L. Favot, R. Matz, C. Lugnier and R. Andriantsitohaina, Biochem. Pharmacol., 2003, 65, 669. 143 S. Martin, G. Giannone, R. Andriantsitohaina and M. C. Martinez, Br. J. Pharmacol., 2003, 139, 1095. 144 C. Y. Chen, L. Yi, X. Jin, M. T. Mi, T. Zhang, W. H. Ling and B. Yu, Chem.-Biol. Interact., 2010, 183, 105. 145 S. E. Rasmussen, H. Frederiksen, K. K. Struntze and L. Poulsen, Mol. Nutr. Food Res., 2005, 49, 159. 146 S. D. Sharma and S. K. Katiyar, Pharm. Res., 2010, 27, 1092. 147 M. O. Shin, S. Yoon and J. O. Moon, Arch. Pharmacal Res., 2010, 33, 167. 148 M. H. Pan, S. Y. Lin-Shiau, C. T. Ho, J. H. Lin and J. K. Lin, Biochem. Pharmacol., 2000, 59, 357. 149 C. Y. Lo, S. Li, D. Tan, M. H. Pan, S. Sang and C. T. Ho, Mol. Nutr. Food Res., 2006, 50, 1118. 150 Y. C. Liang, D. C. Tsai, S. Y. Lin-Shiau, C. F. Chen, C. T. Ho and J. K. Lin, Nutr. Cancer, 2002, 42, 217.

Food Funct., 2010, 1, 15–31 | 31

View Online

REVIEW


Review of in vitro digestion models for rapid screening of emulsion-based systems David Julian McClements* and Yan Li

Downloaded on 21 October 2010 Published on 24 September 2010 on http://pubs.rsc.org | doi:10.1039/C0FO00111B

Received 6th August 2010, Accepted 7th September 2010 DOI: 10.1039/c0fo00111b There is increasing interest in understanding and controlling the digestion of emulsified lipids within the food and pharmaceutical industries. Emulsion-based delivery systems are being developed to encapsulate, protect, and release non-polar lipids, vitamins, nutraceuticals, and drugs. These delivery systems are also being used to control the stability and digestion of lipids within the human gastrointestinal tract so as to create foods that enhance satiety and reduce hunger. In vitro digestion models are therefore needed to test the efficacy of different approaches of controlling lipid digestion under conditions that simulate the human gastrointestinal tract. This article reviews the current status of in vitro digestion models for simulating lipid digestion, with special emphasis on the pH stat method. The pH stat method is particularly useful for the rapid screening of food emulsions and emulsion-based delivery systems with different compositions and structures. Successful candidates can then be tested with more rigorous in vitro digestion models, or using animal or human feeding studies.

1. Introduction There is growing interest in understanding and controlling the digestibility of lipids within the human gastrointestinal (GI) tract.1–5 The pharmaceutical industry is using this knowledge to design lipid-based delivery systems that either increase the bioavailability of highly lipophilic drugs or that deliver these drugs to specific locations within the GI tract.6,7 The food industry is using a similar approach to design food-grade delivery systems to encapsulate, protect, and release bioactive lipid components, with the aim of either improving their bioavailability or controlling their delivery.4,5,8,9 There are a number of bioactive lipid components that may benefit from encapsulation within this type of delivery system, including u-3 fatty acids, conjugated linoleic acid, butyrate, phytosterols, carotenoids, antioxidants, coenzyme Q, and vitamins A and D.4,10–14 The availability of effective delivery systems for lipophilic bioactive components could lead to the creation of functional foods specifically designed to maintain or improve human health. Functional foods could be designed to increase the digestibility of lipids in individuals with health conditions that impair the normal digestive process.1,15 Functional foods could be designed to control human satiety, satiation, and hunger by controlling the rate and extent of lipid digestion in different regions of the GI tract.16–20 For example, recent studies show that emulsions that remain stable to gravitational separation in the stomach and/or which have a delayed digestion in the small intestine can stimulate the release of gut hormones that induce satiety and reduce food intake.21,22 Functional foods could be designed to deliver bioactive components to specific locations within the GI tract where they can exhibit their functional attributes, e.g., anticancer components could be released in the colon.23 Analytical tools are needed to screen the efficacy of the various emulsion-based delivery systems that have been designed and Biopolymers and Colloids Research Laboratory, Department of Food Science, University of Massachusetts, Amherst, MA, 01003, USA

32 | Food Funct., 2010, 1, 32–59

developed to control lipid digestion and release. Ultimately, the efficacy of newly designed delivery systems should be tested in animal or human feeding studies, but there are ethical, economic, and practical reasons that make this unrealistic. Some prototype delivery systems may be unsafe or unsuitable for human consumption. Animal feeding studies often involve subjecting animals to uncomfortable conditions and/or sacrifice. Feeding studies are usually expensive, time-consuming, and prone to appreciable subject-to-subject variations. Consequently, there is a need for in vitro analytical tools that can be used to screen delivery systems before more extensive animal or human studies are carried out.4,5 The purpose of this article is to provide an overview of some of the most commonly used in vitro testing methods for studying the digestion of emulsified lipids. We begin by providing a brief overview of the physicochemical and physiological processes that occur when emulsified lipids pass through the human gastrointestinal tract. There have been major advances in this area over the past decade or so, which have greatly facilitated the design of in vitro test methods. Next, we define the concept of lipid bioavailability in the context of the digestion and release of lipophilic components. Finally, we describe a number of in vitro methods that have been developed to test the digestion of emulsified lipids, discussing their relative advantages and disadvantages. In particular, we focus on the pH stat method, which is finding increasing utilization as a convenient tool for rapidly screening different emulsion-based systems.

2. Overview of in vivo lipid digestion An understanding of the basic physicochemical and physiological processes that occur as an emulsified lipid passes through the human gastrointestinal (GI) tract is required to develop effective in vitro models that accurately simulate lipid digestion.4,5,8,14,24 After ingestion, emulsified lipids experience a complex series of physical and chemical changes as they pass through the mouth, stomach, small intestine, and large intestine, which affect their ability to be digested and/or absorbed (Fig. 1 and 2). In this This journal is ª The Royal Society of Chemistry 2010


View Online

Fig. 1 Schematic diagram of the physicochemical conditions in the different regions of the the human GI tract. Picture of human body was obtained from http://en.wikipedia.org/wiki/Digestive_tract (Copyright free).

section, we provide an overview of the major physicochemical and physiological events that occur in each region of the GI tract. A more detailed description has been given in several recent review articles.4,5,25,26

2.1.

Passage through the gastrointestinal tract

We begin by providing an overview of the composition and properties of the various regions within the GI tract.

2.1.1. Pre-ingestion. The lipid droplets in foods and beverages have a variety of different compositions, physical states, and structural properties.27 The lipid phase may be either nondigestible (e.g., mineral oils) or digestible (e.g., triacylglycerol oils). It may vary in its physical state and polymorphic form, e.g., being liquid, solid, or partially solid at body temperature. Lipid droplets are usually surrounded by a coating consisting of emulsifier molecules and other adsorbed matter. The most common emulsifiers used in foods are proteins, polysaccharides, surfactants and phospholipids.28–30 Additional materials (such as minerals, solid particles, or biopolymers) may adsorb on top of these emulsifier layers. Consequently, lipid droplet coatings may vary in their electrical charge, thickness, permeability, environmental responsiveness, resistance to displacement, and susceptibility to enzymatic digestion.27 The lipid droplets themselves may vary in their physical dimensions (e.g., particle size distribution and shape) and in their aggregation state (e.g., isolated, flocculated or partially coalesced). There may also be considerable variations in the physicochemical and structural properties of the matrix that surrounds the lipid droplets. The droplets may be simply dispersed within a low viscosity aqueous liquid (as in soft drinks, nutritional beverages, or milk), they may be embedded within larger particles (as in filled hydrogel particles), or they may be distributed within macroscopic gel-like or solid matrices (as in jellies, meat products, cheese, ice cream, or hard candies). Many of these factors may impact the behavior, digestibility, and ultimate fate of lipid droplets within the human GI tract. Indeed, there have been concerted efforts recently to rationally design emulsion-based delivery systems to control lipid digestibility based on knowledge of these and other factors.4,5,14,21,22,31 2.1.2. Mouth. The main function of the mouth is to ingest the foods, and to convert them into a form suitable for swallowing.

Fig. 2 Schematic diagram of the complex physicochemical and physiological processes that may occur during lipid digestion and absorption of emulsified lipids in the human GI tract.


Food Funct., 2010, 1, 32–59 | 33


View Online

The composition, structure, and properties of lipid droplets change appreciably during mastication due to the complex physiochemical and physiological processes that occur within the human mouth.32–35 An ingested food or beverage undergoes a number of processes: it is mixed with saliva; it may change its pH, ionic strength, and temperature; it may be acted upon by various digestive enzymes (e.g., lingual lipase, amylase, protease); it may interact with biopolymers in the saliva (e.g., mucin); it may interact with the surfaces of the tongue and mouth; it experiences a complex flow profile; and, it may be physically broken down into smaller pieces by chewing.36–43 Ideally, all of these factors should be simulated in an in vitro digestion model, although in practice many of them are often ignored because they are assumed not to have a major impact on lipid digestion. One of the most important factors that influence the behavior of emulsified lipids in the mouth is their interaction with saliva. Human saliva is usually around pH 5.5 to 6.1 during fasting and around pH 7 to 8 after food ingestion.44 Saliva is typically secreted at a rate of about 0.2 to 4 ml per minute,35 with a total saliva output of 500 to 1500 mL per day.36 Saliva contains water (99%), minerals ( T20 Digestion induces a change in lipid composition which affects the solubilization capacity of the lipid phase Protein interfacial cross-linking did not have a big impact on lipid digestion Emulsifier type effects aggregation behavior of lipid droplets throughout in vitro digestion model Dietary fiber type effects aggregation behavior of lipid droplets throughout in vitro digestion, through bridging and/ or depletion mechanisms. Solid fat particles are digested more slowly than lipid fat droplets.

M: pH 7 (1 h) S: pH 2 (1 h) SI: pH 5.3, pancreatic lipase, bile (2 h) SI: pH 7.5 (2 h) SI: pH 7.5, CaCl2 (2 h)

SI: (Pancreatic lipase, bile salts)

SI: (Pancreatic lipase, bile salts)

M: (a-amylase, Mucin, BSA) S: (Pepsin, Mucin) SI: (Pancreatin, Lipase, Bile salt)

Digestion rate increases with decreasing droplet size, decreasing oil molecular weight, but does not depend strongly on emulsifier type The rate and extent of lipid digestion was decreased when chitosan and chitosan/alginate coatings were present around droplets

SI: (Pancreatic lipase, bile salts, pH 7)


Lipid droplets with different initial protein compositions are all digested


M: pH 7 (1 h) S: pH 2 (1 h) SI: pH 5.3, pancreatic lipase, bile (2 h) SI: pH 7.5 (2 h) SI: (Pancreatic lipase, bile salts, pH 7)


Comments

Digestion Steps Modeled

209

172

208

155

195

192

207

206

131

132

202

References

Table 1 Summary of previous studies using in vitro digestion models used to investigate the digestion and absorption of emulsified food lipids. Samples Tested Key: SEDS ¼ Self-emulsifying delivery system; O ¼ Oil; E ¼ Emulsifier. Digestion Steps Key: M ¼ mouth, S ¼ stomach; SI ¼ small intestine; C ¼ colon. All were carried out at 37 C unless stated. Emulsifier type: LF ¼ lactoferrin; BLG ¼ blactoglobulin; WPI ¼ whey protein isolate; Cas ¼ caseinate; T20 ¼ Tween 20; Chit ¼ Chitosan; Alg ¼ Alginate; MG ¼ monoglyceride; CHO ¼ carbohydrate


View Online

Food Funct., 2010, 1, 32–59 | 41

42 | Food Funct., 2010, 1, 32–59 Optical microscopy z-potential Particle size Appearance FFA, Glucosamine z-potential Particle size FFA release Optical microscopy z-potential Particle size FFA z-potential Particle size FFA Lipolysis products

Lipolysis products

SDS-PAGE Particle size z-potential Optical microscopy Interfacial tension Bioaccessibility FFA released

Particle size z-potential FFA released Interfacial tension Particle size FFA released Protein analysis Particle size z-potential Microstructure FFA released

Polysaccharides

Polysaccharide type TPP concentration Interfacial composition

Bile type [Bile] [Calcium] Triglycerides type

Triglycerides type Emulsifiers Protein type Protein adsorption

Oil amount Emulsifier type NaCl & CaCl2 Emulsifier type

Emulsifier type Microstructure

O/W Emulsions O ¼ Tuna oil E ¼ Lec, Lec/Chit

O/W Emulsions O ¼ Corn oil E ¼lyso-Lec, lyso-Lec/Chit

O/W Emulsions O ¼ Corn oil E ¼ Lec, Lec/Chit, Lec/Chit/Pec

O/W Emulsions O ¼ olive oil E ¼ phosphatidylcholine

Oil O ¼ MCT, soybean oil

O/W Emulsions O ¼ triacylglycerols E ¼ PEG

O/W Emulsions O ¼ Olive oil E ¼ b-Cas/BLG

Oil suspension

SEDDS O ¼ Soybean oil E ¼ Tweens, Spans

O/W Emulsion O ¼ Olive oil E ¼ Galactolipids

Oil bodies & O/W emulsions O ¼ Sunflower seed oil E ¼ Natural, WPI or T20 O/W Emulsion O ¼ Fish oil E ¼ Cas, Cas-CHO complex Emulsifier type

Parameters Measured

Experimental Variables

Samples Tested

Table 1 (Contd. )

Increasing amounts of chitosan reduced the amount of FFA produced. Chitosan was degraded by lipase Coating droplets with non-cross linked or cross-linked chitosan decreased the digestion rate. Coating droplets with chitosan decreased lipid digestion, but having an additional pectin coating increased digestion again. FFA released increased with increasing calcium concentration by amount depending on bile type The rate and extent of lipid digestion was faster for medium chain triglycerides than long chain triglycerides Formulation effects solubilization of encapsulated drugs in mixed micelles Protein hydrolysis by proteases is altered when adsorbed to lipid droplet surfaces

M: pH 7 (1 h) S: pH 2 (1 h) SI: pH 5.3, pancreatic lipase, bile (2 h) SI: pH 7.5 (2 h) SI: (Pancreatic lipase, bile salts, pH 7) SI: (Pancreatic lipase, bile salts, pH 7)

S: pH 5.5 (0.5 h) SI: pH 6.25, pancreatic lipase, bile (1 h) S: pH 2.5 (1 h) SI: pH 6.5, pancreatic lipase, bile (0.5 h)

Increasing the oil content increases the bioaccessibility of lipophilic components Digestion rate increases with calcium addition, and depends on surfactant type Digestion rate depends on surfactant type

Digestion of oil bodies is slower than emulsion droplets Interfacial covalent (Maillard) caseinate-carbohydrate complexes protect droplets against coalescence

S: pH 2.0 (1 h) SI: pH 7.5, pancreatic lipase, bile (0.5 h) SI: pH 6.5, pancreatic lipase, bile (0.5 h) SI: pH 7.0, pancreatic lipase, bile (0.5 h)

SI: pH 7.0, pancreatic lipase, bile S: pH 1.5, pepsin (1 h) SI: pH 6.8, pancreatin, bile (2 h)

SI: (Pancreatic lipase/colipase, bile salts/, pH 7.5)

SI: (Pancreatic lipase, bile salts, pH 7.5)

Comments



216

215

84

175

214

178

213

124, 212

211

86

72

210

References

View Online


This journal is ª The Royal Society of Chemistry 2010 Dietary fibers can inhibit lipid digestion by an amount depending on their structure Gastric lipase has greater activity on the fine emulsion. Free fatty acid concentration plays a key role in the progressive inhibition of lipolysis MCT is hydrolyzed faster than LCT. Lipolysis rate is increased with decreasing particle size. Calcium is a key factor during digestion

S: human gastric juice (0.5 h)

S: pH 5.4, gastric juice (0–0.5 h) SI: pH 7.5, pancreatin, bile (1 h)

Particle size Lipase activity

Particle size Pancreatic lipase activity

Droplet size Triglycerides type Hydrolysis of gastric lipase Droplet size Triacylglycerol composition Calcium pH

O/W Emulsion O ¼ LCT & MCT E ¼ Lec, Sugar esters

O/W Emulsion O ¼ LCT & MCT E ¼ Lec, Sugar esters

Extract Effects

O/W Emulsion O ¼ SCT, LCT E ¼ Lec O/W Emulsion O ¼ Triolein E ¼ Lec

SI: pH 7.5, pancreatin, bile (0.5 h)

SI: pH 7.5, pancreatin, bile (0.5/1 h)

Particle size Viscosity FFA released

Oil type

Oil suspension O ¼ MCT, LCT

Polysaccharide type (guar gum, gum arabic, pectin)

Drug solubilization

Oil type

SI: pH 6.5, pancreatin (10 min)

S: pH 5.4, gastric juice (0.5 h) SI: pH 7.5, pancreatin, bile (1 h)

FFA released

Oil type [Lipase]

Oil O ¼ SCT, MCT, LCT E ¼ MG SMEDDS O ¼ SCT, MCT, LCT E ¼ Surfactants

Interfacial covalent (Maillard) caseinate-carbohydrate complexes reduced lipid digestion. Initial digestion rate increased with [Lipase] and depends on oil type

Particle size FFA released

Particle size Viscosity Microstructure FFA released Microstructure FFA released

Emulsifier type

O/W Emulsion O ¼ Fish oil E ¼ Cas, Cas-CHO complex

The digestion rate depends on initial emulsifier type, with MG inhibiting digestion

TIM Model - Dynamic S: Acid pH, pepsin, lipase, minerals SI: z Neutral pH, pancreatin, bile SI: pH 6.8, pancreatin, bile (0.5 h)

Lipid composition can influence drug solubilization behavior and formulation affects the lipid digestion rate TG-drug suspension has relatively high solubilizing capacity of colloidal phases produced on TG digestion A green tea extract inhibits lipid digestion

FFA released Interfacial tension

Emulsifier type

O/W Emulsion O ¼ Fish oil E ¼ MG, BLG, Lyso-Lec

Comments


SI: pH 7.5, pancreatin, bile (0.5 h)

Parameters Measured


Samples Tested

Table 1 (Contd. )


125

198

222

221

220

218, 219

163

217

200

References

View Online

Food Funct., 2010, 1, 32–59 | 43


View Online

models involve adjusting the sample to a highly acidic pH (e.g., pH 1.2) for a fixed period (e.g., 2 h) with some form of mechanical agitation (e.g., stirring). More sophisticated digestion models include a range of different components in the SGF, including acids, buffers, salts, organic molecules, biopolymers, phospholipids, and digestive enzymes.44,57,108 In particular, it is important to note that the stomach contains gastric lipase, which may promote some initial lipid digestion within the stomach. Recipes for preparing simulated gastric juices of varying complexity have been published.2,108,113 A mechanical gut model has been developed to simulate the complex flow profiles, dynamic secretions, and mechanical forces that occur in the human stomach by researchers at the Institute of Food Research (Norwich, UK).114 Most researchers ignore droplet interactions with the surfaces of the stomach in their in vitro digestion models due to the inherent complexity of simulating the stomach’s surface in the laboratory. Nevertheless, these interactions may be important in applications where the lipid droplets are designed to adhere to the stomach wall lining. The test sample that results from mixing the food sample with the simulated gastric fluid can be referred to as the ‘‘chyme sample’’. 5.2.3. Small intestine. The major factors that need to be considered when designing an in vitro digestion step to simulate the behavior of lipid droplets within the small intestine are pH changes (from acid to neutral), enzyme activities (particularly lipase), biological surfactants (particularly bile and phospholipids), and mineral content (particularly calcium). Simulated small intestinal fluids (SSIF) of varying compositional complexity have previously been used within in vitro digestion models (Table 1). The simplest SSIF usually contain a mixture of lipase (or pancreatin) and bile salts (or bile extract) at a pH around neutral. More sophisticated models utilize SSIF that contain buffers, salts, small organic molecules, proteins, enzymes, co-enzymes, bile salts and phospholipids.2,44,108 SSIF composition has been shown to play a major role in determining the rate and extent of lipid digestion determined using in vitro models (see below). It is therefore important to establish an appropriate SSIF composition for a particular sample being tested, e.g., the type and concentration of the components within the SSIF that accurately reflect what happens in vivo. As in the stomach, most researchers ignore the interactions of the lipid droplets with the surfaces of the small intestine in their in vitro digestion models. Nevertheless, a number of researchers have recently examined the impact of the mucous layer on the behavior of lipid droplets and other particles under simulated small intestinal conditions.115 The lipid droplets may become trapped within the mucous layer depending on their size and charge, which is likely to impact how quickly they are digested and absorbed. The test sample that results from mixing the food sample with the simulated small intestinal fluid can be referred to as the ‘‘digest sample’’. 5.2.4. Colon. The colon is one of the most difficult regions to simulate in the laboratory. In vitro testing methods designed to simulate the nutritional and environmental conditions in the human large intestine range from simple static batch microbial 44 | Food Funct., 2010, 1, 32–59

cultures to multiple stage continuous cultures.116–118 A food sample is typically incubated in one or more simulated colonic fluids (SCF) that contain populations of bacteria representative of those normally found in the human large intestine. These bacteria may be cultivated from animal caecal contents or human feces. One difficulty in accurately simulating the human colon is the considerable variations in bacterial populations that exist between individuals. Rather than using bacteria, it is possible to formulate SCF that contain a mixture of enzymes typically produced by colonic bacteria e.g., glycosidases to degrade dietary fibers and proteases to degrade proteins.80,119 Due to the difficulties in setting up and maintaining in vitro colonic models many researchers prefer to go directly to animal models.117 Alternatively, if there is strong evidence that the sample is fully digested and absorbed within the small intestine, then this step can be ignored. 5.3.

In vitro versus in vivo correlations

In vitro studies offer several advantages over in vivo studies, because they are usually faster, less expensive, more versatile, and provide more details about physicochemical mechanisms.2,105,120 Nevertheless, it is extremely difficult to accurately mimic the complex physicochemical and physiological processes that occur in the human digestive tract. For this reason, it is usually advisable to combine in vitro studies with in vivo studies using animals and humans (where possible). In addition, it is important to establish in vitro–in vivo correlations to ensure that any in vitro method being used to test a particular sample is reliable.2,121,122 In this case, the rate and/or extent of lipid digestion may be measured for similar test samples using an in vitro method (e.g., pH stat) and an in vivo method (e.g., human feeding study), and then the results correlated to one another. Eventually, one would like to obtain mathematical models that can predict the real-life performance of a sample from results obtained using an in vitro test model. 5.4.

Physicochemical parameters measured in digestion studies

A variety of analytical techniques can be used to characterize the changes in the properties of emulsified lipids as they pass through simulated GI conditions. A number of the most important and commonly used are highlighted in this section: 5.4.1. Enzyme activity: Formation of digestion products. A variety of digestive enzymes are active in different locations within the human GI tract, including lipases, phospholipases, proteases, amylases, and glycosidases.51,63,80 An accurate in vitro digestion model should therefore contain appropriate types and levels of digestive enzymes, which will depend on the nature of the sample being tested. Lipases. One of the most important parameters to measure in an in vitro digestion model is the rate and extent of lipid digestion due to the activity of gastric and/or pancreatic lipase, i.e., conversion of triacylglycerols (TAG) and diacylglycerols (DAG) into monoacylglycerols (MAG) and free fatty acids (FFA). The most widely used method of measuring lipid digestion is to determine the amount of free fatty acids produced by titration This journal is ª The Royal Society of Chemistry 2010


View Online

with an alkali solution.120 The automated ‘‘pH-stat method’’ based on this principle is discussed in a latter section (Section 6). Nevertheless, other methods can also be used. For example, the amounts of triacylglycerols, diacylglycerols monoacylglycerols, free fatty acids and phospholipids present in the system can be determined at specific digestion times using chromatography methods, such as thin layer chromatography or TLC.123,124 The concentration of specific fatty acids in the lipid and/or aqueous phases can be measured over time using gas chromatography.123 This information can be used to determine which chain lengths, degrees of saturation, and sn-positions of fatty acids on the triacylglycerols molecules are most susceptible to digestion. The human GI tract also contains phospholipases capable of removing free fatty acids from phospholipids and esterases capable of cleaving some non-ionic surfactants, and so it may be important to include these enzymes when testing systems containing these components.125 Proteases. If a lipid droplet is initially coated with a proteinbased emulsifier or if it is initially embedded within a proteinbased matrix, then it may be important to monitor the rate and extent of protein digestion, since this may indirectly influence lipid digestion.93,126 For example, the lipase may be unable to access the lipid droplet surfaces until the protein has been removed by hydrolysis into amino acids. Hence, the lipid digestion rate could depend on the protein digestion rate. Protein digestion can also be measured using the pH-stat method,127 although most previous studies have utilized chromatography (particularly HPLC) or electrophoresis (particularly SDSPAGE) to monitor the conversion of proteins into peptides and amino acids.93,113,128 The concentration and type of specific proteins present within a sample can be determined by combining electrophoresis and mass spectrometry methods.126 Glycosidases and amylases. If a lipid droplet is trapped within a dietary fiber or starch matrix, then it may be important to monitor the digestion of these components by glycosidases or amylases, respectively.80,118 The rate and extent of polysaccharide digestibility is typically monitored by determining the amount of monosaccharides released over time using chemical, enzymatic, chromatography, electrophoresis or spectroscopic methods. As with proteins, the lipid digestion rate may depend on the polysaccharide digestion rate if the lipid droplets are encapsulated within impenetrable polysaccharide matrices. 5.4.2. Particle size distribution and microstructure. The specific surface area of an emulsion is inversely related to the size of the droplets that it contains.129 Lipid digestion is an interfacial phenomenon that requires the lipase molecules to adsorb to oil droplet surfaces before hydrolysis can occur.15,63 Consequently, the rate of lipid digestion often depends on the size of the oil droplets in an emulsion.125,130 In addition, the size of the droplets may change as they pass through the different regions of the GI tract due to fragmentation, coalescence, flocculation, or digestion processes. Consequently, it is often important to have analytical tools to measure the particle size distribution of emulsions as they pass through simulated GI conditions. Optical microscopy techniques are suitable for studying emulsions that contain lipid droplets greater than about 1 mm in radius.98,99 This journal is ª The Royal Society of Chemistry 2010

Specific stains or dyes can be used to highlight particular components within an emulsion and determine its location, e.g., oil soluble dyes,113,131,132 protein stains,133 or polysaccharide stains.100 Thus, one can determine whether a component is present at the oil–water interface or dispersed within the surrounding aqueous phase, and whether its location changes during the digestion process. Electron microscopy (SEM or TEM) can also be used to measure the structural features and organization of the lipid droplets and other colloidal particles present in the digestive fluids. A number of instrumental methods are also available for measuring the particle size distribution (PSD) of emulsions, including static light scattering (SLS), dynamic light scattering (DLS), particle counting, and ultrasonic spectrometry.27,134 Each of these methods has a range of particle diameters that it can reliably detect. For example, SLS instruments can typically detect particles from about 0.1 to 1000 mm, whereas DLS instruments can detect particles in the range 1 nm to 5 mm. Instrumental particle size analyzers are able to provide rapid analysis of the full PSD of emulsion samples in a few minutes, and are therefore extremely convenient for monitoring changes in particle dimensions during the lipid digestion process. They can be used to monitor the breakup, coalescence, flocculation, or degradation of lipid droplets, or to determine the dimensions of other colloidal species present within the digestion fluids such as micelles or vesicles. Nevertheless, these instrumental methods often have a number of limitations when applied to studying lipid digestion. There are often many components within the sample itself or from the simulated GI fluids that can scatter light and therefore contribute to the measured particle size distribution. For example, there may be insoluble matter in the bile extract or pancreatin used to prepare SSIF that obscure the light scattering signal from the lipid droplets. It may therefore be advisable to filter these SSIF solutions prior to utilization in the in vitro digestion model. 5.4.3. Interfacial composition and properties. The composition and properties of the interfacial layer coating the lipid droplets usually changes as an emulsion passes through the GI tract. Consequently, it is useful to have analytical tools that can measure interfacial compositions or at least detect alterations in interfacial compositions. A number of direct and indirect methods have been used to obtain information about interfacial composition. Fluorescent probes can be used to tag surfaceactive species (such as proteins, phospholipids or polysaccharides) to determine changes in their location during the digestion process. The fluorescently-tagged molecules can either be observed directly under a fluorescent microscope or they can be analyzed by fluorescent spectroscopy. Front face fluorescence reflectance spectroscopy measurements can be carried out on emulsion samples without any sample preparation,135,136 whereas fluorescent transmission measurements can be carried out on transparent aqueous solutions after a suitable isolation step e.g., centrifugation, dialysis and/or filtration. Measurements of droplet charge (z-potential) can be used to provide information about changes in interfacial composition, e.g., due to the displacement of one surface-active substance by another.129,131 Knowledge of the droplet z-potential may also be important in its own right, since the charge on the droplets will determine how Food Funct., 2010, 1, 32–59 | 45


View Online

they interact with other components and surfaces within the GI tract. Cationic particles may become trapped within the anionic mucous layer (mucoadhesion), which will alter their ability to be digested and absorbed.137,138 Interfacial tension and rheology measurements are commonly used to detect changes in interfacial composition at planar air–water or oil–water interfaces, providing information that can be related to the behavior of lipid droplet surfaces under similar conditions.94,139 Chemical analysis methods can be used to measure changes in the aqueous phase composition during digestion, which can be used to infer changes in interfacial composition if the total amount of the component in the system is known: CAds ¼ CAq CTotal. A number of different microscopy methods have been used to examine the structural organization of adsorbed components at the oil–water interface, such as atomic force microscopy and confocal fluorescent microscopy.93,94 5.4.4. Formation of colloidal structures. A number of analytical tools have been used to characterize the various kinds of colloidal structures generated during the lipid digestion process, such as liquid crystals, mixed micelles and vesicles. These methods include light scattering,140,141 X-ray scattering,142,143 neutron scattering,144 electron microscopy,145,146 electron spin resonance and NMR.147 In addition, some techniques can provide information about the distribution of lipid digestion products between the oil, water and colloidal phases, e.g., electron paramagnetic resonance.148 The solubilization of digestion products and lipophilic components within the colloidal structures can usually be determined using standard analytical methods, e.g., chemical, spectroscopic, chromatographic or electrophoresis methods.

shear rheometers, uniaxial compression methods, and flow profiling techniques.27,149–151 The flow profiles in a reaction chamber can be monitored by imaging methods, such as those based on X-ray, NMR or acoustics. Alternatively, they can be simulated using appropriate mathematical models that take into account the geometry of the vessel and the nature of the applied mechanical forces.152 5.4.7. Physical state. A number of studies show that the physical state (solid versus liquid) of lipid droplets influences the rate and extent of their digestion.153–155 Consequently, it may be useful to determine the physical state of lipid droplets during passage through a simulated GI tract if a high melting point fat phase is used. The physical state of lipid droplets can be determined using a number of analytical techniques, including DSC and NMR.27 Information about the packing of the crystals within the lipid droplets can be obtained by X-ray diffraction studies.156,157 5.4.8. Release of lipophilic components. Researchers are often interested in monitoring the release of bioactive lipophilic components encapsulated within lipid droplets during the digestion process. One of the most commonly used methods is to centrifuge the digested sample (Fig. 4a), which typically separates

5.4.5. Binding interactions and aggregation. A number of different kinds of binding interactions may occur in the GI tract that could alter lipid digestibility: biopolymers may bind mineral ions, enzymes, lipid droplets, phospholipids, and surfactants; chelating agents may bind calcium; fatty acids and bile salts may bind calcium (Section 2.1.5). For example, cationic dietary fibers such as chitosan are known to strongly bind anionic bile salts, fatty acids, phospholipids, and lipid droplets, which may interfere with the normal digestion process.100 The method used to study the binding interactions will depend on the nature of the species involved. Some commonly used analytical methods include equilibrium dialysis, isothermal titration calorimetry, centrifugation, specific chemical reactions, chromatography, electrophoresis, and spectroscopy. 5.4.6. Flow profiles and rheology. The rheological characteristics of the digestive fluids in the GI tract may play an important role in determining the rate and extent of lipid digestion.61,113 For instance, their rheology may influence the flow profile and mechanical forces generated within the GI tract, or the mass transport of components through them. The rheology of digestive juices may range from low viscosity liquids, to visco-elastic fluids, to gel-like materials depending on their composition and environmental conditions. Consequently, it is often important to be able to characterize the rheological characteristics of the system. The rheology may be measured using a number of different analytical instruments, such as viscometers, dynamic 46 | Food Funct., 2010, 1, 32–59

Fig. 4 (a) Schematic of an in vitro digestion model used to determine the digestion and release of lipids encapsulated within nano-laminated lipid droplets. The picture of the pH-stat titrator is kindly donated by Metrohm USA, Inc. A triacylglycerol (TAG) is converted into two free fatty acids (FFA) and one monoacylglycerol (MAG) by lipase. (b) Schematic diagram of the three phases typically formed after centrifugation of the material remaining after digestion in simulated small intestine conditions.



View Online

into three different layers (Fig. 4b): a pellet at the bottom, an aqueous phase in the middle, and an oil phase at the top.158 The pellet typically contains dense insoluble matter, such as aggregates containing undigested proteins, dietary fibers, bile salts, free fatty acids, and minerals. For example, insoluble calcium soaps of free fatty acids are usually present in this layer. The aqueous phase typically contains mixed micelles and vesicles that contain bile salts, phospholipids, and lipid digestion products (MAG and FFA). In addition, any lipophilic agents that were originally encapsulated in the lipid droplets may be solubilized within the hydrophobic interiors of these micelles and vesicles, e.g., carotenoids. The cream layer contains any undigested lipid in the form of oil droplets or bulk oil. After centrifugation the different layers present can be collected separately and then analyzed to determine their composition, e.g., using chemical, spectroscopic, electrophoresis, or chromatographic methods. This approach can be used to determine the amount of lipophilic components released from the lipid droplets after digestion, which is important when determining the bioavailability of encapsulated substances.120,159 5.4.9. Absorption of lipophilic components. The absorption of lipophilic components (digestion products or encapsulated agents) by epithelium cells can be simulated in vitro using various physical, biological, or cell-culture models: Physical methods. For some types of lipid it is assumed that the amount of digestion products released from the sample is representative of the amount of digestion products absorbed by the epithelium cells, i.e., the rate limiting step is lipid digestion, rather than absorption. The amount of lipid digestion products released can be determined by measuring their concentration in the aqueous phase, which can be measured directly or after they have been separated from the rest of the material by centrifugation, filtration, or dialysis.160,161 For example, the free fatty acids released from emulsified lipid droplets through the action of pancreatic lipase can simply be measured by acid titration or enzymatic techniques.86,162,163 The concentration of specific bioactive lipids solubilized by mixed micelles/vesicles can be determined using a suitable analytical method, usually after the middle (micelle) phase has been separated from the cream layer and pellet by centrifugation.164–166 Ex vivo permeation methods. A section of the GI tract is cut from an animal after it has been sacrificed, and is then washed to remove any residual components. Part of the intestine is then clamped between two chambers: one of the chambers contains the sample to be analyzed (donor chamber), while the other chamber contains only buffer solution (receiver chamber).167 The transport of the samples across the chamber is then measured over time using suitable analytical methods. Alternatively, the sample to be tested can be placed inside an intact section of GI, which is then placed in an appropriate buffered solution. The amount of material that moves across the intestinal walls and into the surrounding buffer solution can then measured using an appropriate analytical method. Cell culture methods. Caco-2 cells are cell cultures that mimic the human intestinal epithelium.168–170 They can be used in two This journal is ª The Royal Society of Chemistry 2010

different ways to assess the absorption of lipid digestion products: (i) after the digested food material has been left in contact with a membrane coated with Caco-2 cells, the amount of lipid digestion products that pass through the coated membrane can be measured; (ii) the amount of lipid digestion products that are absorbed by the cells themselves can be determined. A suitable analytical technique can then be used to measure the location or quantify the amount of material absorbed, e.g., microscopy, chromatography, spectrometry or chemical methods.

6. pH-stat method 6.1.

Principle of the pH-stat method

The pH-stat method is an analytical tool widely used in pharmaceutical and food research for the in vitro characterization of lipid digestion under simulated small intestinal conditions.120,122,125,171 It is based on measurements of the amount of free fatty acids released from lipids, usually triacylglcyerols, after lipase addition at pH values close to neutral. The sample to be analyzed is placed within a temperature-controlled reaction chamber that contains simulated small intestinal fluid (SSIF) (Fig. 4a). The SSIF should contain appropriate levels of the major digestive components known to influence lipid digestion, such as lipase, co-lipase, bile salts, phospholipids, and mineral ions (Table 2). It is usually assumed that the lipase in the SSIF catalyzes lipid digestion leading to the generation of two FFAs and one MAG per TAG molecule, although further digestion can occur in some situations. The concentration of alkali (NaOH) that must then be added to the digestion cell to neutralize the FFAs produced by lipid digestion, and thereby maintain the pH at the initial pre-set value (e.g., pH 7.0), is recorded versus time (Fig. 4a). The pH-stat method is relatively simple and rapid to carry out and enables comparison of different systems under similar experimental conditions. This technique can therefore be used to rapidly screen the impact of different physicochemical factors expected to affect lipid digestion. Recently, a simple mathematical model was developed to describe the FFA versus time profiles obtained by the pH stat method.172 The percentage of total free fatty acids released (F) as a function of time (t) measured by the pH-stat method is characterized by the following equation: 2 ! 3kMt F ¼ fmax 1 1 þ (1) 2d0 r0 Here, fmax provides a measure of the total extent of digestion (i.e., the maximum percentage of the total FFA present that is released at the end of the reaction), k provides a measure of the rate of digestion (i.e., mmols of FFA released per unit droplet surface area per unit time), d0 is the initial droplet diameter, r0 is the oil droplet density, and M is the molar mass of the oil. A pHstat profile can then be characterized in terms of just two parameters: fmax and k, which can be determined by finding the values which give the best fit between the experimental data and the mathematical model. It should be noted that the pH stat method only simulates the small intestine, and it is usually necessary to simulate the other parts of the digestive tract to get more realistic results. For Food Funct., 2010, 1, 32–59 | 47

48 | Food Funct., 2010, 1, 32–59

O/W Emulsions

Oil SNEDDS O/W Emulsions

O/W Emulsions O/W Emulsions O/W Emulsions Oil suspension

O/W Emulsions

Oil suspension O/W Emulsions

Bile Ca2+ Lipase activity Interfacial composition Influence of dietary fiber Pancreatic lipase activity pH Bile Pancreatic lipase Lipid type Lipolysis time Lipase Bile Lipolysis time Lipid composition

Emulsifier type Ions pH Surfactant/Glycerides Triglycerides Emulsifier type

1000 TBU/mL 800 TBU/mL 0–10 mg/mL 200 tributyrin units/mL

10.5 mg/mL

2 nM (10 nM colipase) 0.4 mg/mL 1 mg/mL (Lipase:colipase ¼ 1 : 5) 0–4.8 mg/mL

0.2% 0.2% 0.2% 0.039 mg/mL 25 mg/mL 0.3% 10%

270–1340 units/mL

1000 IU/mL 2.9 mg/mL

50 mg/mL 0.4% 30.6 mM

2.5 mg/mL

1.6 mg/mL

Lipase

0.5%

0.4%

[CaCl2] [EDTA] [Bile]

O/W Emulsions O ¼ corn oil E ¼ BLG, lecithin, or caseinate

SEDDS

Lipid


Samples Tested

5 mM (1.25 mM phosphatidylcholine)

5/20 mM 5 mM (1 mM phosphatidylcholine) 0–25 mg/mL

9.7 mM 2.4 mg/mL 0–8 mM (0.74 mM phospholipid) 0–20 mg/mL

4–16 mM

5 mM 4.2 mg/mL

5 mM (1.25 mM lecithin)

0–5 mg/mL

Bile

5 mM

5 mM 0.045 mM/min 30 mM

0–30 mM

10 mM

4–20 mM

5 mM

5–20 mM

0–20 mM

Calcium

35 min

30 min 30 min 2h

0–2 h 2h 0–3 h 2h

2–24 h 5 min 2h 2h 40 min

20 min

20 min

Digestion times

7.5

7.5 6.5 7.5

7.0 7.5 7.5 6.5

6.5

6.8 6.5–7.0

6.5

7.0

pH

225

124,212 141 224

223 195,210 211 166

83

167 192

175

84

References

Table 2 Summary of the simulated small intestinal fluid compositions used in previous pH-stat studies of the digestion of emulsified lipids. All experiments were carried out at 37 C unless stated


View Online


View Online

example, a sample could be passed through a simulated mouth and stomach model, and then analyzed using the pH stat method.


6.2.

Influence of SSIF composition on the pH-stat method

One of the most important factors affecting the digestion rate determined using the pH-stat method is the composition of the simulated small intestinal fluid (SSIF) used.2 Previous researchers have used various SSIF compositions when carrying out in vitro lipid digestion studies using the pH stat method (Table 2). In addition, a number of workers have examined the influence of specific SSIF components on the rate and extent of lipid digestion. Ideally, the conditions used should closely simulate those found in the human GI tract (Section 2), and the digestion results obtained should correlate closely with those obtained using in vivo studies. The role of the major components within SSIF is highlighted below: 6.2.1. Lipase and other enzymes. Pancreatic lipase is the key component in any in vitro model designed to simulate lipid digestion within the small intestine. Consequently, it is important to use an appropriate type and concentration of pancreatic lipase in the pH-stat method. Previous researchers have used various types and forms of lipase in SSIF, including pancreatin, pancreatic lipases, and non-pancreatic lipases. Pancreatin is a complex mixture of digestive enzymes (lipase, protease, amylase, etc.) and other biological components produced by the exocrine cells of the pancreas, which is typically obtained from animal sources, such as pigs or cows. The chemical composition and functional performance of pancreatin (and consequently its enzyme activity) varies depending on its biological origin, isolation, and purification procedures, and hence there are often considerable batch-to-batch and supplier-to-supplier variations.173 Purified pancreatic lipases are also available commercially that have been isolated from various animal and human sources, although these are more expensive that using pancreatin. In addition, it is important to use an appropriate amount of colipase with pancreatic lipase to ensure its optimum performance. The advantage of using pancreatic lipases is that they are chemically more well-defined, and there is less batch-to-batch variation. Some researchers have used non-pancreatic lipase sources for their in vitro lipid digestion studies, e.g., Candida rugosa, Candida cylindracea, Rhizopus niveus, and Mucor meihei.174 These lipases have the advantage of been highly pure and reproducible, and less expensive than pancreatic lipase. However, they may not accurately mimic the behavior of pancreatic lipase in the lipid digestion process. The catalytic activity of lipase depends on its origin and history. For example, the catalytic activity of an enzyme ingredient may decrease if it is exposed to excessively high temperatures or if it is stored too long. Hence, researchers should be careful not to subject lipase ingredients to temperature abuse, and should prepare fresh lipase preparations for each experiment. The catalytic activity of lipase also depends on solution and environmental conditions, such as temperature, pH, ionic strength, and the presence of chemical denaturants.71,175–177 These conditions should therefore be standardized in any in vitro digestion test. It is therefore recommended that each batch of This journal is ª The Royal Society of Chemistry 2010

lipase should be standardized prior to utilization.120 A commonly used method for determining lipase activity is to measure the amount of free fatty acids released from a fixed amount of a standardized emulsified lipid (e.g., triolein or tributyrin) after a specific digestion time under standardized conditions (pH, ionic strength, temperature).120,167 Nevertheless, the rate of lipid digestion has previously been shown to depend on emulsifier type and droplet size distribution,130,131 and so these parameters should also be standardized. At present there is no consensus on the best values to use for these parameters. We propose using lyso-lecithin as a standard emulsifier since it can form stable emulsions and is readily available from chemical suppliers, and using lipid droplets with a standard mean diameter (d32) around 2 mm since these can be produced using simple high shear mixers and are fairly stable over the experimental time scales involved. The concentration of pancreatic lipase in the human small intestine depends on many factors, including the individual, health status, age, time of day, and type and amount of food consumed.15,63 It is therefore difficult to recommend one definitive lipase level to use in an in vitro test method. Ideally, one should examine a range of lipase concentrations that encompasses those typically found in the human GI tract. However, it is usually assumed that humans have a great excess of lipase in the GI tract, and so it is advisable to use a relatively high level of lipase in in vitro studies, e.g., equivalent to 2.4 mg/mL pancreatin. It should also be noted that there may be various other enzymes present in the small intestine that may directly or indirectly alter the rate of lipid digestion. If lipid droplets are coated by digestible emulsifiers (such as proteins, phospholipids, and some surfactants) or if they are embedded within gel-like or solid particles (such as proteins, or polysaccharides), then the digestion of these components may be important. For example, if lipid droplets are coated by a layer of adsorbed protein molecules, then this layer may have to be digested by proteases before the lipase can reach the triacylglycerols.93 Similarly, if lipid droplets are embedded within a protein hydrogel particle, then it may be necessary for the protein matrix to be fully or partially digested by proteases before the lipase can reach the triacylglycerols.13 Some of these other digestive enzymes are naturally present in pancreatin, e.g., proteases and amylases. On the other hand, it may be necessary to add some or all of these enzymes if pure pancreatic lipase or non-pancreatic lipase is used. For samples containing lipids encapsulated within other digestible components it would be informative to run experiments with and without non-lipase digestive enzymes to determine their influence on the overall lipid digestion rate. An example of the influence of lipase concentration on the rate and extent of lipid digestion of b-lactoglobulin stabilized corn oil-in-water emulsions measured using the pH stat method is shown in Fig. 5a. The rate and extent of lipid digestion increased as the lipase concentration in the reaction vessel increased. At low lipase levels (#0.2 mg/mL), FFAs were released slowly and most of the lipids within the droplets remained undigested after 30 min ( protein (caseinate or WPI).131 Nevertheless, in a recent study we found that the rate of lipid digestion was fairly similar for MCT oil-in-water emulsions stabilized by four different types of emulsifier: b-Lg, Tween 20, lecithin and lyso-lecithin.172 Dietary fiber coatings. It has been proposed that the rate of lipid digestion can be controlled by coating lipid droplets with one or more layers of dietary fiber.201 The rationale behind this proposal is the fact that dietary fibers should not be digested in the stomach or small intestine, and therefore they may prevent lipase from adsorbing to lipid droplet surfaces (provided the dietary fibers are not displaced from the droplet surfaces and that the layers formed are impermeable to lipase diffusion). The pH stat method has recently been used to study the impact of dietary fiber type, number of layers, sequence of layers, and layer crosslinking on the rate and extent of lipid digestion.72,86,201,202 These studies found that the lipid digestion rate could be decreased by 54 | Food Funct., 2010, 1, 32–59

depositing one or more dietary fiber layers around the lipid droplets, but that the droplets were still digested eventually. Dietary fiber coatings may therefore be a useful means of retarding lipid digestion in the human GI tract, which could be utilized for the development of functional foods to promote satiety. Droplet physical state. A number of in vitro studies have shown that the physical state of lipid droplets can influence their digestibility by pancreatic lipase.153,154,203,204 These studies found that solid lipid particles were digested by lipase, but at a slower rate than liquid lipid droplets. Recently, we carried out a study using two emulsions with the same lipid type (tripalmitin), but with one containing lipid droplets that were completely liquid and the other containing lipid particles that were completely solid.155 We found that the rate and extent of lipid digestion were greater in the emulsions containing liquid droplets, but that lipid digestion still occurred in the systems containing solid particles. Other researchers have shown that fat crystallization within lipid droplets may also indirectly influence the rate of lipid digestion.52 In this case, emulsions were designed so that they contained partly crystalline droplets that underwent partial coalescence in the small intestine.27,205 The partially coalesced emulsions exhibited slower digestion than stable emulsions, which was attributed to the fact that it was more difficult for the lipase molecules to reach the lipid droplet surfaces within the large clumps of fat droplets in the unstable system. Ingredient interactions. Foods and beverages generally have much more complicated compositions than the simple model systems used in in vitro digestion studies. A number of the components typically found in foods may impact lipid digestion. For example, we recently examined the influence of calcium binding agents (EDTA and alginate) on the rate and extent of lipid digestion.84 We found that both EDTA and alginate could greatly suppress the digestion of triacylglycerols containing long chain fatty acids, which was attributed to their ability to bind free calcium ions. Consequently, there would have been an accumulation of LCFA at the lipid droplet surfaces, which would have inhibited lipase activity.

7. Conclusions There has been growing interest by food scientists in understanding and controlling the digestion of lipids within the human gastrointestinal tract. The main driving forces for this interest are the development of emulsion-based delivery systems to encapsulate, protect and release lipophilic bioactive components within the GI tract, and the possibility of modulating human hunger and appetite by controlling the location and rate of lipid digestion within the GI tract. This article provides an overview of the major physicochemical events that occur during lipid digestion, and reviews a number of in vitro testing methods that have been developed to monitor lipid digestion. In particular, we focused on the pH stat method for simulating lipid digestion in the small intestine, since this method is useful as a rapid screening tool for studying the influence of product composition and structure on lipid digestibility. Considerable advances have been made in this area throughout the past decade, which is providing This journal is ª The Royal Society of Chemistry 2010

View Online

the fundamental knowledge required to rationally develop new food-based strategies to tackle food related diseases, such as heart disease, diabetes, cancer, and hypertension.

Acknowledgements This material is partly based upon work supported by United States Department of Agriculture, CREES, NRI Grants.


References 1 Y. Pafumi, et al., Mechanisms of inhibition of triacylglycerol hydrolysis by human gastric lipase, J. Biol. Chem., 2002, 277(31), 28070–28079. 2 C. J. H. Porter and W. N. Charman, In vitro assessment of oral lipid based formulations, Adv. Drug Delivery Rev., 2001, 50, S127–S147. 3 C. J. H. Porter, N. L. Trevaskis and W. N. Charman, Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs, Nat. Rev. Drug Discovery, 2007, 6(3), 231–248. 4 D. J. McClements, E. A. Decker and Y. Park, Controlling Lipid Bioavailability through Physicochemical and Structural Approaches, Crit. Rev. Food Sci. Nutr., 2009, 49(1), 48–67. 5 H. Singh, A. Q. Ye and D. Horne, Structuring food emulsions in the gastrointestinal tract to modify lipid digestion, Prog. Lipid Res., 2009, 48(2), 92–100. 6 C. J. H. Porter and K. M. Wasan, Lipid-based systems for the enhanced delivery of poorly water soluble drugs, Adv. Drug Delivery Rev., 2008, 60(6), 615–616. 7 C. W. Pouton, Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system, Eur. J. Pharm. Sci., 2006, 29(3–4), 278–287. 8 D. J. McClements, et al., Designing food structure to control stability, digestion, release and absorption of lipophilic food components. in 2nd International Symposium on Delivery of Functionality in Complex Food Systems. 2007. Amherst, MA. 9 G. S. Patten, et al., Site Specific Delivery of Microencapsulated Fish Oil to the Gastrointestinal Tract of the Rat, Dig. Dis. Sci., 2009, 54(3), 511–521. 10 A. Shefer and S. Shefer, Novel encapsulation system provides controlled release of ingredients, Food Technology, 2003, 57, 40–43. 11 J. Ubbink, Flavor delivery systems: Trends, technologies and applications, Abstracts of Papers of the American Chemical Society, 2002, 223, U34–U34. 12 J. Ubbink and J. Kruger, Physical approaches for the delivery of active ingredients in foods, Trends Food Sci. Technol., 2006, 17(5), 244–254. 13 L. Y. Chen, G. E. Remondetto and M. Subirade, Food proteinbased materials as nutraceutical delivery systems, Trends Food Sci. Technol., 2006, 17(5), 272–283. 14 D. J. McClements, et al., Structural Design Principles for Delivery of Bioactive Components in Nutraceuticals and Functional Foods, Crit. Rev. Food Sci. Nutr., 2009, 49(6), 577–606. 15 G. Fave, T. C. Coste and M. Armand, Physicochemical properties of lipids: New strategies to manage fatty acid bioavailability, Cellular and Molecular Biology, 2004, 50(7), 815–831. 16 C. Beglinger and L. Degen, Fat in the intestine as a regulator of appetite - role of CCK, Physiol. Behav., 2004, 83(4), 617–621. 17 D. E. Cummings and J. Overduin, Gastrointestinal regulation of food intake, J. Clin. Invest., 2007, 117(1), 13–23. 18 E. Karra and R. L. Batterham, The role of gut hormones in the regulation of body weight and energy homeostasis, Mol. Cell. Endocrinol., 2010, 316(2), 120–128. 19 W. Langhans and N. Geary, Overview of the Physiological Control of Eating, in Frontiers in Eating and Weight Regulation, 2010. p. 9–53. 20 A. D. Strader and S. C. Woods, Gastrointestinal hormones and food intake, Gastroenterology, 2005, 128(1), 175–191. 21 M. Golding and T. J. Wooster, The influence of emulsion structure and stability on lipid digestion, Curr. Opin. Colloid Interface Sci., 2010, 15(1–2), 90–101.


22 R. V. Seimon, et al., The droplet size of intraduodenal fat emulsions influences antropyloroduodenal motility, hormone release, and appetite in healthy males, Am. J. Clin. Nutr., 2009, 89(6), 1729–1736. 23 Y. Li, et al., Emulsion-Based Delivery Systems for Tributyrin, a Potential Colon Cancer Preventative Agent, J. Agric. Food Chem., 2009, 57(19), 9243–9249. 24 D. J. McClements, E. A. Decker and J. Weiss, Emulsion-based delivery systems for lipophilic bioactive components, J. Food Sci., 2007, 72(8), R109–R124. 25 D. J. McClements, E. A. Decker, and Y. Park, Physicochemical and structural aspects of lipid digestion, in Understanding and Controlling the Microstructure of Complex Foods, D. J. McClements, Editor 2007, CRC Press: Boca Raton, FL. p. 483–503. 26 M. C. Michalski, Specific molecular and colloidal structures of milk fat affecting lipolysis, absorption and postprandial lipemia, Eur. J. Lipid Sci. Technol., 2009, 111(5), 413–431. 27 D. J. McClements, Food Emulsions: Principles, Practice, and Techniques. 2nd ed. CRC series in contemporary food science. 2005, Boca Raton: CRC Press. 28 S. Stauffer, Emulsifiers, 1999, St Paul, MN: Eagen Press. 29 R. J. Whitehurst, Emulsifiers in Food Technology, 2006, Oxford, UK: Blackwell Publishing. 30 I. Kralova and J. Sjoblom, Surfactants Used in Food Industry: A Review, J. Dispersion Sci. Technol., 2009, 30(9), 1363–1383. 31 R. V. Seimon, et al., The Particle Size of Intraduodenal (ID) Fat Emulsions Modifies Antropyloroduodenal (APD) Motility, Hormone Release and Appetite in Healthy Males, Gastroenterology, 2009, 136(5), A25–A25. 32 T. Sanz and H. Luyten, In vitro evaluation of genistein bioaccessibility from enriched custards, Food Hydrocolloids, 2007, 21(2), 203–211. 33 T. Sanz and H. Luyten, Release, partitioning and stability of isoflavones from enriched custards during mouth, stomach and intestine in vitro simulations, Food Hydrocolloids, 2006, 20(6), 892–900. 34 T. Sanz and H. Luyten, Effect of thickening agent in the in vitro mouth, stomach and intestine release of tyrosol from enriched custards, Food Hydrocolloids, 2006, 20(5), 703–711. 35 A. van der Bilt, Oral physiology, mastication and food perception, in Designing Functional Foods: Measuring and Controlling Food Structure Breakdown and Nutrient Absorption, D. J. McClements and E. A. Decker, Editors. 2009, CRC Press: Boca Raton, FL. p. 3–37. 36 M. H. Vingerhoeds, et al., Emulsion flocculation induced by saliva and mucin, Food Hydrocolloids, 2005, 19(5), 915–922. 37 M. E. Malone, I. A. M. Appelqvist and I. T. Norton, Oral behaviour of food hydrocolloids and emulsions. Part 1. Lubrication and deposition considerations, Food Hydrocolloids, 2003, 17(6), 763–773. 38 M. E. Malone, I. A. M. Appelqvist and I. T. Norton, Oral behaviour of food hydrocolloids and emulsions. Part 2. Taste and aroma release, Food Hydrocolloids, 2003, 17(6), 775–784. 39 T. B. J. Blijdenstein, et al., Scaling behavior of delayed demixing, rheology, and microstructure of emulsions flocculated by depletion and bridging, Langmuir, 2004, 20(26), 11321–11328. 40 E. H. A. de Hoog, et al., Lubrication of oral surfaces by food emulsions: the importance of surface characteristics, J. Food Sci., 2006, 71(7), E337–E341. 41 E. Silletti, et al., The role of electrostatics in saliva-induced emulsion flocculation, Food Hydrocolloids, 2007, 21(4), 596–606. 42 E. A. Gwartney, D. K. Larick and E. A. Foegeding, Sensory texture and mechanical properties of stranded and particulate whey protein emulsion gels, J. Food Sci., 2004, 69(9), S333–S339. 43 A. Sarkar, K. K. T. Goh and H. Singh, Colloidal stability and interactions of milk-protein-stabilized emulsions in an artificial saliva, Food Hydrocolloids, 2009, 23(5), 1270–1278. 44 L. Kalantzi, et al., Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies, Pharm. Res., 2006, 23(1), 165–176. 45 F. M. L. Amado, et al., Analysis of the human saliva proteome, Expert Rev. Proteomics, 2005, 2(4), 521–539. 46 R. Vitorino, et al., Analysis of salivary peptides using HPLCelectrospray mass spectrometry, Biomed. Chromatogr., 2004, 18(8), 570–575.

Food Funct., 2010, 1, 32–59 | 55


View Online

47 R. Vitorino, et al., Identification of human whole saliva protein components using proteomics, Proteomics, 2004, 4(4), 1109– 1115. 48 N. W. Weisbrodt, Swallowing, in Gastrointestinal Physiology, 6th Edition, L. R. Johnson, Editor 2001, Mosby: St. Louis, MI. p. 27–35. 49 H. L. Mu and C. E. Hoy, The digestion of dietary triacylglycerols, Prog. Lipid Res., 2004, 43(2), 105–133. 50 P. Tso, Overview of digestion and absorption, in Biochemical and Physiological Aspects of Human Nutrition, K. D. Crissinger and M. H. Stipanuk, Editors. 2000, W.B. Saunders Company: Philadelphia, Pennsylvania, p. 75–90. 51 K. E. Barrett, Gastrointestinal Physiology, 2006, New York, NY: McGraw-Hill. 52 L. Lundin, M. Golding and T. J. Wooster, Understanding food structure and function in developing food for appetite control, Nutr. Diet., 2008, 65, S79–S85. 53 L. Marciani, et al., Delaying gastric emptying and enhancing cholecystokinin release and satiety by using acid stable fat emulsions, Gastroenterology, 2006, 130(4), A227–A227. 54 N. W. Weisbrodt, Gastric emptying, in Gastrointestinal Physiology, 6th Edition, L. R. Johnson, Editor 2001, Mosby: St. Louis, MI. p. 37–45. 55 N. W. Weisbrodt, Motility of the small intestine, in Gastrointestinal Physiology, 6th Edition, L. R. Johnson, Editor 2001, Mosby: St. Louis, MI. p. 47–56. 56 C. Ekmekcioglu, A physiological approach for preparing and conducting intestinal bioavailability studies using experimental systems, Food Chem., 2002, 76(2), 225–230. 57 A. Lindahl, et al., Characterization of fluids from the stomach and proximal jejunum in men and women, Pharm. Res., 1997, 14(4), 497–502. 58 K. Schulze, Imaging and modelling of digestion in the stomach and the duodenum, Neurogastroenterol. Motil., 2006, 18(3), 172–183. 59 W. Schwizer, M. Fox and A. Steingotter, Non-invasive investigation of gastrointestinal functions with magnetic resonance imaging: towards an ‘‘ideal’’ investigation of gastrointestinal function, Gut, 2003, 52, 34–39. 60 A. Shafik, et al., Mechanism of gastric emptying through the pyloric sphincter: A human study, Medical Science Monitor, 2007, 13(1), CR24–CR29. 61 I. T. Norton, W. J. Frith and S. Ablett, Fluid gels, mixed fluid gels and satiety, Food Hydrocolloids, 2006, 20(2–3), 229–239. 62 M. Mukherjee, Human digestive and metabolic lipases - a brief review, J. Mol. Catal. B: Enzym., 2003, 22(5–6), 369–376. 63 E. Bauer, S. Jakob and R. Mosenthin, Principles of physiology of lipid digestion, Asian-Australasian Journal of Animal Sciences, 2005, 18(2), 282–295. 64 M. Armand, Lipases and lipolysis in the human digestive tract: where do we stand?, Curr. Opin. Clin. Nutr. Metab. Care, 2007, 10(2), 156–164. 65 N. Miled, et al., Discrimination between closed and open forms of lipases using electrophoretic techniques, Anal. Biochem., 2005, 338(2), 171–178. 66 D. C. Whitcomb and M. E. Lowe, Human pancreatic digestive enzymes, Dig. Dis. Sci., 2007, 52(1), 1–17. 67 E. Jurado, et al., Kinetic model for the enzymatic hydrolysis of tributyrin in O/W emulsions, Chem. Eng. Sci., 2006, 61(15), 5010– 5020. 68 I. Read, Effects of calcium supplementation on circulating lipids Potential pharmacoeconomic implications, Drugs Aging, 2004, 21(1), 7–17. 69 T. Vaskonen, Dietary minerals and modification of cardiovascular risk factors, J. Nutr. Biochem., 2003, 14(9), 492–506. 70 T. Karupaiah and K. Sundram, Effects of stereospecific positioning of fatty acids in triacylglycerol structures in native and randomized fats: a review of their nutritional implications, Nutrition and Metabolism, 2007, 4(16), 1–17. 71 P. Reis, et al., Lipases at interfaces: A review, Adv. Colloid Interface Sci., 2009, 147–148, 237–250. 72 M. Hu, et al., Influence of Tripolyphosphate Cross-Linking on the Physical Stability and Lipase Digestibility of Chitosan-Coated Lipid Droplets, J. Agric. Food Chem., 2010, 58(2), 1283–1289. 73 A. Tan, et al., Silica Nanoparticles To Control the Lipase-Mediated Digestion of Lipid-Based Oral Delivery Systems, Mol. Pharmaceutics, 2010, 7(2), 522–532.

56 | Food Funct., 2010, 1, 32–59

74 M. Lowe, The triglyceride lipases of the pancreas, J. Lipid Res., 2002, 43(12), 2007–2016. 75 Y. Gargouri, et al., Studies on the Detergent Inhibition of Pancreatic Lipase Activity, Journal of Lipid Research, 1983, 24(10), 1336–1342. 76 E. Roger, et al., Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery, Nanomedicine, 2010, 5(2), 287–306. 77 B. Bermudez, et al., Digestion and absorption of olive oil, Grasas Y Aceites, 2004, 55(1), 1–10. 78 A. W. Basit, Advances in colonic drug delivery, Drugs, 2005, 65(14), 1991–2007. 79 H. J. Flint, S. H. Duncan, and P. Louis, Gut microbial ecology, in Designing Functional Foods: Measuring and Controlling Food Structure Breakdown and Nutrient Absorption, D. J. McClements and E. A. Decker, Editors. 2009, CRC Press: Boca Raton, FL. p. 38–65. 80 L. Yang, Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora, J. Controlled Release, 2008, 125(2), 77–86. 81 K. M. Tuohy, et al., Metabolism of Maillard reaction products by the human gut microbiota - implications for health, Mol. Nutr. Food Res., 2006, 50(9), 847–857. 82 D. M. Jacobs, et al., Non-Digestible Food Ingredients, Colonic Microbiota and the Impact on Gut Health and Immunity: A Role for Metabolomics, Curr. Drug Metab., 2009, 10(1), 41–54. 83 N. H. Zangenberg, et al., A dynamic in vitro lipolysis model I. Controlling the rate of lipolysis by continuous addition of calcium, Eur. J. Pharm. Sci., 2001, 14(2), 115–122. 84 M. Hu, et al., Role of calcium and calcium-binding agents on the lipase digestibility of emulsified lipids using an in vitro digestion model, Food Hydrocolloids, 2010, 24(8), 719–725. 85 I. Braccini and S. Perez, Molecular basis of Ca2+-induced gelation in alginates and pectins: The egg-box model revisited, Biomacromolecules, 2001, 2(4), 1089–1096. 86 S. Mun, et al., Influence of interfacial composition on in vitro digestibility of emulsified lipids: Potential mechanism for chitosan’s ability to inhibit fat digestion, Food Biophys., 2006, 1(1), 21–29. 87 P. Rayment, et al., Investigation of alginate beads for gastrointestinal functionality, Part 1: In vitro characterisation, Food Hydrocolloids, 2009, 23(3), 816–822. 88 C. Hoad, et al., Investigation of alginate beads for gastro-intestinal functionality, Part 2: In vivo characterisation, Food Hydrocolloids, 2009, 23(3), 833–839. 89 J. N. Losso, The biochemical and functional food properties of the Bowman-Birk inhibitor, Crit. Rev. Food Sci. Nutr., 2008, 48(1), 94–118. 90 M. P. Raghavendra, P. R. Kumar and V. Prakash, Mechanism of inhibition of rice bran lipase by polyphenols - A case study with chlorogenic acid and caffeic acid, J. Food Sci., 2007, 72(8), E412– E419. 91 P. Reis, et al., Lipases at interfaces: Unique interfacial properties as globular proteins, Langmuir, 2008, 24(13), 6812–6819. 92 C. L. Cooper, et al., Polyelectrolyte-protein complexes, Curr. Opin. Colloid Interface Sci., 2005, 10(1–2), 52–78. 93 A. Mackie and A. Macierzanka, Colloidal aspects of protein digestion, Curr. Opin. Colloid Interface Sci., 2010, 15(1–2), 102–108. 94 J. Maldonado-Valderrama, et al., The effect of physiological conditions on the surface structure of proteins: Setting the scene for human digestion of emulsions, Eur. Phys. J. E, 2009, 30(2), 165–174. 95 J. Maldonado-Valderrama, et al., Interfacial characterization of beta-lactoglobulin networks: Displacement by bile salts, Langmuir, 2008, 24(13), 6759–6767. 96 G. A. van Aken and E. H. A. de Hoog, Oral processing and perception of food emulsions: relevence for fat reduction in foods, in Designing Functional Foods: Measuring and Controlling Food Structure Breakdown and Nutrient Absorption, D. J. McClements and E. A. Decker, Editors. 2009, CRC Press: Boca Raton, FL. p. 265–294. 97 G. A. van Aken, M. H. Vingerhoeds, and E. H. A. de Hoog, Colloidal behavior of food emulsions under oral conditions, in Food Hydrocolloids, Interactions, Microstructure and Processing, E. Dickinson, Editor 2005, The Royal Society of Chemistry: Cambridge, UK. p. 356–366.



View Online

98 J. S. Patton and M. C. Carey, Watching Fat Digestion, Science, 1979, 204(4389), 145–148. 99 J. S. Patton, et al., The Light-Microscopy of Triglyceride Digestion, Food Microstructure, 1985, 4(1), 29–41. 100 T. Helgason, et al., Influence of molecular character of chitosan on the adsorption of chitosan to oil droplet interfaces in an in vitro digestion model, Food Hydrocolloids, 2009, 23(8), 2243–2253. 101 C. H. M. Versantvoort, E. Van de Kamp, and C. J. M. Rompelberg, Development and applicability of an in vitro digestion model in assessing the bioaccessibility of contaminants from food, in Report Number 3201020022004, National Institute of Public Health and the Environment: Bilthoven, The Netherlands. p. 1–87. 102 B. Holst and G. Williamson, Nutrients and phytochemicals: from bioavailability to bioefficacy beyond antioxidants, Curr. Opin. Biotechnol., 2008, 19(2), 73–82. 103 H. Verhagen, et al., Assessment of the efficacy of functional food ingredients-introducing the concept ‘‘kinetics of biomarkers’’, Mutat. Res., Fundam. Mol. Mech. Mutagen., 2004, 551(1–2), 65– 78. 104 S. Scholz and G. Williamson, Interactions affecting the Bioavailability of dietary polyphenols in vivo, Int. J. Vitam. Nutr. Res., 2007, 77(3), 224–235. 105 J. Y. Yoo and X. D. Chen, GIT Physicochemical Modeling - A Critical Review, International Journal of Food Engineering, 2006, 2(4). 106 M. Minekus, et al., A computer-controlled system to simulate conditions of the large intestine with peristaltic mixing, water absorption and absorption of fermentation products, Appl. Microbiol. Biotechnol., 1999, 53(1), 108–114. 107 K. Venema, R. Havenaar, and M. Minekus, Improving In vitro Simulation of the Stomach and Intestines, in Designing Functional Foods: Measuring and Controlling Food Structure Breakdown and Nutrient Absorption, D. J. McClements and E. A. Decker, Editors. 2009, CRC Press: Boca Raton, FL. p. 314–339. 108 C. H. M. Versantvoort, et al., Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food, Food Chem. Toxicol., 2005, 43(1), 31–40. 109 D. M. Dresselhuis, et al., Fat retention at the tongue and the role of saliva: Adhesion and spreading of ‘protein-poor’ versus ‘proteinrich’ emulsions, J. Colloid Interface Sci., 2008, 321(1), 21–29. 110 D. M. Dresselhuis, et al., Tribology of o/w emulsions under mouthlike conditions: Determinants of friction, Food Biophys., 2007, 2(4), 158–171. 111 G. A. van Aken, M. H. Vingerhoeds and E. H. A. de Hoog, Food colloids under oral conditions, Curr. Opin. Colloid Interface Sci., 2007, 12(4–5), 251–262. 112 I. A. M. Appelqvist, Measuring the Oral Behavior of Foods, in Designing Functional Foods: Measuring and Controlling Food Structure Breakdown and Nutrient Absorption, D. J. McClements and E. A. Decker, Editors. 2009, CRC Press: Boca Raton, FL. p. 265–294. 113 A. Sarkar, et al., Behaviour of an oil-in-water emulsion stabilized by beta-lactoglobulin in an in vitro gastric model, Food Hydrocolloids, 2009, 23(6), 1563–1569. 114 A. Mercuri, et al., Dynamic gastric model (DGM): a novel in vitro apparatus to assess the impact of gastric digestion on the droplet size of self-emulsifying drug-delivery systems, J. Pharm. Pharmacol., 2008, 60, 4. 115 A. des Rieux, et al., Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach, J. Controlled Release, 2006, 116(1), 1–27. 116 C. J. Rummey and I. R. Rowland, In vivo and in vitro models of the human colonic flora, Crit. Rev. Food Sci. Nutr., 1992, 31, 299–331. 117 G. T. Macfarlane and S. Macfarlane, Models for intestinal fermentation: association between food components, delivery systems, bioavailability and functional interactions in the gut, Curr. Opin. Biotechnol., 2007, 18(2), 156–162. 118 A. C. Ouwehand, et al., Non-starch polysaccharides in the gastrointestinal tract, in Designing Functional Foods: Measuring and Controlling Food Structure Breakdown and Nutrient Absorption, D. J. McClements and E. A. Decker, Editors. 2009, CRC Press: Boca Raton, FL. p. 126–147. 119 J. F. A. Souto-Maior, et al., Phosphated crosslinked pectin as a potential excipient for specific drug delivery: preparation and physicochemical characterization, Polym. Int., 2009, 59(1), 127–135.


120 A. Dahan and A. Hoffman, Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: Correlation with in vivo data and the relationship to intraenterocyte processes in rats, Pharm. Res., 2006, 23(9), 2165–2174. 121 C. W. Pouton and C. J. H. Porter. Formulation of lipid-based delivery systems for oral administration: Materials, methods and strategies. in Annual Meeting of the American-Association-ofPharmaceutical-Scientists. 2006. San Antonio, TX. 122 A. Dahan and A. Hoffman, Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs, J. Controlled Release, 2008, 129(1), 1–10. 123 S. Amara, et al., Lipolysis of natural long chain and synthetic medium chain galactolipids by pancreatic lipase-related protein 2, Biochim. Biophys. Acta, Mol. Cell Biol. Lipids, 2010, 1801(4), 508– 516. 124 L. Sek, C. J. H. Porter and W. N. Charman, Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis, J. Pharm. Biomed. Anal., 2001, 25(3–4), 651–661. 125 M. Armand, et al., Effects of Droplet Size, Triacylglycerol Composition, and Calcium on the Hydrolysis of Complex Emulsions by Pancreatic Lipase - an Invitro Study, J. Nutr. Biochem., 1992, 3(7), 333–341. 126 P. J. Moughan, Digestion and Absorption of Proteins and Peptides, in Designing Functional Foods: Measuring and Controlling Food Structure Breakdown and Nutrient Absorption, D. J. McClements and E. A. Decker, Editors. 2009, CRC Press: Boca Raton, FL. p. 148–170. 127 B. Pedersen and B. O. Eggum, Prediction of Protein Digestibility by invitro Procedures Based on 2 Multi-Enzyme Systems, Zeitschrift Fur Tierphysiologie Tierernahrung Und Futtermittelkunde-Journal of Animal Physiology and Animal Nutrition, 1981, 45(4), 190–200. 128 A. Sarkar, K. K. T. Goh and H. Singh, Properties of oil-in-water emulsions stabilized by beta-lactoglobulin in simulated gastric fluid as influenced by ionic strength and presence of mucin, Food Hydrocolloids, 2010, 24(5), 534–541. 129 D. J. McClements, Emulsion Design to Improve the Delivery of Functional Lipophilic Components, in Annual Review of Food Science and Technology, Vol. 1, 2010. p. 241–269. 130 L. Lundin and M. Golding, Structure design for healthy food, Australian Journal of Dairy Technology, 2009, 64(1), 68–74. 131 S. Mun, E. A. Decker and D. J. McClements, Influence of emulsifier type on in vitro digestibility of lipid droplets by pancreatic lipase, Food Res. Int., 2007, 40(6), 770–781. 132 A. Sarkar, D. S. Horne and H. Singh, Interactions of milk proteinstabilized oil-in-water emulsions with bile salts in a simulated upper intestinal model, Food Hydrocolloids, 2010, 24(2–3), 142–151. 133 R. Lutz, et al., On the confocal images and the rheology of whey protein isolated and modified pectins associated complex, Colloids Surf., B, 2009, 69(1), 43–50. 134 D. J. McClements, Critical review of techniques and methodologies for characterization of emulsion stability, Crit. Rev. Food Sci. Nutr., 2007, 47(7), 611–649. 135 V. Rampon, et al., Evidence that homogenization of BSA-stabilized hexadecane-in-water emulsions induces structure modification of the nonadsorbed protein, J. Agric. Food Chem., 2003, 51(20), 5900–5905. 136 V. Rampon, et al., Front-face fluorescence spectroscopy study of globular proteins in emulsions: Displacement of BSA by a nonionic surfactant, J. Agric. Food Chem., 2003, 51(9), 2482–2489. 137 H. Bouwmeester, et al., Review of health safety aspects of nanotechnologies in food production, Regul. Toxicol. Pharmacol., 2009, 53(1), 52–62. 138 W. I. Hagens, et al., What do we (need to) know about the kinetic properties of nanoparticles in the body?, Regul. Toxicol. Pharmacol., 2007, 49(3), 217–229. 139 P. Reis, et al., Competition between lipases and monoglycerides at interfaces, Langmuir, 2008, 24(14), 7400–7407. 140 C. Leggio, et al., Small-angle X-ray scattering and light scatteringon lysozyme and sodium glycocholate micelles, J. Phys. Chem. B, 2005, 109(50), 23857–23869. 141 D. G. Fatouros, B. Bergenstahl and A. Mullertz, Morphological observations on a lipid-based drug delivery system during in vitro digestion, Eur. J. Pharm. Sci., 2007, 31(2), 85–94.

Food Funct., 2010, 1, 32–59 | 57


View Online

142 Y. Nonomura, et al., Phase behavior of bile acid/lipid/water systems containing model dietary lipids, J. Colloid Interface Sci., 2009, 339(1), 222–229. 143 D. G. Fatouros, et al., Structural development of self nano emulsifying drug delivery systems (SNEDDS) during In vitro lipid digestion monitored by small-angle X-ray scattering, Pharm. Res., 2007, 24(10), 1844–1853. 144 R. P. Hjelm, et al., Structure of conjugated bile salt-fatty acidmonoglyceride mixed colloids: Studies by small-angle neutron scattering, J. Phys. Chem. B, 2000, 104(2), 197–211. 145 D. G. Fatouros, et al., Physicochemical Characterization of Simulated Intestinal Fed-State Fluids Containing LysoPhosphatidylcholine and Cholesterol, Dissolution Technologies, 2009, 16(3), 47–50. 146 D. G. Fatouros, et al., Colloidal Structures in Media Simulating Intestinal Fed State Conditions with and Without Lipolysis Products, Pharm. Res., 2009, 26(2), 361–374. 147 J. Singh, et al., Aggregate properties of sodium deoxycholate and dimyristoylphosphatidylcholine mixed micelles, J. Phys. Chem. B, 2008, 112(13), 3997–4008. 148 A. Rube, S. Klein and K. Mader, Monitoring of in vitro fat digestion by electron paramagnetic resonance spectroscopy, Pharm. Res., 2006, 23(9), 2024–2029. 149 M. A. Rao, Rheology of Fluids and Semisolid Foods: Principles and Applications, 1999, New York: Springer. 433. 150 T. F. Tadros, Fundamental Principles of Emulsion Rheology and Their Applications, Colloids Surf., A, 1994, 91, 39–55. 151 C. W. Macosko, Rheology: Principles, Measurements and Applications, 1994, New York, NY: VCH Publishers. 152 D. H. Liao, J. B. Zhao and H. Gregersen, Gastrointestinal tract modelling in health and disease, World J. Gastroenterol., 2009, 15(2), 169–176. 153 C. Olbrich, O. Kayser and R. H. Muller, Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) - effect of surfactants, storage time and crystallinity, Int. J. Pharm., 2002, 237(1–2), 119–128. 154 R. H. Muller, D. Ruhl and S. A. Runge, Biodegradation of solid lipid nanoparticles as a function of lipase incubation time, Int. J. Pharm., 1996, 144(1), 115–121. 155 L. Bonnaire, et al., Influence of lipid physical state on the in vitro digestibility of emulsified lipids, J. Agric. Food Chem., 2008, 56(10), 3791–3797. 156 S. Ueno, Y. Hamada and K. Sato, Controlling polymorphic crystallization of n-alkane crystals in emulsion droplets through interfacial heterogeneous nucleation, Cryst. Growth Des., 2003, 3(6), 935–939. 157 M. Higami, et al., Simultaneous synchrotron radiation X-ray diffraction - DSC analysis of melting and crystallization behavior of trilauroylglycerol in nanoparticles of oil-in-water emulsion, J. Am. Oil Chem. Soc., 2003, 80(8), 731–739. 158 D. G. Fatouros and A. Mullertz, In vitro lipid digestion models in design of drug delivery systems for enhancing oral bioavailability, Expert Opin. Drug Metab. Toxicol., 2008, 4(1), 65–76. 159 M. L. Failla, T. Huo, and S. K. Thakkar. In vitro screening of relative bioaccessibility of carotenoids from foods. in 10th Asian Congress of Nutrition. 2007. Taipei, TAIWAN: H E C Press, Healthy Eating Club Pty Ltd. 160 J. O. Christensen, et al., Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols, Eur. J. Pharm. Sci., 2004, 23(3), 287–296. 161 T. Do Thi, et al., Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS, Eur. J. Pharm. Sci., 2009, 38(5), 479–488. 162 S. Mun, E. A. Decker and D. J. McClements, Influence of droplet characteristics on the formation of oil-in-water emulsions stabilized by surfactant-chitosan layers, Langmuir, 2005, 21(14), 6228–6234. 163 M. Brogard, et al., Anew standardized lipolysis approach for characterization of emulsions and dispersions, J. Colloid Interface Sci., 2007, 308(2), 500–507. 164 V. Tyssandier, et al., Processing of vegetable-borne carotenoids in the human stomach and duodenum, American Journal of PhysiologyGastrointestinal and Liver Physiology, 2003, 284(6), G913–G923. 165 V. Tyssandier, B. Lyan and P. Borel, Main factors governing the transfer of carotenoids from emulsion lipid droplets to micelles,

58 | Food Funct., 2010, 1, 32–59

166

167

168

169 170 171 172

173 174 175

176 177 178 179 180

181

182 183 184 185 186 187

Biochim. Biophys. Acta, Mol. Cell Biol. Lipids, 2001, 1533(3), 285– 292. A. J. Wright, C. Pietrangelo and A. MacNaughton, Influence of simulated upper intestinal parameters on the efficiency of beta carotene micellarisation using an in vitro model of digestion, Food Chemistry, 2008, 107(3), 1253–1260. A. Dahan and A. Hoffman, The effect of different lipid based formulations on the oral absorption of lipophilic drugs: The ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats, Eur. J. Pharm. Biopharm., 2007, 67(1), 96–105. C. H. M. Versantvoort, et al., Monolayers of IEC-18 cells as an in vitro model for screening the passive transcellular and paracellular transport across the intestinal barrier: comparison of active and passive transport with the human colon carcinoma Caco-2 cell line (vol 11, pg 335, 2002), Environ. Toxicol. Pharmacol., 2003, 13(1), 55–55. E. Reboul, et al., Bioaccessibility of carotenoids and vitamin E from their main dietary sources, J. Agric. Food Chem., 2006, 54(23), 8749– 8755. C. Dhuique-Mayer, et al., beta-Cryptoxanthin from Citrus juices: assessment of bioaccessibility using an in vitro digestion/Caco-2 cell culture model, Br. J. Nutr., 2007, 97(5), 883–890. N. O. Nilsson and P. Belfrage, Continuous Monitoring of Free Fatty-Acid Release from Adipocytes by Ph-Stat Titration, Journal of Lipid Research, 1979, 20(4), 557–560. Y. Li and D. J. McClements, New Mathematical Model for Interpreting pH-Stat Digestion Profiles: Impact of Lipid Droplet Characteristics on in Vitro Digestibility, J. Agric. Food Chem., 2010, 58(13), 8085–8092. J. M. Lohr, et al., Properties of different pancreatin preparations used in pancreatic exocrine insufficiency, Eur. J. Gastroenterol. Hepatol., 2009, 21(9), 1024–1031. P. D. de Maria, et al., Role of apparent pK(a) of carboxylic acids in lipase-catalyzed esterifications in biphasic systems, J. Mol. Catal. B: Enzym., 2009, 59(1–3), 220–224. H. Ali, A. Siddiqui and S. Nazzal, The Effect of Media Composition, pH, and Formulation Excipients on the In Vitro Lipolysis of SelfEmulsifying Drug Delivery Systems (SEDDS), J. Dispersion Sci. Technol., 2010, 31(2), 226–232. D. Y. Colin, et al., Exploring the active site cavity of human pancreatic lipase, Biochem. Biophys. Res. Commun., 2008, 370(3), 394–398. P. Reis, et al., Lipase reaction at interfaces as self-limiting processes, C. R. Chim., 2009, 12(1–2), 163–170. A. Macierzanka, et al., Emulsification alters simulated gastrointestinal proteolysis of beta-casein and beta-lactoglobulin, Soft Matter, 2009, 5(3), 538–550. B. S. Chu, et al., Modulating Pancreatic Lipase Activity with Galactolipids: Effects of Emulsion Interfacial Composition, Langmuir, 2009, 25(16), 9352–9360. Y. Li, M. Hu and D. J. McClements, Factors Affecting Lipase Digestibility of Emulsified Lipids using an in vitro Digestion Model: Proposal for a Standardized pH-Stat Method, Food Chemistry, 2010, Submitted. J. S. Patton and M. C. Carey, Inhibition of Human Pancreatic Lipase-Colipase Activity by Mixed Bile Salt-Phospholipid Micelles, American Journal of Physiology, 1981, 241(4), G328– G336. N. H. Zangenberg, et al., A dynamic in vitro lipolysis model II: Evaluation of the model, Eur. J. Pharm. Sci., 2001, 14(3), 237–244. T. F. Whayne and J. M. Felts, Activation of Lipoprotein Lipase - an Evaluation of Calcium as a Cofactor, Journal of the American Oil Chemists Society, 1971, 48(2), A101. T. F. Whayne and J. M. Felts, Activation of Lipoprotein Lipase Evaluation of Calcium, Magnesium, and Ammonium as Cofactors, Circulation Research, 1971, 28(6), 649. H. Kimura, et al., Activation of Human Pancreatic Lipase Activity by Calcium and Bile-Salts, Journal of Biochemistry, 1982, 92(1), 243–251. S. Hwang, et al., Highly efficient production of monoglycerides by the continuous removal of fatty acids from lipase-catalyzed oil hydrolysis, Biocatal. Biotransform., 2009, 27(5–6), 290–295. J. K. Lorenzen, et al., Effect of dairy calcium or supplementary calcium intake on postprandial fat metabolism, appetite, and


View Online

188 189 190 191


192 193 194 195

196 197 198 199 200 201 202

203 204 205 206

207

208

209

subsequent energy intake, American Journal of Clinical Nutrition, 2007, 85(3), 678–687. K. E. Scholz-Ahrens and J. Schrezenmeir, Milk minerals and the metabolic syndrome, Int. Dairy J., 2006, 16(11), 1399–1407. X. U. Rui, Calcium binding of peptides derived from enzymatic hydrolysates of whey protein concentrate, Int. J. Dairy Technol., 2009, 62(2), 170–173. S. B. Kim and J. W. Lim, Calcium-binding peptides derived from tryptic hydrolysates of cheese whey protein, Asian-Australasian Journal of Animal Sciences, 2004, 17(10), 1459–1464. T. D. Perry, R. T. Cygan and R. Mitchell, Molecular models of alginic acid: Interactions with calcium ions and calcite surfaces, Geochim. Cosmochim. Acta, 2006, 70(14), 3508–3532. S. J. Hur, E. A. Decker and D. J. McClements, Influence of initial emulsifier type on microstructural changes occurring in emulsified lipids during in vitro digestion, Food Chem., 2009, 114(1), 253–262. J. Fallingborg, Intraluminal pH of the human gastrointestinal tract, Danish Medical Bulletin, 1999, 46(3), 183–196. T. Snabe, M. T. Neves-Petersen and S. B. Petersen, Enzymatic lipid removal from surfaces-lipid desorption by a pH-induced ‘‘electrostatic explosion’’, Chem. Phys. Lipids, 2005, 133(1), 37–49. M. Beysseriat, E. A. Decker and D. J. McClements, Preliminary study of the influence of dietary fiber on the properties of oil-inwater emulsions passing through an in vitro human digestion model, Food Hydrocolloids, 2006, 20(6), 800–809. K. Nakahara, et al., Inhibition of Postprandial Hyperglycemia by Oolong Tea Extract (OTE), Phytother. Res., 1994, 8(7), 433–435. C. J. H. Porter, et al. Enhancing intestinal drug solubilisation using lipid-based delivery systems. in Annual Meeting of the AmericanAssociation-of-Pharmaceutical-Scientists. 2006. San Antonio, TX. P. Borel, et al., Hydrolysis of Emulsions with Different Triglycerides and Droplet Sizes by Gastric Lipase in vitro - Effect on Pancreatic Lipase Activity, J. Nutr. Biochem., 1994, 5(3), 124–133. M. Wickham, et al., Modification of a phospholipid stabilized emulsion interface by bile salt: effect on pancreatic lipase activity, Journal of Lipid Research, 1998, 39(3), 623–632. P. M. Reis, et al., Influence of Surfactants on Lipase Fat Digestion in a Model Gastro-intestinal System, Food Biophys., 2008, 3(4), 370– 381. D. J. McClements, Design of Nano-Laminated Coatings to Control Bioavailability of Lipophilic Food Components, J. Food Sci., 2010, 75(1), R30–R42. U. Klinkesorn and D. J. McClements, Impact of Lipase, Bile Salts, and Polysaccharides on Properties and Digestibility of Tuna Oil Multilayer Emulsions Stabilized by Lecithin-Chitosan, Food Biophys., 2010, 5(2), 73–81. C. Olbrich, O. Kayser and R. H. Muller, Enzymatic degradation of Dynasan 114 SLN - effect of surfactants and particle size, J. Nanopart. Res., 2002, 4(1/2), 121–129. C. Olbrich and R. H. Muller, Enzymatic degradation of SLN - effect of surfactant and surfactant mixtures, Int. J. Pharm., 1999, 180(1), 31–39. P. Walstra, Physical Chemistry of Foods, 2003, New York, NY: Marcel Decker. A. Abdalla, S. Klein and K. M€ader, A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: Characterization, dissolution, in vitro digestion and incorporation into solid pellets, Eur. J. Pharm. Sci., 2008, 35(5), 457–464. S. Sandra, E. A. Decker and D. J. McClements, Effect of interfacial protein cross-linking on the in vitro digestibility of emulsified corn oil by pancreatic lipase, J. Agric. Food Chem., 2008, 56(16), 7488– 7494. U. Lesmes, P. Baudot and D. J. McClements, Impact of Interfacial Composition on Physical Stability and In Vitro Lipase Digestibility of Triacylglycerol Oil Droplets Coated with Lactoferrin and/or Caseinate, J. Agric. Food Chem., 2010, 58(13), 7962–7969. V. Gudipati, S. Sandra, D. J. McClements and E. A. Decker, Oxidative Stability and in Vitro Digestibility of Fish Oil-in-Water


210 211

212

213

214 215

216

217 218

219

220

221

222

223

224 225

Emulsions Containing Multilayered Membranes, J. Agric. Food Chem., 2010, 58(13), 8093–8099. U. Klinkesorn and D. J. McClements, Influence of chitosan on stability and lipase digestibility of lecithin-stabilized tuna oil-inwater emulsions, Food Chem., 2009, 114(4), 1308–1315. M. Wickham, M. Garrood, J. Leney, P. D. G. Wilson and A. FilleryTravis, Modification of a phospholipid stabilized emulsion interface by bile salt: effect on pancreatic lipase activity, J. Lipid Res., 1998, 39(3), 623–632. L. Sek, C. J. H. Porter, A. M. Kaukonen and W. N. Charman, Evaluation of the in vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products, J. Pharm. Pharmacol., 2002, 54(1), 29–41. S. Fernandez, S. Chevrier, N. Ritter, B. Mahler, F. Demarne, F. Carriere and V. Jannin, In Vitro Gastrointestinal Lipolysis of Four Formulations of Piroxicam and Cinnarizine with the Self Emulsifying Excipients Labrasol (R) and Gelucire (R) 44/14, Pharm. Res., 2009, 26(8), 1901–1910. E. Hedren, V. Diaz and U. Svanberg, Estimation of carotenoid accessibility from carrots determined by an in vitro digestion method, Eur. J. Clin. Nutr., 2002, 56(5), 425–430. D. A. White, I. D. Fisk, S. Makkhun and D. A. Gray, In Vitro Assessment of the Bioaccessibility of Tocopherol and Fatty Acids from Sunflower Seed Oil Bodies, J. Agric. Food Chem., 2009, 57(13), 5720–5726. C. M. Oliver, M. A. Augustin and L. Sanguansri, Maillard-based casein-carbohydrate microcapsules for the delivery of fish oil: emulsion stability during in vitro digestion, Australian Journal of Dairy Technology, 2009, 64(1), 80–83. C. Chung, L. Sanguansri and M. A. Augustin, Effects of modification of encapsulant materials on the susceptibility of fish oil microcapsules to lipolysis, Food Biophys., 2008, 3(2), 140–145. C. J. H. Porter, A. M. Kaukonen, B. J. Boyd, G. A. Edwards and W. N. Charman, Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation, Pharm. Res., 2004, 21(8), 1405–1412. C. J. H. Porter, A. M. Kaukonen, A. Taillardat-Bertschinger, B. J. Boyd, J. M. O’Connor, G. A. Edwards and W. N. Charman, Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: Studies with halofantrine, J. Pharm. Sci., 2004, 93(5), 1110–1121. A. M. Kaukonen, B. J. Boyd, W. N. Charman and C. J. H. Porter, Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids, Pharm. Res., 2004, 21(2), 254–260. C. Juhel, M. Armand, Y. Pafumi, C. Rosier, J. Vandermander and D. Lairon, Green tea extract (AR25 (R)) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro, J. Nutr. Biochem., 2000, 11(1), 45–51. B. Pasquier, M. Armand, C. Castelain, F. Guillon, P. Borel, H. Lafont and D. Lairon, Emulsification and lipolysis of triacylglycerols are altered by viscous soluble dietary fibres in acidic gastric medium in vitro, Biochemical Journal, 1996, 314, 269–275. B.-S. Chu, G. T. Rich, M. J. Ridout, R. M. Faulks, M. S. J. Wickham and P. J. Wilde, Modulating Pancreatic Lipase Activity with Galactolipids: Effects of Emulsion Interfacial Composition, Langmuir, 2009, 25(16), 9352–9360. A. Sarkar, D. S. Horne and H. Singh, Pancreatin-induced coalescence of oil-in-water emulsions in an in vitro duodenal model, Int. Dairy J., 2010, 20(9), 589–597. S. F. Han, T. T. Yao, X. X. Zhang, L. Gan, C. L. Zhu, H. Z. Yua and Y. Gan, Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: Effects of lipid composition and formulation, Int. J. Pharm., 2009, 379(1), 18–24.

Food Funct., 2010, 1, 32–59 | 59

View Online

REVIEW


Combining nutrition, food science and engineering in developing solutions to Inflammatory bowel diseases – omega-3 polyunsaturated fatty acids as an example Lynnette R. Ferguson,*ad Bronwen G. Smithbd and Bryony J. Jamesc

Downloaded on 21 October 2010 Published on 22 September 2010 on http://pubs.rsc.org | doi:10.1039/C0FO00057D

Received 2nd July 2010, Accepted 13th August 2010 DOI: 10.1039/c0fo00057d The Inflammatory bowel diseases, Crohn’s disease and ulcerative colitis, are debilitating conditions, characterised by lifelong sensitivity to certain foods, and often a need for surgery and life-long medication. The anti-inflammatory effects of long chain omega-3 polyunsaturated acids justify their inclusion in enteral nutrition formulas that have been associated with disease remission. However, there have been variable data in clinical trials to test supplementary omega-3 polyunsaturated fatty acids in inducing or maintaining remission in these diseases. Although variability in trial design has been suggested as a major factor, we suggest that variability in processing and presentation of the products may be equally or more important. The nature of the source, and rapidity of getting the fish or other food source to processing or to market, will affect the percentage of the various fatty acids, possible presence of heavy metal contaminants and oxidation status of the various fatty acids. For dietary supplements or fortified foods, whether the product is encapsulated or not, whether storage is under nitrogen or not, and length of time between harvest, processing and marketing will again profoundly affect the properties of the final product. Clinical trials to test efficacy of these products in IBD to date have utilised the relevant skills of pharmacology and gastroenterology. We suggest that knowledge from food science, nutrition and engineering will be essential to establish the true role of this important group of compounds in these diseases.

Introduction Inflammatory bowel diseases (IBD) appear in two forms, Crohn’s disease (CD) and ulcerative colitis (UC). Both are debilitating diseases, for which pharmaceutical treatments are moderately successful, albeit having significant side-effects. We have previously suggested that nutritional (or nutrigenomic) solutions may be appropriate,1,2 and there have been a number of clinical trials in this area. However, if nutritional therapies are to be successfully developed, it is essential that we move beyond pharmaceutical thinking, and put the full power of an integrated set of knowledge on effects of food science and engineering behind new developments. The potential of omega3 polyunsaturated acids (n-3 PUFA) in IBD is reviewed in this light. Fish oil is a common source of n-3 PUFA, and there is reason to believe that increasing fish oils or other sources of n-3 PUFA may have health benefits in IBD.3,4 However, their role is controversial, with variable data among different studies and between individual responses. In all of these reviews and in specific studies identified therein and below, the wide variation in dosages and formulations used, and often lack of information on a Discipline of Nutrition, FM&HS, The University of Auckland, Auckland, New Zealand b Food Science Programmes, FoS, The University of Auckland, Auckland, New Zealand c Department of Chemical and Materials Engineering, FoE, The University of Auckland, Auckland, New Zealand d Nutrigenomics New Zealand; Web: http://www.nutrigenomics.org.nz

60 | Food Funct., 2010, 1, 60–72

storage conditions and administration methods, makes it difficult to reach an informed opinion on potential benefits, or to recommend dosages for specific treatment goals. The method of presentation of the n-3 PUFA could be expected to have a direct impact on the bioavailability and efficacy of the nutrient. It has been shown that with foods high in naturally occurring n-3 PUFA the cooking method has a direct impact on the amount of EPA and DHA retained in the product.5–7 The options for including PUFA into fortified foods include direct addition of a high n-3 PUFA source such as fish oil, or incorporation of stabilised emulsions or microcapsules. The impact of subsequent food processing steps, such as cooking, is not well reported in the literature. Although many commercial products such as breads and spreads incorporate these ingredients, much of the knowledge of their preparation is proprietary. Where the impact of heating is reported,8,9 the effect on EPA and DHA levels appears to be minimal. By far the greater concern is the oxidative stability of the PUFA during storage, and antioxidants are widely incorporated into PUFA ingredients. Alternatively the n-3 PUFA is incorporated in the form of microencapsulated particles, which have improved oxidation resistance and the potential to protect the PUFA from interaction with the food matrix.10 There are a number of currently available systematic and Cochrane reviews, to effects of enteral nutrition formulas containing n-3 PUFA or of high dose supplementation with either oils or capsules of various sorts on the induction or maintenance of remission in IBD.11–15 However, sample numbers are often small and results are variable. Bassaganya-Riera and This journal is ª The Royal Society of Chemistry 2010

View Online

Hontecillas16 concluded ‘‘there is an urgent need for placebocontrolled, large-scale, multicenter clinical trials’’. We would contend that an equally urgent need is to integrate current knowledge of food science and engineering to ensure strict definitions of sample composition, storage and delivery to optimise the likely effects of these materials, before even planning such important trials.


Polyunsaturated fatty acids and common dietary sources The chemistry of fatty acids has been well described elsewhere17 but a few characteristics are outlined here. Fatty acids are linear hydrocarbon molecules which vary in the length of their acyl chain and bond type, and this gives rise to their nomenclature. Chains which consist entirely of single bonds are referred to as being saturated, while those with one double bond are monounsaturated, and those with two or more are described as polyunsaturated fatty acids (PUFA).18 Each chain is further characterized by the presence of a methyl group and a carboxyl group at either end of the molecule. The designation omega, u- or n- to PUFA refers to the position of the first double bond from the terminal methyl carbon Hence, n-3 PUFA have the first double bond in the third position, whereas for n-6 PUFA it is in the sixth position. Common names also exist for several. The n-3 PUFA group includes octadecatrienoic usually termed a-linolenic acid (18:3n-3), eicosopentaenoic acid (EPA) (20:5n-3) and docosahexaenoic acid (DHA) (22:6n-3). When inflammatory conditions are being considered, two n-6 PUFA should also be noted and these are linoleic acid (LA) (18:2n-6) and arachidonic acid (AA) (20:4n-6). Structures of some key compounds are illustrated on Fig. 1. Linoleic and a-linolenic acids participate in biochemical pathways. LA can undergo elongation and saturation to AA, and a-linolenic acid can be metabolized to EPA and DHA,4 although this process is less efficient in men than in women.19 AA has been associated with inflammation as this is the precursor for eicosanoids, whereas EPA and DHA have been shown to have ameliorating effects for inflammatory conditions.3 Thus, the

Fig. 1 n-3 Fatty acids. A ¼ a-linolenic acid, 18:3n-3; B ¼ eicosapentaenoic, 20:5n-3; C ¼ docosahexaenoic acid, 22:6n-3.


relative amounts of LA and a-linolenic acid in a food have some biological relevance, but not all cell types may respond the same way. For example the infiltration of monocytes or macrophage cells in the terminal ileum of SAMP1/Yit mice was impaired by chows containing either fish oil or perilla oil, with the perilla oil being more effective. Unfortunately the complete fatty acid profile of the oils was not reported except to say that the fish oil contained 25–30% EPA and DHA, and the perilla oil was 55– 60% a-linolenic acid with overall concentration of 8% w/w n-3 PUFA.20 Oily fish and fish oil usually contain more EPA and DHA than other foods, but not all extracted oils or oily foods are created equal. Moreover, compositional data can be confusing and unintentionally misleading, if not all the information is considered.21 Fish are biological entities and their tissue composition will reflect their genetics, diet, musculature, sea temperature and global location, season and spawning cycles. Fish store oil in their liver and tissues, primarily as a reserve for gonad development. Wild fish have more freedom to roam or migrate than farmed and as a consequence may have less fatty tissue. Thus, their lipid content and profile may be very different from those of farmed fish. However, the advantage of the farmed fish is that their diet can be controlled and may include supplementation with n-3 PUFA. Nevertheless, one cannot assume that dietary intake will always result in an equivalent change in tissue composition, and the responses may not always be as expected.22 Because of concerns of depletion of fish resources, attention is shifting towards more sustainable production of long chain n-3 PUFA. An oil rich in these products can be produced from microalgae such as Micromonas pusilla,23 and a diet enriched in such an oil shows similar protective properties to one enriched in fish oil, at least in experimental models.24 Other authors (e.g.25) are seeking a sustainable, land-based production system for long chain n-3 PUFA, including metabolic engineering of an artificial pathway that produces such compounds in plants.

Evidence for n-3 PUFA playing a role in human IBD Where dietary supplements or fortified foods are advocated for use, this is usually to address a nutritional deficiency in a population group. However, there is no reason to believe that IBD patients are deficient in these essential fatty acids. For example, no significant differences were found between the long-chain n-3 PUFA status of IBD patients compared with controls, and data did not support the concept of EPA or DHA deficiency in patients with IBD.26 These observations would agree with other studies. However, there seems some reason to believe that IBD patients may show an excessive n-3:n-6 PUFA ratio. The fatty acid composition of plasma phospholipids, anthropometric characteristics, and dietary intake data were measured on 29 UC patients, 20 CD patients, and 31 healthy controls.27 The authors reported a significantly lower lipid intake in IBD patients as compared with controls, but proportionally higher levels of n-6 fatty acids, thereby implicating n-3:n-6 PUFA ratios rather than n-3 PUFA levels per se in the pathophysiology of the disease. The significance of n-3:n-6 PUFA ratios to human health have been highlighted by several authors, including Simopoulos28 and Calder;3,4. A high n-6/n-3 ratio, is found in current Western diets, although it was not a characteristic of traditional diets. There is Food Funct., 2010, 1, 60–72 | 61


View Online

some reason to believe that this high ratio promotes the pathogenesis of many chronic diseases, in addition to IBD. A high dietary LA intake not only leads to LDL oxidation, but also interferes with the incorporation of n-3 PUFA into cell membrane phopholipids. Both n-3 and n-6 PUFA influence gene expression, but whereas n-3 PUFA have anti-inflammatory effects, reducing the expression of TNF-a, IL-1b, IL-6 and IL-8, high levels of n-6 PUFA increase the expression of pro-inflammatory genes. If n-3 PUFA do indeed have a beneficial effect in IBD, this might be expected to most effectively manifest itself in highly controlled studies such as those considering enteral nutrition. Under these circumstances, the entire diet is strictly controlled, and the formulae are unlikely to contain substances that may trigger disease symptoms. A Cochrane Database systematic review compared different enteral nutrition formulas in inducing or maintaining remission in active CD.12 While it was concluded that there was evidence for the nature and amount of fat affecting both outcomes, none of the trials included had comparable formulas with and without n-3 PUFA, or varied the ratios of n-3:n-6 PUFA. The closest was the report that compared an n-6 PUFA-containing formula with one containing monounsaturated fatty acids, and showed the latter to be superior.29 Two enteral supplements enriched with n-3 fatty acids and/or n-6 fatty acids were compared, with results suggestive of superior results for the n-3 enriched formula.30 However, remission was not an endpoint of that study, and both formulas improved clinical and biochemical markers during the course of the experiment. Even in the absence of a deficiency, n-3 PUFA dietary supplements may be beneficial because of their known antiinflammatory effects. Fig. 2 provides an illustration of some of the points at which n-3 PUFA might act to reduce chronic inflammation in IBD. A systematic review studied both published and unpublished trials on the effects of n-3 fatty acids on IBD between 1966 and 2003.4,11 The authors identified 13 controlled trials that assessed the effects on pathologically confirmed rates of induced remission or relapse, or requirements for steroids and other immunosuppressive agents in IBD. However, there was an enormous variability in considered end points across the various studies. Three studies (but only one reaching adequate statistical significance) suggested that n-3 PUFA reduced corticosteroid requirements, but there were no other consistent effects across studies. The therapeutic potential of n-3 PUFA in IBD was again reviewed.13 The authors reported that the most commonly reported adverse effects of fish oil supplements are a fishy aftertaste and gastrointestinal upsets. When recommending n-3 PUFA, the authors suggested that clinicians should be aware of any possible adverse effects. Neither review put a high emphasis on the form of the supplement and/or storage/administration conditions. Two sets of Cochrane Database systematic reviews are available on effects of n-3 PUFA supplementation on maintenance of remission in IBD. A focus on CD14 included data on patients of any age group, who were in remission at the time of recruitment, and were followed for at least six months. The intervention must have been fish oil or n-3 PUFA, given in a pre-defined dosage. The primary outcome was the rate of relapse, while secondary 62 | Food Funct., 2010, 1, 60–72

Fig. 2 Schematic representation of some of the points at which n-3 PUFA may affect the development of chronic inflammation in IBD. Long chain n-3 fatty acids (EPA and DHA) are incorporated into cell membranes where they influence the production of eicosanoids, resolvins, and cytokines. A number of n-3 PUFA act as substrates for the synthesis of eicosanoids, which in turn may directly down-regulate inflammation. This biosynthetic process may also competitively reduce the formation of eicosanoids from n-6 PUFA, which again may reduce inflammation. Long chain n-3 PUFA can also down-regulate the activation of the expression of pro-inflammatory genes, including TNF-a, Cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS) or various interleukins (IL), possibly through their effects on transcription factors or through their conversion to resolvins. They also have effects on T cell reactivity and antigen presentation (not illustrated).

outcomes included changes in disease activity scores, time to first relapse and adverse events. Six studies met the criteria for eligibility, and showed a marginally significant benefit of n-3 PUFA therapy for maintaining remission. However, the studies were both clinically and statistically heterogeneous, and two large studies showed negative results. There was also evidence for publication bias. Although no serious adverse events were seen, a pooled analysis showed a significantly higher rate of diarrhoea and symptoms of the upper gastrointestinal tract in the n-3 PUFA treatment group. The authors concluded that existing data do not support routine maintenance treatment of CD with n-3 PUFA.15 A further analysis focused on the use of fish oil for induction of remission in UC. Six studies were included, 3 of cross-over design and 3 of parallel design. No data were pooled for analysis due to differences in outcomes and methodology among the included studies. One small study showed a positive benefit for induction of remission, while some of the other included studies showed some positive benefits for secondary This journal is ª The Royal Society of Chemistry 2010

Trial design

n-3 PUFA form and dose Method of administration

Study endpoint

Result

Reference

The initial-onset Japanese Non blinded, Patients were prohibited About 3400 mg/day (2 units) Fatty acid composition In a subset of 20 initial-onset 31Uchiyama et al. (2010) patients were composed non crossover from consuming the main of ALA were ingested of the erythrocyte patients, the mean n-3/nof 12 UC patients (3 sources of dietary n-6 from 7 mL/day of perilla membranes and 6 ratio significantly males, 9 females, mean PUFA: i.e., vegetable oil; (Egoma) oil in addition to disease activity after increased after age 32.9 years and 8 CD seasonings such as a daily intake of 1700 mg 12–18 months intervention. In the patients (5 males, 3 margarine, dressings, and from fish oil (EPA, intervention follow-up group the ratio females, mean age 29.0 mayonnaise; foods DHA), taken as oil (no in the remission group (n years) who had not cooked in vegetable oil; storage recommendation, ¼ 145) was significantly undergone any diet and snacks. The target n-3 PUFA food exchange higher than that in the therapy before dietary for n-3 PUFA ingestion table relapse group (n ¼ 85). intervention. The followwas a total of 5100 mg. The ratio decreased up group was divided into The patients were able to significantly in those who 2 subgroups: the confirm the n-3 and n-6 suffered a relapse after remission and relapse PUFA contents of each the beginning of groups, and fatty acid food using an ‘‘n-3 PUFA treatment. composition was food exchange table’’ compared between the 2 subgroups. Among the UC patients, those in whom the severity was evaluated as mild were assigned to the remission group. The others were assigned to the relapse group. Among the CD patients, those in whom neither endoscopy nor contrast-enhanced radiography revealed an active lesion were assigned to the remission group. The others were assigned to the relapse group. 32 Bjørkkjær et al., 2009 18 out-patients at Randomized, controlled, Seal Oil (purchased from Ten mL were self-adminis- Plasma arachidonic acid Significant and positive tered through a nasoHaukeland University to EPA ratio and double blind pilot trial changes from baseline to JFM Sunile AS, Os, pharyngeal feeding tube Hospital (Bergen, prostaglandin E2 comparing whale oil with Norway) or Whale Oil study end were observed for 10 days, three times Norway) between 18 and seal oil, but with no levels, decreased IBD- in both groups for all (donated by Myklebust daily before meals. 75 years old with IBD, as placebo group. related joint pain and endpoints. There were no Trading AS, Myklebost, assessed by IBD-disease activity, significant differences Norway). The oils were a gastroenterologist, in and improved quality seen between seal oil or protected with nitrogen combination with of life. whale oil. on top in bottles, and presence of joint pain. stored in a refrigerator during the study, otherwise in a 20 C freezer. EPIC1: 363 patients total. Patients were eligible if Epanova capsules consisting 1-g of n-3 PUFA Clinical relapse, or No significant difference in 33Feagan et al. (2008) 188 patients were they had experienced of 50% to 60% EPA and encapsulated in initiation of treatment the relapse rate was found assigned to receive n-3 a disease exacerbation 15% to 25% DHA as a delayed-release soft for active CD. between the patients PUFA and 186 patients within the past year and a free fatty acid, The gelatin capsule (Epanova; treated with n-3 or to receive placebo. were in remission for at placebo capsule consisted Tillotts Pharma AG, placebo. least 3 months but not Ziefen, Switzerland)

Population and numbers

Table 1 Examples of human intervention studies to test effects of n-3 PUFA on IBD


View Online


Food Funct., 2010, 1, 60–72 | 63

Trial design


Study endpoint

Result

Reference

longer than 12 months. of 1 g of medium-chain Patients were randomly triglyceride oil. assigned to receive either 4 1g/d of n-3 PUFA or placebo for 52 weeks. No other treatments for CD were permitted. EPIC2: 375 patients. 189 Patients with active disease As for EPIC1. As for EPIC1 As for EPIC1 The relapse rate was 84/187 33Feagan et al. (2008) patients were randomised were treated with (44.9%) and 94/188 (50%) to n-3 PUFA and 190 a standardized 16-week in the n-3 and placebo patients to placebo. tapering course of either groups, respectively prednisone or budesonide. Eight weeks after the initiation of corticosteroid treatment, a disease was assessed. If this was less than an agreed cut off, the patient was eligible for randomization. Patients were randomly assigned to receive either 4 g/d of n-3 PUFA or placebo for 58 weeks. No other treatments for CD were permitted. A total of 38 children (5 to A double blind, placeboTRIOLIP-SOFAR, Italy; Time dependent 5-ASA (50 Primary outcome was A very high relapse rate was 34Romano et al., 2005 16 years of age, 53% controlled trial of one 1.2 g/d of EPA and 0.6 g/ mg/kg/d) + n-3 PUFA in relapse rate within found in the placebo male), 18 in the n-3 day of DHA, as year duration. one year. Time to first group of this study. The GI-resistant capsules PUFA group and 20 in triglycerides, versus relapse was also authors concluded that the controls. They were identical placebo of time recorded, but not enteric coated n-3 PUFA recruited from pediatric dependent 5-ASA (50 mg/ systematically in addition to 5-ASA are gastroenterology centers kg/d) + olive oil presented. effective for maintenance in Italy. At baseline, of remission in pediatric participants were in CD. In this study, remission. compliance was optimal, no patients were lost to follow-up and all patients were analyzed. The median time to first relapse was eight months in the intervention group compared to one month in the placebo group. A total of 78 adults (18 to 67 A double blind, placebo1.8 g/day of EPA and 0.9 g/ Enteric coated fish oil hard Relapse rates over one Significantly fewer patients 35Belluzzi et al., 1996 years of age, 50% men), controlled trial of one day of DHA, as free fatty gelatine capsule with 60 year of follow-up. from the intervention 39 in each arm from year duration. Patients acids, versus identical min delay timed release. Adverse events and group relapsed compared outpatient clinics in Italy. treated with 2.7 g/d of n-3 placebo of 500 mg Oral route of time to first relapse to placebo and it was At baseline, participants PUFA compared with Miglyol 812 (a mixedadministration were also monitored. concluded that enteric were in remission and placebo. acid triglyceride of coated, timed release n-3 high risk for relapse, as fractionated short chain PUFA is highly effective

Population and numbers

Table 1 (Contd. )


View Online

64 | Food Funct., 2010, 1, 60–72


Trial design


Study endpoint

Result

Reference

judged by an increase in fatty acids made up of in maintaining remission at least one of three caprylic and capric acid). in CD. serum inflammatory markers. A multicenter study in A double blind, placebo5g/d of highly concentrated Gelatin n-3 PUFA capsules. Primary outcome was No difference in the relapse 36Lorenz-Meyer et al., 1996 Germany. A total of 135 controlled trial of one n-3 PUFA (3.3 g/day of Oral route of the relapse- free time rate of the intervention adults (17 to 65 years of year duration. Steroids EPA and 1.8 g/day of administration period after group. The estimated 1age, 31% men) with CD, were still administered DHA, as ethyl Esther) randomization. year relapse rate was 69% 70 in the n-3 PUFA arm during the first two versus identical placebo Relapse rate and in both groups. The and 65 in the control arm. months of the study, but of corn oil. adverse events were authors concluded that At baseline, participants no other co-interventions also monitored. gelatin capsules of ethyl were in remission, were allowed. Patients ester fish oil capsules are induced by a course of were instructed to not effective for corticosteroids. consume a diet low in maintenance of remission arachidonic acid and rich in CD. in fiber and were followed every three months until one year. 37 Almallah et al., 1998 18 out-patients (9 male, 9 A double-blind, placebo- Active group: 15 ml of fish Patients received either 15 Sigmoidoscopic score, After 3 months of female) with UC. All had controlled randomised oil extract that provided ml of fish oil extract or 15 histological score, supplementation, all the distal procto-colitis. study, and a parallel a total of 3.2g of EPA and ml of sunflower oil as NK cytotoxicity and patients in the EFA group, for a 6 month 2.4g of DHA. Placebo placebo, and were flow cytometry. group went into treatment period group: 15 ml of sunflower instructed to take 5 ml, 3 Assessments were remission. After 6 months oil. All oil supplements times a day. Oil done at monthly supplementation with included 3% vitamin E. preparations were intervals. EPA/DHA there was supplied by Callanish Ltd a significant (Isle of Lewis, Scotland). improvement in disease There were no special activity as shown by the instructions for storage, reduction of the clinical although the material score, compared with contained a small amount baseline In the placebo of an antioxidant. Oral group, there was no route of administration, significant change in the oil taken as a liquid. clinical score, as compared with baseline. 38 Aslan et al., 1992 17 male patients with mild A double-blind, placebo- Active group: Max-EPA (15 Oral route of administration Disease activity, clinical Significant reduction in to moderate UC. Oral controlled, crossover capsules provided a total and laboratory disease activity index. steroids (95) for three of the ‘pure’ juices, PG01, PG02, PG03 while values of OP-1 > control, indicating that onion powder contained phytosterols. This could partially explain the hypocholesterolemic activity of onion because phytosterols compete with cholesterol for absorption. In fact, onion powder demonstrated a dose-dependent increase in the excretion of neutral sterols (Table 4). Cholesterol is mainly eliminated via its conversion to bile acids. The present study clearly demonstrated that dietary onion was able to increase the excretion of bile acids by 16–35% (Table 4). This was partially mediated by up-regulation of LXRa and CYP7A1 proteins (Fig. 2). The observation is in agreement with 88 | Food Funct., 2010, 1, 84–89

CHD CYP7A1 HDL HMGR LDL LDLR LXR SREBP-2 TC

Coronary heart disease Cholesterol 7a-hydroxylase High density lipoprotein cholesterol 3-Hydroxy-3-methylglutaryl-CoA reductase Low-density lipoprotein cholesterol LDL receptor Liver X receptor Sterol regulatory element binding protein 2 Total cholesterol.

References 1 K. T. Augusti, Indian J. Exp. Biol., 1996, 34, 634–640. 2 K. Kumari and K. T. Augusti, J. Ethnopharmacol., 2007, 109, 367– 371. 3 E. Block, Garlic and Other Alliums: The Lore and the Science, Royal Society of Chemistry, Cambridge, UK, 2010. 4 R. K. Sogani and K. Katoch, J. Assoc. Physicians India, 1981, 29, 443–446. 5 M. G. Hertog, E. J. Feskens, P. C. Hollman, M. B. Katan and D. Kromhout, Lancet, 1993, 342, 1007–1011. 6 A. Bordia, H. C. Bansal, S. K. Arora and S. V. Singh, Atherosclerosis, 1975, 21(1), 15–19.


View Online

10 Z. Y. Chen, R. Jiao and K. Y. Ma, J. Agric. Food Chem., 2008, 56, 8761–8773. 11 P. T. Chan, W. P. Fong, Y. L. Cheung, Y. Huang, W. K. K. Ho and Z. Y. Chen, J. Nutr., 1999, 129, 1094–1101. 12 N. D. Vaziri and K. H. Liang, Kidney Int., 1996, 50, 887–893. 13 C. K. Lam, Z. S. Zhang, H. Yu, S. Y. Tsang, Y. Huang and Z. Y. Chen, Mol. Nutr. Food Res., 2008, 52, 950–958.


7 M. A. Bang, H. A. Kim and Y. J. Cho, Nutr. Res. Pract., 2009, 3(3), 242–246. 8 Y. Yamamoto and A. Yasuoka, Biosci., Biotechnol., Biochem., 2010, 74(2), 402–404. 9 E. Ostrowska, N. K. Gabler, S. J. Sterling, B. G. Tatham, R. B. Jones, D. R. Eagling, M. Jois and F. R. Sunshea, Br. J. Nutr., 2004, 91(2), 211–218.


Food Funct., 2010, 1, 84–89 | 89

View Online

PAPER


Suppression of breast xenograft growth and progression in nude mice: implications for the use of orally administered sphingolipids as chemopreventive agents against breast cancer Kirk W. Simon,a Larry Tait,b Fred Miller,b Chun Cao,c Kevin P. Davy,c Tanya LeRoithd and Eva M. Schmelz*ce


Received 2nd August 2010, Accepted 28th August 2010 DOI: 10.1039/c0fo00108b Sphingolipids are lipid messengers involved in the regulation of many different cellular processes. Sphingolipid enzymes and bioactive metabolites have been targets of in vitro and in vivo efforts to suppress cancer growth, progression and metastasis of various cancer types. Dietary sphingomyelin effectively suppressed colon cancer in several rodent models without causing toxic side effects. In the present study, we determined if the effect of sphingolipid metabolites derived from the hydrolysis of dietary sphingomyelin is restricted to the intestinal tract or if their systemic concentrations are sufficient to suppress cancers of distant sites. For these studies, we used MCF10AT1 cells, a model for progressive breast cancer, injected into the mammary fatpad of nude mice as a single cell suspension. The mice were fed 0.1% sphingomyelin supplements in a semi-purified AIN76A control diet when the lesions were palpable. The study was terminated when the first lesions had grown to 5 mm. In the sphingomyelin-fed group, there was a trend to smaller lesion size and, importantly, a delayed progression to more malignant stages without apparent side effects. This may be the result of significantly reduced rates of proliferation and angiogenesis, while no increase of apoptosis was detected. Changes in aberrantly expressed proteins in the sphingomyelin-fed group, such as E-cadherin, VEGF and sphingosine kinase-1, may be associated with the suppression of tumor growth. These results demonstrate that diet-derived sphingolipids can efficiently suppress the growth and progression of MCF10AT1 xenografts, suggesting that dietary sphingomyelin may also be effective against cancers of other sites.

Introduction Breast cancer incidence and mortality has remained high, despite improved diagnostic and treatment efforts to eradicate the disease. An estimated 192,370 women were newly diagnosed in 2009 and 40,170 will die from breast cancer in the United States of America.1 Early detection improves survival,2 but preventive efforts may be more effective at maintaining health and increasing survival. Many in vitro and in vivo studies have demonstrated the preventive potential of dietary compounds; these often lack toxic side effects, and together with an easy route of administration could increase the patients’ compliance with and well-being during the prevention regimen.

a Department of Nutrition and Food Science, Wayne State University, Detroit, MI, USA b Department of Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA c Department of Human Nutrition, Foods and Exercise (HNFE), Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA d Department of Anatomic Pathology and Biomedical Sciences & Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA e Department of Human Nutrition, Foods and Exercise (HNFE), Corporate Research Center Building 23 (0913), Room 1011, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA. E-mail: [email protected]; Fax: +1 540-231-2947; Tel: +1 540-231-3649

90 | Food Funct., 2010, 1, 90–98

Sphingolipids are membrane-bound lipids with both structural and signaling properties. Sphingolipid metabolites are generated by growth factors, cytokines, cellular stresses and other factors, and as lipid second messengers are involved in the generation of an appropriate cellular response. These responses include the regulation of cell growth, differentiation, cell death, motility, angiogenesis, inflammation and many more processes in a concentration, structure, time and cell type-specific manner.3,4 Several enzymes in sphingolipid metabolism have been identified as targets for drug treatments to generate a sphingolipid pattern that exerts anticancer activities, such as the suppression of cell growth, motility, angiogenesis, etc. Among these enzymes are sphingomyelinases,5,6 glucosylceramide synthase,7 sphingosine kinase 1,8,9 sphingosine-1-phosphate lyase,10 sphingosine-1-phosphate phosphatase11,12 and others. However, the inhibitors are sometimes not sufficiently specific and can cause adverse side effects. Furthermore, cancer cells can exhibit an aberrant expression or activity of these enzymes, rendering the cells resistant to the regulatory stimuli. Thus, the delivery of bioactive metabolites directly to the cancer cells is an attractive alternative. We have shown in previous studies that administration of natural or synthetic complex sphingolipids via the diet suppressed chemically-induced colon cancer13–18 or cancer caused by gene mutations in mice19,20 by up to 80%. There were no side effects of this route of administration in any of our studies, and even very high doses used in other studies were tolerated well.21 This journal is ª The Royal Society of Chemistry 2010


View Online

Diet-derived sphingolipid metabolites are taken up in the gastrointestinal tract, and a small portion is transported to the liver via the lymphatic system, mostly as sphingosine and fatty acids.22–24 Free sphingoid bases can also be re-utilized for the synthesis of more complex sphingolipids such as sphingomyelin (SM), and can be incorporated into chylomicrons and secreted from the intestinal tract; the impact of dietary SM on the content of SM in plasma lipoproteins, however, remains unclear.25 To determine if the diet provides sufficient amounts of bioactive metabolites to prevent cancer of distant sites in the body, in the present study, we investigated if orally administered SM can suppress breast cancer growth and progression. The amounts used in this study, 0.1% by weight, were highly effective against colon cancer (see above) without causing serious side effects, and are about 5–10 times higher than the daily intake in humans, which has been estimated at 0.01 to 0.02% of the diet.26 A recent study demonstrated that in humans, a dose of 250 mg SM is sufficient to increase SM and SM metabolites in the colon.24 The focus of this study is to determine if SM supplements are sufficient to affect breast xenograft growth and progression using, in contrast to a strictly chemopreventive approach, in which the diet is supplemented before cell injection, a study design in which SM is added to the diet when the lesions are palpable. As a model for proliferative breast disease, we used MCF10AT1 cells, pre-malignant human breast epithelial cells derived from the spontaneously immortalized, normal appearing MCF10A cells by transfection with a constitutively active Ha-ras.27 Although ras mutations are rare events in humans and only found in approximately 5% of patients, the aberrant activation of Ras and down-stream targets of Ras are seen in human breast cancer overexpressing ErbB-228 or Notch,29 and it is thought that activated Ras can contribute to transformation, unlimited proliferation,29,30 motility and invasion.31 Ha-ras alone, however, is not sufficient to induce transformation.32 Lesions formed in this system include mild to moderate hyperplasia, atypical hyperplasia, carcinoma in situ, moderately differentiated carcinoma, and undifferentiated carcinoma, as well as histologically normal ducts.32 Thus, the MCF10AT1 cell line represents a model for the slow and heterogeneous progression of preneoplastic breast cells and provides a transplantable xenograft model of human proliferative breast disease with proven neoplastic potential32,33 that is ideal to test the capacity of natural compounds to suppress breast cancer development and progression in vivo.

cells while on the semi-purified AIN76A diet; once the lesions were palpable, the SM group received 0.1% SM in the diet, and the development of the lesions was compared to the controls who did not receive any supplements. SM supplements did not affect the health of the mice as reflected by their general appearance and weight. The mean weight of the control group (27.8 2.3 g) did not differ significantly from the SM-fed group (25.8 0.5 g) (p ¼ 0.663). This confirms earlier studies from our and other’s laboratories that neither a sphingolipid-free diet nor SM supplements to the diet (up to 1% by weight21) cause adverse side effects, and SM is therefore safe to use as a dietary supplement in our studies. Since cells were injected at two conlateral sites per mouse, the development of 30 lesions (2 per mouse) was possible in each group. In the control group, 22 lesions were detected (1.47 per mouse), and 25 in the SM-fed group (1.67 per mouse); this difference is not statistically significant (p ¼ 0.417). There were 2 mice without lesions in each group (13.3%). This lesion development lies in the expected range for this cell line when injected into nude mice in a Matrigel solution.27 The volume of the lesions was lower in the SM-fed group, albeit not statistically significant (99.33 23.99 mm3 in the control and 63.72 7.89 mm3 in the SM-fed group; p ¼ 0.190). This is especially interesting, since we added the SM supplements only after the lesions were already palpable and not as a strictly preventive regimen before cell injection. MCF10AT1 cells were organized as ducts rather than as cell clusters; this confirms previous findings demonstrating that these cells form structures that resemble normal human breast ducts when injected into nude mice in a Matrigel solution.27 The lesions were solid and without a necrotic core. It is important to note the difference in the amount of stromal tissue in individual xenografts. Some lesions consisted mostly of epithelial cells, and there was very little stromal tissue visible (Fig. 1A), while it was more abundant in others, and the epithelial cells appeared as small islands of ducts (Fig. 1B, arrows). Stromal tissue has been shown to generate a microenvironment that regulates breast cell growth, migration, morphology, differentiation, migration and survival.34 In cancer, the cancer cells signal to alter protein secretion of the stroma but stroma activated by inflammatory signals is involved in tumor development and progression (see

Results and discussion Sphingomyelin suppressed tumor development and progression. Sphingolipids are natural components of the diet that are hydrolyzed in the intestinal tract to the bioactive metabolites ceramide and sphingosine, which are taken up by the intestinal cells and either degraded or incorporated into complex sphingolipids.22,23 The exposure to these bioactive metabolites is sufficient to suppress colon cancer in mice.13–20 Only a small fraction of the absorbed sphingolipid metabolites reaches systemic distribution;22,23 therefore, the highest dose effective in colon cancer prevention was used for the present study. Female NCR nude mice (8 weeks old) were injected with MCF10AT1 This journal is ª The Royal Society of Chemistry 2010

Fig. 1 MCF10AT1 xenograft architecture. MCF10AT1 cells are organized either as tightly packed breast-like ducts with little (A) or high (B, arrows) amounts of stromal tissue with no apparent difference between the control group fed the AIN76A diet alone and the SM supplemented group (0.1%, by weight).

Food Funct., 2010, 1, 90–98 | 91

View Online


Fig. 3 Suppression of progression. Mice (n ¼ 15 per group) were injected with MCF10AT1 cells while being fed the AIN76A diet. After the lesions were palpable (after 4 weeks), the diet of the SM group was supplemented with 0.1% of SM. Using the criteria in the Experimental, the area of the highest disease stage found in one lesion determined the overall category of the lesion. (different at p < 0.05).

immunohistochemical methods but changes in gene expression levels in the stroma as a result of SM treatment will be considered in future studies using real-time PCR. We next determined the progression of the MCF10AT1 cells using the criteria outlined in the Experimental section to define the different disease stages, as shown in Fig. 2. Most of the xenografts in the SM-fed group progressed to stage 2 (22 or 88%), characterized by moderate hyperplasia, bridging and papillary hyperplasia. Only two areas of stage 3 (8%) and one of stage 5 (4%) were detected in this group. In contrast, half of the xenografts in control animals progressed further and exhibited areas of stage 3 (6 or 27.3%), 4 (2 or 9.1%) and 5 (3 or 13.6%) (different from the SM-fed group at p ¼ 0.0212) (Fig. 3). This lies closely in the range of the progression rate reported for this cell line.27 These results indicate that SM supplements suppressed or delayed the progression of these lesions, confirming our hypothesis that diet-derived SM metabolites are sufficient to exhibit a systemic effect and suppress breast cancer progression without causing side effects. Thus, dietary sphingolipids are not only effective against colon (our previous studies) and liver cancer35 but can successfully target cancer of distant sites in the body. Whether dietary sphingolipids are as effective against more aggressive breast cancer lesions is currently being investigated in our laboratory. Fig. 2 MCF10AT1 xenograft lesions. The lesions were graded using the criteria outlined in the Experimental to approximate the scoring system in place for human surgical specimen: A, stage 0, normal ducts; B, stage 1, mild hyperplasia with multiple layers (arrows); C, stage 2, moderate hyperplasia with bridging (arrow); D, stage 3, atypical hyperplasia; E, stage 4, carcinoma in situ; F, stage 5, invasive carcinoma (arrow); G, fibrocystic structure (arrow) and hyperplastic duct.

recent review34). Thus, the interactions of tumor stroma and epithelial cells can have a profound effect on the progression of the epithelial cells, and the tumor size per se may not truly reflect the preventive potential of the tested compound; the epithelial and stroma geno- and phenotype may be more critical. In this study, the amount of stroma was not the same in sections of different areas of a single xenograft or among the lesions found in one mouse; thus, an association of SM supplements and the epithelial cell to stroma ratio could not be made by 92 | Food Funct., 2010, 1, 90–98

Sphingomyelin reduced cell proliferation but did not induce apoptosis Sphingolipid metabolites regulate cell growth both in vitro and in vivo. Since unlimited proliferation is considered a driving force for progression, the effect of the SM supplements on the rate of proliferation in the breast xenografts was determined using Ki-67 expression as a marker. As shown in Fig. 4, SM supplements significantly suppressed the proliferation of MCF10AT1 xenografts (22.9 2.1% Ki-67 positive nuclei in the control group vs. 11.6 1.7% in the SM-fed group; p < 0.001). One objective of many anticancer treatments is the induction of apoptosis in cancer cells to eradicate tumors. Sphingolipid metabolites induce apoptosis in many cancer cell lines in vitro; therefore, we also evaluated the rate of apoptosis in the MCF10AT1 xenografts. There were very few epithelial cells in This journal is ª The Royal Society of Chemistry 2010

View Online


by the general appearance of the mice, a comparable weight gain and blood parameters we have reported previously (normal blood urea nitrogen, creatinine, albumin, serum glutamate pyruvate transaminase, alkaline phosphatase, etc.14). This may be the result of a limited digestion of complex sphingolipids, which prevents the generation of toxic levels of bioactive sphingolipid metabolites in the intestinal tract.42 Even the feeding of SM over two generations did not affect the health of rats,21 suggesting that the supplementation of the diet with SM is a safe route of administration. Sphingomyelin reduced VEGF expression and the number of blood vessels in the xenografts The growth and progression of tumors are dependent on a sufficient supply of nutrients and oxygen, and thus on the establishment of blood vessels. In addition to the vascular endothelial growth factor (VEGF) secretion by endothelial and stromal cells, breast cancer cells also secrete VEGF to stimulate angiogenesis by enhancing endothelial migration, proliferation and survival,43 but also to attract mesenchymal stem cells that differentiate into stroma.44 To evaluate if the suppression of growth and progression of MCF10AT1 xenografts by dietary SM is associated with a reduced angiogenesis, the expression of VEGF in the xenografts was determined by immunohistochemistry. VEGF was expressed in endothelial cells without apparent differences among the treatment groups, but there was also significant immunostaining of the epithelial cells. The control

Fig. 4 Inhibition of proliferation by orally administered sphingomyelin. Sections from the control (Ctrl) or sphingomyelin-fed (SM) group (n ¼ 15 per group, 5 images per section) were immunostained for Ki-67 as a marker for proliferation and expressed as percent Ki-67 positive cells. *p < 0.001.

either group that were stained positive for activated caspase-3, with most sections being completely negative (not shown). The lack of apoptosis was verified by evaluating the shape of the nuclei in H&E stained sections—condensed or fragmented nuclei of epithelial cells were rarely detected, indicating that orally administered SM did not induce apoptosis in the xenografts. This low rate of apoptosis in MCF10AT1 xenografts is not specific for our study but has been reported before in MCF10AT1 cells grown in three-dimensional cultures36 or as xenografts37,38 These results confirm our previous observations and the reports of other groups that dietary sphingolipids do not induce apoptosis above normal levels in the colon,16,17 liver35,39,40 or spleen.40 Instead, we have previously observed a suppression of aberrant proliferation in the colonic mucosa.16,17 Thus, dietary sphingolipids may exert their antitumor effect against colon and breast cancer in part by reducing the rate of proliferation. This is in contrast to many other natural compounds that clearly show an association of tumor suppression and the induction of apoptosis by many different pathways41 but may be associated with the lack of toxic side effects of dietary sphingolipids, which was apparent This journal is ª The Royal Society of Chemistry 2010

Fig. 5 Regulation of angiogenesis by dietary sphingomyelin. Sections of tumors from the control group (Ctrl) and SM-fed group (SM) were immunostained with VEGF (A, B) or Pecam-1 (C). A moderate to high expression of VEGF was detected in the lower grade ducts of the control group (A) with high levels in higher grades (unspecific luminal staining). Low to moderate levels were seen in the SM-fed group (B). PECAM-1 staining was used to visualize endothelial cells (C), and blood vessels were counted in 10 high-powered viewing fields (HPVF) per section (D). The number of blood vessels per HPVF was significantly higher in the control (Ctrl) group than in the SM-fed group (p < 0.001).

Food Funct., 2010, 1, 90–98 | 93


View Online

group expressed moderate to high levels of VEGF in lower grade ducts (Fig. 5A) but higher levels in more advanced stages. Undetectable/very low to moderate levels of VEGF were observed in the SM-fed group (Fig. 5B) (luminal staining is unspecific). Higher grade lesions (stage 5) in either group showed substantial VEGF staining. These results confirm previous findings, demonstrating a reduction of VEGF mRNA expression levels in the colonic mucosa of Min mice after feeding sphingolipids for four weeks.20 Immunostaining for Pecam-1 allowed for the visualization of blood vessels (Fig. 5C) in the xenografts. In the control group, there were 5.41 0.26 blood vessels per high-powered viewing field (Fig. 5D); SM significantly reduced the number of blood vessels to 3.39 0.18 (p < 0.001). There was no consistent difference in the size of these blood vessels between the groups, but it appeared that there were generally more and larger vessels associated with the stromal tissue than with areas of tightly packed epithelial tissue. These results demonstrate the suppression of angiogenesis by SM, possibly via suppression of VEGF expression. It has been shown that stromal cells directly adjacent of tumor cells promote angiogenesis via the activation of gene expression;45 the secretion of VEGF by stromal cells has been

suggested to be a contributing factor.46 Thus, the phenotype of the stroma appears to be critical for tumor growth and progression, and the effect of dietary SM on tumor-associated stroma and its secretion of growth factors and other tumorsupporting proteins needs to be evaluated in more detail. Expression levels of gene products associated with progression of breast cancer The promotion and progression of tumor cells is associated with changes in the expression levels of specific proteins, usually identified as tumor suppressors or promoters. In heterogenic diseases such as breast cancer, this protein expression pattern can be employed to predict the progression of the tumor cells and their response to treatment, and therefore these proteins are potential biomarkers for in vivo efficacy determinations. To confirm the suppression of progression by orally administered SM and to identify targets that are altered by the treatment, we used immunohistochemistry to evaluate changes in gene products that have been associated with breast cancer progression and may be a potential biomarker for SM efficacy against breast cancer in vivo.

Fig. 6 Expression levels and the localization of proteins associated with breast cancer progression are altered with dietary SM. E-cadherin expression in the control group (A low, B high magnification) and the SM-group (C low, D high magnification); H4K16ac in control (E) and SM-group (F); (G) cytokeratin expression confirms the epithelial origin of the ducts; (H) Vimentin expression in the control group; (I, K) Vimentin-positive myoepithelial cells; (L) SK1 expression; (M) ceramide kinase expression (the luminal staining of the duct-like structure is unspecific).

94 | Food Funct., 2010, 1, 90–98



View Online

The loss of E-cadherin is a frequent early event in cancers of many organs such as colon, the ovaries and also breast.47 This has been associated with changes in cellular architecture that may permit the epithelial–mesenchymal transition (EMT), cancer progression and invasion.48,49 In our study, there was weak to no expression of E-cadherin in the control group, even in lower grade lesions (Fig. 6A). Higher magnification showed an expression of E-cadherin in some ducts, predominantly located in the cytoplasm (Fig. 6B). The staining in these cells was sometimes diffuse but also appeared granulated, sometimes localized in the perinuclear area. In contrast, most of the ducts in the SM-fed group exhibited E-cadherin positive staining in at least some cells of each duct (Fig. 6C). Here, E-cadherin was often localized at the membranes (Fig. 6D), but diffuse or sometimes granular cytoplasmic expression was often seen in ducts lacking membranous E-cadherin. The appearance of cytosolic E-cadherin in the early stages has been described in premalignant breast lesions as a result of increased endocytosis, leading to a loss of membrane anchoring that weakens adhesion, and altered cell dissociation, motility and invasive potential.49,50 Later stages of breast cancer, even ductal carcinoma in situ, often demonstrate a complete loss of E-cadherin protein expression.51 Overexpression of E-cadherin in MDA-MB-231 cells partially restored the epithelial morphology with increased cell–cell contacts and adhesion, and reduced migration properties.52 It is not known if there is a different function of the cytosolic and membrane-bound E-cadherin since the cells increased the expression levels in both cellular fractions,52 but the expression and recruitment of tumor suppressors such as PTEN are dependent on the E-cadherin/b-catenin complex at the adherens junctions.53 Natural compounds in the diet can restore the expression of E-cadherin and suppress invasion.54 Thus, the regulation of E-cadherin expression and localization may affect several signaling intermediates restoring cellular differentiation and suppressing proliferation. Since E-cadherin expression is often down-regulated via epigenetic silencing—also reported in breast cancer55—we investigated the global methylation of histones as a marker for transcriptional regulation; the loss of histone 4 lysine 16 acetylation (H4K16ac) has been suggested to be a hallmark of human cancer cells56 and has been found to be associated with larger breast tumors.57 H4K16 hypoacetylation also has been observed in the silencing of E-cadherin.58 As shown in Fig. 6E and 6F, SM feeding leads to an increase in H4K16 acetylation, which followed the stage distribution of the tissue in most cases; in SM-fed mice, positive nuclei were also seen in stage 3 (Fig. 6F). The cytosolic staining seen with this antibody is unspecific since it was still visible in the sections treated with blocking peptides. While these results need to be confirmed in a larger study, and further corroborated by chromatin immunoprecipitation and quantitative PCR analysis for specific epigenetically regulated genes, they suggest that dietary SM indeed affects histone marks involved in epigenetic silencing and thereby potentially influences the expression of genes such as E-cadherin. The mechanisms for gene expression regulation are currently a research focus in our laboratory. Next, we investigated the expression of vimentin, expressed after EMT, and thus indicative of progression. All ducts expressed cytokeratin, confirming their epithelial nature This journal is ª The Royal Society of Chemistry 2010

(Fig. 6G). There was no vimentin expression in the lower grade lesions of either group, but a diffuse staining in higher grade lesions in both groups (Fig. 6H). Since there were less higher grade lesions in the sphingomyelin-fed group, there was also less vimentin staining. Myoepithelial cells also stained strongly positive for vimentin, as has been reported previously.59 These cells closely surround the ducts formed by the MCF10AT1 cells (Fig. 6I). There was no apparent difference in the number of myoepithelial cells between the groups. However, myoepithelial cells have been shown to regulate breast epithelial polarity, morphogenesis, differentiation, etc. via secretion of regulatory factors such as laminin-1, fibronectin, matrix metalloproteinases, ephrin receptor B4, pleiotrophin and others, and are thought to suppress breast cancer progression.60 While there is a reported loss of myoepithelial cells during breast cancer progression,60 the most drastic and consistent changes during this progression occur in myoepithelial cells, specifically in genes encoding secretory and cell surface proteins.61 Since this can alter their function and interaction with breast epithelial cells and affect their role in cancer progression, the changes in their gene expression levels—and functions—in response to sphingolipid metabolites is therefore an important question. We have investigated the expression of other proteins often associated with breast cancer progression but did not find either a consistent or reproducible change in their expression (CXCL4, SDF-1, Her-2, pHer-2 EGFR, pEGFR), or their expression levels were low or not changed by dietary SM (Cyclin D1, N-cadherin, F4/80). However, as reported above, several molecular markers for breast cancer progression were aberrantly expressed in advanced stages and were affected by the dietary SM, suggesting that these proteins may be involved in the suppression of breast cancer progression by dietary SM. Expression of sphingosine kinase-1 and ceramide kinase Changes in the expression of enzymes regulating the sphingolipid metabolism that result in changes in the expression pattern of sphingolipid metabolites have been reported in several cancers, including breast cancer. Sphingosine kinase-1 (SK1) generates sphingosine-1-phosphate, which, in contrast to sphingosine or ceramide, mostly promotes cell growth, motility, inflammation, tumorigenesis, angiogenesis and invasion, and therefore has been implicated in the uncontrolled growth of cancer cells.8,62 SK1 exhibits higher expression levels in estrogen receptor-negative breast tumors and has been associated with a higher rate of metastasis and a worse outcome.63 SK1 expression was detected in the cytosol of approximately half of the fibrocystic structures (depicted in Fig.2G) in the control lesions (Fig. 6L) and only occasionally in the duct-like structures. There was no SK1 expression, even in the higher-grade ductal structures in the SM-fed group, and only an infrequent staining of the fibrocystic structures. Nuclear SK1 was only detected in small areas of one lesion per group, and therefore appears not to be important in the progression of MCF10AT1 lesions. Ceramide kinase is a less well-described member of the sphingolipid metabolic enzyme family that generates ceramide1-phosphate (C1P). In lung cancer cells, C1P increased survival and stimulated proliferation.64 We did not detect drastic differences between the controls and the sphingomyelin-fed group in Food Funct., 2010, 1, 90–98 | 95

View Online


both groups: ceramide kinase was weakly to strongly expressed in the cytosol of few epithelial cells, and often also in the nucleus (Fig. 6M). A high ceramide kinase expression, however, has been shown in estrogen receptor negative breast cancers and was associated with a worse prognosis.65 It has been reported that C1P in macrophages and other immune cells plays a role in inflammatory processes (see the recent review66). Thus, the cancer cells may not be the only critical cell population expressing ceramide kinase; this needs to be investigated in an immune competent model.

Experimental Cell culture MCF10AT1 cells were obtained from the Cell Core at the Karmanos Cancer Institute at Wayne State University, Detroit, MI. Cells were routinely cultured at 37 C in DMEM/Ham’s F12 (1 : 1) (Gibco, Invitrogen), supplemented with 5% horse serum (Gibco), 10 mg ml1 insulin (Sigma, St. Louis, MO), 0.02 mg ml1 EGF (Calbiochem, San Diego, CA), 0.5 mg ml1 hydrocortisone (Sigma) and 0.1 mg ml1 cholera toxin (Calbiochem) in 5% CO2 in a humidified atmosphere.

criteria of Dawson et al. (1996). The lesions were classified according to the highest grade found in the xenograft. The categories were defined as follows: 0 simple small tubules with 1–2 cell layers, no nuclear enlargement. 1 mild hyperplasia, simple small tubules with >2 cell layers but no bridging or architectural complexity, variable nuclear contours. 2 moderate hyperplasia, mildly distended ducts, 4 or more layers of epithelial cells, bridging, irregularly shaped lumen, papillary hyperplasia. 3 atypical hyperplasia, grossly distended ducts, marked cellular proliferation often forming luminal mass, some loss of polarity, cells become monotonous, tendency to clear cytoplasm with distinct borders, enlarged, non-round nuclei, small nucleoli, occasional mitoses. 4 carcinoma in situ, distended ducts filled with uniform cells, rigid intraluminal bridges forming round spaces, occasional central necrosis, distinct cell boundaries, uniform round, hyperchromatic, enlarged nuclei, frequent mitoses. 5 invasive carcinoma, glandular, squamous or undifferentiated.

Animals and diets

Immunohistochemical analyses

Female NCR nude mice (seven weeks old) were purchased from Taconic (Germantown, NY). Upon arrival, they were randomly divided into two experimental groups (n ¼ 15 per group) and weighed to ensure an equal weight. After acclimatization for one week, they were placed on the semi-purified AIN 76A diet (Dyets, Bethlehem, PA). This diet is essentially sphingolipid-free,67 in contrast to the newer formulations that contain soy oil and may contain significant amounts of glucosylceramide. Since sphingolipids are not essential nutrients, placing animals on sphingolipidfree diets is not harmful and has neither caused adverse effects in any of our studies, nor those published by others.

Tissue sections were immunostained using our established procedures.19 Briefly, sections were deparaffinized in xylene, re-hydrated through graded alcohol and steamed in citrate buffer (Target Retrieval Solution, Dako, Carpinteria, CA) for antigen retrieval if suggested for the specific antibody by the manufacturer. Endogenous peroxidase activity was blocked with Peroxoblock (Zymed, Carlsbad, CA). Blocking of the sections for 1 h was followed by overnight incubation at 4 C with the indicated antibodies, without primary antibody or with antibody plus blocking peptide as negative or antibody specificity controls. The sections were rinsed, incubated with the appropriate secondary antibodies for 1 h at room temperature, and treated with the ABC staining systems (Vector, Burlingame, CA) according to the manufacturer’s instructions. The immunocomplex was visualized with diaminobenzidine (Dako). The sections were briefly counterstained with hematoxylin (Zymed) and permanently mounted with Histomount (Zymed). All images were digitally captured on a Nikon Eclipse 80i epifluorescence microscope, equipped with DIC, digital cameras, and acquisition and analysis software (NIS Elements). Images were processed with Adobe Photoshop. Antibodies used in this study were generated against Ki-67 (Dako), activated Caspase-3 (Cell Signaling, Danvers, MA), ceramide kinase (Abgent, San Diego, CA), CRCX4 (R&D), cytokeratin (Sigma), SDF-1 (R&D), E-cadherin (R&D Systems), H4K14ac (abcam), N-cadherin (abcam), EGFR (Upstate Biolabs, Chicago, IL), F4/80 (abcam), Her-2 and phospho-Her-2 (Cell Signaling), VEGF (Santa Cruz), SK1 (Imgenex, San Diego, CA), Vimentin (Dako) and Pecam1 (Santa Cruz). The quantitation of proliferation was achieved by immunostaining for Ki-67. A red filter was used to obscure staining and pictures were taken from 5 randomly selected areas per slide in a blinded manner. The nuclei stained positively for Ki67, all unstained epithelial nuclei were counted, and the rate of proliferation was

Xenografts and treatment Cells were grown to approximately 70% confluence and harvested by gentle trypsination. 1 107 cells were mixed into 100 ml of cold Matrigel (BD, Franklin Lakes, NJ) and subcutaneously injected into the area of two contralateral mammary fatpads per mouse. When the xenografts were palpable (approximately 1–2 mm in diameter, 4 weeks later), one group of mice was placed on the AIN 76A diet containing 0.1% sphingomyelin (by weight) (Avanti, Alabaster, AL), while the control group did not receive any dietary supplements. After the xenografts reached a size of about 5 mm (16 weeks after injection), the mice were killed, the xenografts excised, measured, fixed overnight in 10% neutral buffered formalin, embedded in paraffin and sectioned for immunohistochemical analyses at 4–5mm. The tumor volume was calculated by the formula: V ¼ {W2 L} O 2, where V is the tumor volume, W is the width and L is the length. Determination of progression Hematoxylin and eosin-stained sections of each animal were graded in a blinded manner for progression according to the 96 | Food Funct., 2010, 1, 90–98



View Online

expressed Ki67 positive as a percentage of all nuclei. Data are expressed as mean SEM.

funds from the Prevention Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.

Determination of angiogenesis

References

Sections were immunostained (as described above) for Pecam1 to visualize blood vessels in the xenografts. 10 high-powered viewing fields per section were randomly selected by a person unaware of the treatment at 40 magnification, and all the visible blood vessels that stained positive for Pecam-1 and/or showed blood cells were counted. Other vessels that might have been lymphatic vessels and microvessels without Pecam1 staining were not counted in any section. Furthermore, the diameter of the blood vessels were not measured since the random angle of sectioning the vessels did not allow for the quantitation of this parameter. 20 tumors per group were analyzed by this method. Data are expressed as the mean number of blood vessels per highpowered viewing field SEM.

1 M. J. Horner, L. A. G. Ries, M. Krapcho, M. Neyman, R. Aminou, N. Howlader, S. F. Altekruse, E. J. Feuer, L. Huang, A. Mariotto, B. A. Miller, D. R. Lewis, M. P. Eisner, D. G. Stinchcomb, B. K. Edwards (eds). SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. 2 H. D. Nelson, K. Tyne, A. Naik, C. Bougatsos, B. K. Chan and L. Humphrey, Ann. Intern. Med., 2009, 151, 727–737 (W237–W742). 3 W. Zheng, J. Kollmeyer, H. Symolon, A. Momin, E. Munter, E. Wang, S. Kelly, J. C. Allegood, Y. Liu, Q. Peng, H. Ramaraju, M. C. Sullards, M. Cabot and A. H. Merrill, Jr, Biochim. Biophys. Acta, Biomembr., 2006, 1758, 1864–1884. 4 N. Bartke and Y. A. Hannun, J. Lipid Res., 2009, 50 Suppl., S91–96. 5 G. Grammatikos, V. Teichgraber, A. Carpinteiro, T. Trarbach, M. Weller, U. R. Hengge and E. Gulbins, Antioxid. Redox Signaling, 2007, 9, 1449–1456. 6 E. L. Smith and E. H. Schuchman, Mol. Ther., 2008, 16, 1565–1571. 7 Y. Y. Liu, T. Y. Han, A. E. Giuliano and M. C. Cabot, J. Biol. Chem., 1999, 274, 1140–1146. 8 V. E. Nava, J. P. Hobson, S. Murthy, S. Milstien and S. Spiegel, Exp. Cell Res., 2002, 281, 115–127. 9 M. Kohno, M. Momoi, M. L. Oo, J. H. Paik, Y. M. Lee, K. Venkataraman, Y. Ai, A. P. Ristimaki, H. Fyrst, H. Sano, D. Rosenberg, J. D. Saba, R. L. Proia and T. Hla, Mol. Cell. Biol., 2006, 26, 7211–7223. 10 M. Serra and J. D. Saba, Adv. Enzyme Regul., 2009. 11 W. I. Leong and J. D. Saba, Biochimie, 2010, 92, 716–723. 12 N. J. Pyne, J. S. Long, S. C. Lee, C. Loveridge, L. Gillies and S. Pyne, Adv. Enzyme Regul., 2009. 13 D. L. Dillehay, S. K. Webb, E. M. Schmelz and A. H. Merrill, Jr, J. Nutr., 1994, 124, 615–620. 14 E. M. Schmelz, D. L. Dillehay, S. K. Webb, A. Reiter, J. Adams and A. H. Merrill, Jr, Cancer Res., 1996, 56, 4936–4941. 15 E. M. Schmelz, A. S. Bushnev, D. L. Dillehay, D. C. Liotta and A. H. Merrill, Jr, Nutr. Cancer, 1997, 28, 81–85. 16 E. M. Schmelz, M. C. Sullards, D. L. Dillehay and A. H. Merrill, Jr, J. Nutr., 2000, 130, 522–527. 17 L. A. Lemonnier, D. L. Dillehay, M. J. Vespremi, J. Abrams, E. Brody and E. M. Schmelz, Arch. Biochem. Biophys., 2003, 419, 129–138. 18 K. W. Simon, P. C. Roberts, M. J. Vespremi, S. Manchen and E. M. Schmelz, Mol. Nutr. Food Res., 2009, 53, 332–340. 19 E. M. Schmelz, P. C. Roberts, E. M. Kustin, L. A. Lemonnier, M. C. Sullards, D. L. Dillehay and A. H. Merrill, Jr, Cancer Res., 2001, 61, 6723–6729. 20 H. Symolon, E. M. Schmelz, D. L. Dillehay and A. H. Merrill, Jr, J. Nutr., 2004, 134, 1157–1161. 21 T. Kobayashi, T. Shimizugawa, T. Osakabe, S. Watanabe and H. Okuyama, Nutr. Res., 1997, 17, 111–123. 22 A. Nilsson, Biochim. Biophys. Acta, Lipids Lipid Metab., 1969, 187, 113–121. 23 E. M. Schmelz, K. J. Crall, R. Larocque, D. L. Dillehay and A. H. Merrill, Jr, J. Nutr., 1994, 124, 702–712. 24 L. Ohlsson, E. Hertervig, B. A. Jonsson, R. D. Duan, L. Nyberg, R. Svernlov and A. Nilsson, Am. J. Clin. Nutr., 2010. 25 A. Nilsson and R. D. Duan, J. Lipid Res., 2005, 47, 154–171. 26 H. Vesper, E. M. Schmelz, M. N. Nikolova-Karakashian, D. L. Dillehay, D. V. Lynch and A. H. Merrill, Jr, J. Nutr., 1999, 129, 1239–1250. 27 P. J. Dawson, S. R. Wolman, L. Tait, G. H. Heppner and F. R. Miller, Am. J. Pathol., 1996, 148, 313–319. 28 F. C. von Lintig, A. D. Dreilinger, N. M. Varki, A. M. Wallace, D. E. Casteel and G. R. Boss, Breast Cancer Res. Treat., 2000, 62, 51–62. 29 S. Mittal, D. Subramanyam, D. Dey, R. V. Kumar and A. Rangarajan, Mol. Cancer, 2009, 8, 128. 30 G. J. Clark and C. J. Der, Breast Cancer Res. Treat., 1995, 35, 133–144.

Statistical analyses Experimental groups were compared using the unpaired t-test after ANOVA for groups that had values sampled from Gaussian distributions. An unpaired t-test followed by Welch’s correction was used when the standard deviations differed significantly among the groups, and the non-parametric Mann– Whitney test was used in groups that did not follow a Gaussian distribution. These statistical analyses were performed with Instat 3.0a (GraphPad Software, Inc.). The association of tumor progression and dietary supplementation was calculated using the one-sided Mantel–Haenszel chi square test.

Conclusion The present study demonstrates for the first time that dietary SM in amounts that are approximately 2.5 to 10 times higher than the estimated human intake of complex sphingolipids26 suppressed the growth and progression of MCF10AT1 xenografts without causing adverse side effects. This was associated with a significantly reduced rate of angiogenesis. Proteins that are aberrantly expressed in breast cancer progression, i.e., E-cadherin, VEGF and enzymes of the sphingolipid metabolism that could generate a pro-tumorigenic microenvironment, i.e., SK1, were targeted by the diet-derived sphingolipid metabolites and exhibited more normal expression levels or protein localization in the SM-fed group, suggesting the possibility that their functions may be restored. Whether these gene products can be used as molecular markers for sphingolipid efficacy in vivo remains to be determined. However, our results demonstrate systemic, in addition to the previously described local, effects of diet-derived sphingolipid metabolites. Whether the amounts of SM that were effective in this pre-malignant breast cancer model can also prevent tumor growth and progression in more advanced models is currently under investigation in our laboratory.

Acknowledgements This study was supported by NCI grant R03 CA101125, The Susan G. Komen Race for the Cure grant BCT0503453 and This journal is ª The Royal Society of Chemistry 2010

Food Funct., 2010, 1, 90–98 | 97


View Online

31 H. Y. Yong, I. Y. Kim, J. S. Kim and A. Moon, Int. J. Oncol., 36, 501–507. 32 B. Wang, H. D. Soule and F. R. Miller, Anticancer Res., 1997, 17, 4387–4394. 33 F. R. Miller, R. J. Pauley and B. Wang, Anticancer Res., 1996, 16, 1765–1769. 34 E. S. Radisky and D. C. Radisky, Rev. Endocr. Metab. Disord., 2007, 8, 279–287. 35 I. Silins, J. Hogberg and U. Stenius, Food Chem. Toxicol., 2006, 44, 1552–1561. 36 A. Sadlonova, S. Mukherjee, D. B. Bowe, S. R. Gault, N. A. Dumas, B. A. Van Tine, N. Frolova, G. P. Page, D. R. Welch, L. Novak and A. R. Frost, Am. J. Pathol., 2007, 170, 1064–1076. 37 S. Iravani, L. Mora, F. R. Miller and P. J. Dawson, Int. J. Oncol., 1998, 12, 369–375. 38 A. Sadlonova, Z. Novak, M. R. Johnson, D. B. Bowe, S. R. Gault, G. P. Page, J. V. Thottassery, D. R. Welch and A. R. Frost, Breast Cancer Res., 2005, 7, R46–R59. 39 I. Silins, M. Nordstrand, J. Hogberg and U. Stenius, Carcinogenesis, 2003, 24, 1077–1083. 40 H. Furuya, S. Ohkawara, K. Nagashima, N. Asanuma and T. Hino, Int. J. Vitam. Nutr. Res., 2008, 78, 41–49. 41 N. Khan, V. M. Adhami and H. Mukhtar, Biochem. Pharmacol., 2008, 76, 1333–1339. 42 L. Nyberg, A. Nilsson, P. Lundgren and R. D. Duan, J. Nutr. Biochem., 1997, 8, 112–118. 43 H. F. Dvorak, T. M. Sioussat, L. F. Brown, B. Berse, J. A. Nagy, A. Sotrel, E. J. Manseau, L. Van de Water and D. R. Senger, J. Exp. Med., 1991, 174, 1275–1278. 44 E. Ritter, A. Perry, J. Yu, T. Wang, L. Tang and E. Bieberich, Ann. Surg., 2008, 247, 310–314. 45 J. A. Tuxhorn, S. J. McAlhany, T. D. Dang, G. E. Ayala and D. R. Rowley, Cancer Res., 2002, 62, 3298–3307. 46 A. C. Levine, X. H. Liu, P. D. Greenberg, M. Eliashvili, J. D. Schiff, S. A. Aaronson, J. F. Holland and A. Kirschenbaum, Endocrinology, 1998, 139, 4672–4678. 47 B. E. Gould Rothberg and M. B. Bracken, Breast Cancer Res. Treat., 2006, 100, 139–148. 48 D. Sarrio, S. M. Rodriguez-Pinilla, D. Hardisson, A. Cano, G. Moreno-Bueno and J. Palacios, Cancer Res., 2008, 68, 989–997. 49 J. Y. Yang, C. S. Zong, W. Xia, Y. Wei, M. Ali-Seyed, Z. Li, K. Broglio, D. A. Berry and M. C. Hung, Mol. Cell. Biol., 2006, 26, 7269–7282. 50 H. Zhang, L. C. Stephens and R. Kumar, Clin. Cancer Res., 2006, 12, 1479–1486.

98 | Food Funct., 2010, 1, 90–98

51 K. Suzuki and K. Takahashi, Biochem. Biophys. Res. Commun., 2006, 349, 255–260. 52 Y. L. Chao, C. R. Shepard and A. Wells, Mol. Cancer, 2010, 9, 179. 53 M. V. Fournier, J. E. Fata, K. J. Martin, P. Yaswen and M. J. Bissell, Cancer Res., 2009, 69, 4545–4552. 54 Q. Chu, M. T. Ling, H. Feng, H. W. Cheung, S. W. Tsao, X. Wang and Y. C. Wong, Carcinogenesis, 2006, 27, 2180–2189. 55 W. C. Reinhold, M. A. Reimers, P. Lorenzi, J. Ho, U. T. Shankavaram, M. S. Ziegler, K. J. Bussey, S. Nishizuka, O. Ikediobi, Y. G. Pommier and J. N. Weinstein, Mol. Cancer Ther., 2010, 9, 1–16. 56 M. F. Fraga, E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero, K. Petrie, N. G. Iyer, A. Perez-Rosado, E. Calvo, J. A. Lopez, A. Cano, M. J. Calasanz, D. Colomer, M. A. Piris, N. Ahn, A. Imhof, C. Caldas, T. Jenuwein and M. Esteller, Nat. Genet., 2005, 37, 391–400. 57 S. E. Elsheikh, A. R. Green, E. A. Rakha, D. G. Powe, R. A. Ahmed, H. M. Collins, D. Soria, J. M. Garibaldi, C. E. Paish, A. A. Ammar, M. J. Grainge, G. R. Ball, M. K. Abdelghany, L. Martinez-Pomares, D. M. Heery and I. O. Ellis, Cancer Res., 2009, 69, 3802–3809. 58 H. M. O’Hagan, H. P. Mohammad and S. B. Baylin, PLoS Genet., 2008, 4, e1000155. 59 C. Mark, B. van Deurs and O. W. Petersen, Differentiation, 1990, 43, 146–156. 60 M. C. Adriance, J. L. Inman, O. W. Petersen and M. J. Bissell, Breast Cancer Res., 2005, 7, 190–197. 61 M. Allinen, R. Beroukhim, L. Cai, C. Brennan, J. Lahti-Domenici, H. Huang, D. Porter, M. Hu, L. Chin, A. Richardson, S. Schnitt, W. R. Sellers and K. Polyak, Cancer Cell, 2004, 6, 17–32. 62 O. Cuvillier, I. Ader, P. Bouquerel, L. Brizuela, B. Malavaud, C. Mazerolles and P. Rischmann, Curr. Mol. Pharmacol., 2010, 3, 53–65. 63 E. Ruckh€aberle, A. Rody, K. Engels, R. Gaetje, G. von Minckwitz, S. Schiffmann, S. Grosch, G. Geisslinger, U. Holtrich, T. Karn and M. Kaufmann, Breast Cancer Res. Treat., 2008, 112, 41–52. 64 P. Mitra, M. Maceyka, S. G. Payne, N. Lamour, S. Milstien, C. E. Chalfant and S. Spiegel, FEBS Lett., 2007, 581, 735–740. 65 E. Ruckh€aberle, T. Karn, A. Rody, L. Hanker, R. Gatje, D. Metzler, U. Holtrich and M. Kaufmann, J. Cancer Res. Clin. Oncol., 2009, 135, 1005–1013. 66 N. F. Lamour and C. E. Chalfant, Curr. Drug Targets, 2008, 9, 674– 682. 67 A. Von der Decken, J. Nutr., 1977, 107, 1340–1348.


View Online

PAPER


Consumption of polyphenolic-rich beverages (mostly pomegranate and black currant juices) by healthy subjects for a short term increased serum antioxidant status, and the serum’s ability to attenuate macrophage cholesterol accumulation Mira Rosenblat, Nina Volkova, Judith Attias, Riad Mahamid and Michael Aviram*

Downloaded on 21 October 2010 Published on 15 September 2010 on http://pubs.rsc.org | doi:10.1039/C0FO00011F

Received 17th May 2010, Accepted 16th July 2010 DOI: 10.1039/c0fo00011f The present study analyzed the antioxidative effects of various beverages, in vitro, and also the effect of short term consumption of beverages richest in polyphenols by healthy subjects on serum antiatherogenic properties. Healthy subjects consumed 250 mL of the selected beverages for 2 h, or daily, for up to 1 week. We hypothesized that differences in the anti-atherogenic properties of the studied beverages could be related, not only to the quantity of polyphenols, but also to their quality. Furthermore, we hypothesized that consumption of these juices by healthy subjects for just a short-term, will increase their serum anti-atherogenic properties, as was demonstrated previously in long-term consumption studies. Of 35 beverages studied, both 100% Wonderful-variety pomegranate and 100% black currant juices were the most potent antioxidants in vitro, as they inhibited copper ion-induced LDL oxidation by up to 94% and AAPH-induced serum lipid peroxidation by up to 38%. Furthermore, they increased in vitro serum paraoxonase 1 (PON1) lactonase activity by up to 51%. Consumption of five selected polyphenol rich beverages by healthy subjects increased serum sulfhydryl group (SH) levels and serum PON1 activities after 2 h, and more so after 1 week of drinking these beverages. These effects were most pronounced after the consumption of 100% Wonderful-variety pomegranate and 100% black currant juices. In conclusion, polyphenolic-rich juices with impressive in vitro antioxidant properties, also demonstrate antioxidant effects in vivo when analyzed for short term consumption. In this respect, 100% Wonderful-variety pomegranate and 100% black currant juices were most the potent.

Introduction Macrophage cholesterol accumulation and foam cell formation are hallmarks of early atherogenesis.1 Oxidative stress contributes to the development and progression of atherosclerosis.2 Cholesterol accumulation in macrophages can result from increased uptake of oxidized LDL and/or a decreased rate of HDL-mediated cholesterol efflux from the cells.1,2 Dietary polyphenols, such as those present in some beverages, were shown to be potent antioxidants3 and cardioprotective agents.4–7 Grape juice consumption by hypertensive individuals for 8 weeks increased serum antioxidant potential,8 and exerts hypolipidemic and anti-inflammatory effects in both hemodialysis patients and in healthy subjects.9 Red wine consumption by healthy subjects inhibited LDL oxidation10 and decreased monocyte migration.11 A more potent cardioprotector than grape juice or red wine was found to be 100% Wonderful-variety pomegranate juice (WPJ), as it protected atherosclerotic patients from further atherosclerosis development.12,13 Consumption of WPJ by healthy subjects for at least 2 weeks, significantly The Lipid Research Laboratory, Technion-Israel Institute of Technology Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences, Rambam Medical Center, Haifa, 31096, Israel. E-mail: [email protected]; Fax: +972-4-8542130; Tel: +972-48542970


reduced the oxidation of both LDL and HDL and increased HDL-associated paraoxonase 1 (PON1) activity.14 Studies in patients with carotid artery stenosis (CAS) that consumed WPJ for 3 years, clearly demonstrated reduced serum oxidative stress, increased serum PON1 activity, and most importantly - a reduction in atherosclerotic lesion size.12 Furthermore, in diabetic patients, WPJ consumption decreased serum and macrophage oxidative stress, decreased oxidized LDL uptake by their cells,13 and increased PON1 association with HDL.15 Similarly, WPJ in vitro was shown to increase PON1 binding to HDL,16 and also to up-regulate PON1 expression in hepatocytes.17 In all the above studies, the effects of beverages were noted after relatively long periods of consumption (weeks, months, and years). There are a limited number of studies which analyzed the acute effects of beverage consumption on serum oxidative stress and atherogenicity. Plasma antioxidant power was increased postprandially after red wine consumption by healthy subjects.18 Black currant juice consumption for 1 week decreased serum lipid peroxidation and increased urinary excretion of quercetin.19 Similarly, twelve hours after consumption of acai juice by healthy subjects, the plasma antioxidant capacity was significantly increased.20 Finally, consumption of a mixture of berry juices, which include acai and palm fruit as the predominant ingredients, increased the serum antioxidant level, and inhibited lipid peroxidation, two hours post-consumption.21 Food Funct., 2010, 1, 99–109 | 99

View Online

The aim of the present study was to compare the antioxidative effects of polyphenolic-rich beverages (and especially, those of 100% Wonderful-variety pomegranate juice, 100% black currant juice, 100% Concord grape juice, acai juice blend and red wine) in vitro, and also to study the effects of their short term consumption by healthy subjects (either 2 h, or daily intake for 1 week) on serum anti-atherogenic properties.

Experimental Downloaded on 21 October 2010 Published on 15 September 2010 on http://pubs.rsc.org | doi:10.1039/C0FO00011F

In vitro studies Table 1 demonstrates the list of the 35 beverages used in the study. Polyphenols. Total polyphenols were determined spectrophotometrically by the method of Singleton, modified for small volumes.22 Gallic acid served as a standard. Gallic acid stock solution was prepared in water at a concentration of 2 mmol/L. Volumes of 10, 20, 40 and 60 microlitres diluted in 1 mL solution (equivalent to 20, 40, 80 and 120 nmol respectively) were used for the standard curve. Free radical scavenging capacity. The free radical-scavenging capacity of the various beverages was analyzed by the DPPH assay.23 DPPH (1,1-diphenyl-2-picrylhydrazyl) is a radical

generating substance that is widely used to monitor the free radical scavenging abilities (the ability of a compound to donate an electron) of various antioxidants. The DPPH radical has a deep violet color due to its impaired electron, and radical scavenging can be followed spectrophotometrically by the loss of absorbance at 517 nm, as the pale yellow non-radical form is produced. The beverages were diluted with water 1 : 10, v : v. Aliquots of 20 mL from the diluted beverages were mixed with 1 mL of 0.1 mmol DPPH/L in ethanol, and the change in optical density at 517 nm was monitored after 5 min. LDL preparation. LDL was isolated from plasma taken from healthy normolipidemic volunteers, by discontinuous density gradient ultracentrifugation.24 The LDL was washed at d ¼ 1.063 g/mL, dialyzed against 150 mmol/L NaCl, 1 mmol/L Na2EDTA (pH 7.4) at 4 C. The LDL was then sterilized by filtration (0.45 mM), kept under nitrogen in the dark at 4 C and used within 2 weeks. The LDL protein concentration was determined with the Folin Phenol reagent.25 Prior to oxidation, LDL was dialyzed against EDTA-free, phosphate buffered saline (PBS) solution, pH 7.4, and at 4 C. Copper ion-induced oxidation. The beverages were diluted with water 1 : 100, v:v. LDL (100 mg of protein/mL) was then preincubated for 1 h at room temperature with 25 mL/mL of the samples of diluted beverages. Then, 5 mmol/L of CuSO4 was

Table 1 List of beverages tested Category

Brand

Product name

100% Pomegranate juice

POM Wonderful Knudsen Langers Odwalla Naked Welch’s Knudsen Lakewood Knudsen Lakewood Knudsen Currant C Knudsen Wyman’s Frutzzo Bossa Nova Naked Sambazon Naked

100% Pomegranate Juice (Wonderful-variety) Just Pomegranate (variety unknown) 100% Pomegranate Juice (variety unknown) Pomegranate Juice (variety unknown) Pomegranate (variety unknown) 100% Concord Grape Juice Concord Grape Pure Concord Grape Just Black Cherry Pure Black Cherry Just Black Cherry Black Currant Nectar Just Blueberry 100% Wild Blueberry 100% Yumberry Acai Juice- The Original Acai Machine Original Blend Red Machine Green Machine Red Rhapsody Mangosteen/antioxidant fruit Acai Mangosteen Acai Blueberry Mangosteen Dragonfruit Goji Cherry Goji Acai Goji Mangosteen Pomegranate Blueberry Pomegranate Blueberry Green Tea with natural flavor Green Tea with citrus BV Napa Cabernet Sauvignon Robert Mondavi Napa Merlot Zinfandel (California)

100% Concord grape juice 100% Black cherry juice 100% Black currant juice and blends 100% Blueberry juice 100% Yumberry Acai juice blends ‘‘Superfruit’’ blends

Odwalla Lakewood Born Dia Bossa Nova Goji Lania

Green tea Red wine

100 | Food Funct., 2010, 1, 99–109

Minute Maid Tropicana Nestea Lipton Beaulieu Mondavi Cline


View Online


added and the tubes were incubated for 2 h at 37 C. At the end of the incubation, the degree of LDL oxidation was determined by measuring the generated amount of thiobarbituric acid reactive substances (TBARS). The TBARS assay was performed at 532 nm, using malondialdehyde (MDA) for the standard curve.26 AAPH-induced serum lipid peroxidation. Serum samples from healthy subjects were diluted 4 with phosphate buffered saline (PBS) and were pre-incubated with no addition (control), or with five polyphenol rich beverages (2 mL/mL of concentrated beverages) for 1 h at room temperature. Then 100 mmol/L of 2,20 azobis, 2-amidinopropane hydrochloride (AAPH, Wako, Japan) was added to all samples and they were further incubated for 2 h at 37 C.27 The extent of lipid peroxidation was measured by the TBARS assay.26 In vivo studies Subjects. Six healthy male subjects (aged 25–30 years) participated in the study. The subjects drank 250 mL of each beverage after an overnight fast. Blood was collected from the subjects 2 h after consumption. They continued daily beverage consumption for 1 week with the evening meal. After 1 week of beverage consumption, blood samples were collected. After a 1 week ‘‘washout period’’, this protocol was repeated with another beverage until each subject had consumed all 5 of the tested beverages. The order of beverages consumed was: first – acai juice blend (Naked), second – 100% Concord grape juice (Lakewood), third – 100% black currant juice (Knudsen), fourth – 100% Wonderful-variety pomegranate juice (POM Wonderful), and last – red wine (Merlot/Mondavi). The subjects served as their own control, as we compared all post-consumption data to the baseline values. All subjects were non-smokers. The study protocol was approved by the Helsinki Committee of the Rambam Medical Center, Israel Ministry of Health, application no. 3073. Serum biochemical parameters. Serum sodium, potassium, glucose and lipids (total cholesterol, HDL cholesterol and triacylglycerol) concentrations were measured using automated enzymatic tests (Tayco Diagnostics- Agis Commercial Agencies, Israel). Serum oxidative stress parameters Basal serum oxidation status. The extent of lipid peroxidation was measured by the TBARS assay.26 Total thiols (SH groups) in serum. The assay procedure determines the amount of protein bound SH groups, as well as of glutathione.28 An aliquot of 10 mL of the above serum samples was mixed with 200 mL of Tris-EDTA buffer, and the absorbance at 412 nm was measured. To these samples 8 mL of 10 mmol/L DTNB was added, and after 15 min of incubation at room temperature, the absorbance was measured again together with a DTNB blank. The total amounts of SH groups were then calculated.

above serum samples were diluted 1 : 10 with ‘‘activity buffer’’ (1 mmol/L CaCl2 in 50 mmol/L Tris HCl, pH 8.0) and then 5 mL were taken for a total reaction volume of 200 mL. Initial rates of hydrolysis were determined spectrophotometrically at 270 nm for 3 min (every 15 s). The assay mixture included 1.0 mmol/L phenyl acetate in ‘‘activity buffer’’. One unit of arylesterase activity equals 1 mmol of phenyl acetate hydrolyzed/min/mL.29 Serum PON1 lactonase activity towards DHC. The assay was performed in 96 well UV plates, in a total volume of 200 mL per well. The above serum samples were diluted 1 : 10 with ‘‘activity buffer’’ (1 mM CaCl2 in 50 mmol/L Tris HCl, pH 8.0), and 3 mL were then taken for the assay. Lactonase activity was measured using dihydrocoumarin (DHC) as the substrate. Initial rates of hydrolysis were determined spectrophotometrically at 270 nm, for 10 min (every 15 s). The assay mixture included 1 mmol/L DHC in ‘‘activity buffer’’. Non-enzymatic hydrolysis of DHC was subtracted from the total rate of hydrolysis. One unit of lactonase activity equals 1 mmol of DHC hydrolyzed/min/mL.29 Macrophage cholesterol metabolism J774A.1 macrophage cell line. The J774A.1 murine macrophage cells were purchased from the American Tissue Culture Collection (ATCC, Rockville, MD). The cells were grown in DMEM containing 5% FCS. Serum-mediated changes in net cholesterol mass in macrophages. J774A.1 macrophages were incubated with 20 mL/mL of the above serum samples for 20 h at 37 C. Then the cells were washed and their lipids extracted with hexane: isopropanol (3 : 2; v : v). The hexane phase was collected and dried under N2. The amount of cellular cholesterol was determined using a kit (CHOL, Roche Diagnostics GMbH, Mannheim, Germany). After extraction of cellular lipids, the cells were dissolved in 0.1 mol/L NaOH for measurement of cellular protein by the Lowry assay.25 Serum-mediated cholesterol efflux from macrophages. J774A.1 macrophage cell line was incubated with [3H]-labeled cholesterol (2 mCi/mL) for 1 h at 37 C followed by cell wash in ice-cold PBS (3) and further incubation in the absence or presence of 20 mL/mL of the above serum samples for 3 h at 37 C. Cellular and medium [3H]-labels were quantified30 and serum-mediated cholesterol efflux was calculated as the ratio of [3H]-label in the medium/([3H]-label in the medium + [3H]-label in cells). Statistics. For comparison of the mean differences between paired groups we used the Wilcoxon rank test and a p-value 100% blueberry juice > 100% black cherry juice, acai juice blend, 100% cranberry juice > 100% orange juice, iced tea beverages, and 100% apple juice.3 This pattern is similar to that shown in the present study, where additional beverages and brands were tested, including 100% black currant juice. In comparison to Knudsen Black Currant juice, Currant C (another black currant juice blend) contains only one-half of the total polyphenol concentration, and demonstrated much lower antioxidative properties than the Knudsen 100% black currant juice. We chose for the in vivo study, the five juices which contained the highest polyphenol concentration: 100% black currant (Knudsen), 100% Wonderful-variety pomegranate (POM Wonderful), red wine (Merlot/Mondavi), acai juice blend (Naked) and 100% Concord grape (Knudsen). The present study is the first to compare the acute effects of the above beverages on serum antiatherogenic properties. We chose 1 week of beverage consumption since we have previously observed a significant reduction in serum oxidative stress after two weeks of 100% Wonderful-variety pomegranate juice or red wine consumption by healthy subjects.14,10 Furthermore, in the current study we evaluated the acute effects 2 h after beverage consumption. Polyphenols in the above beverages were probably absorbed to some extent, as the levels of urinary quercetin,19 or anthocyanins,20,35 or those of plasma catechin,18 were all shown to be significantly increased dose- and time-dependently after acai juice blend, 100% black currant juice or red wine consumption. The bioavailability of the pomegranate active components and metabolites has been demonstrated previously, with ellagic acid detected in the blood and dimethylellagic acid glucuronide (DMEAG), as well as urolithin A and B, found in the urine of most subjects after consumption of 100% pomegranate juice.36–39 An important issue in the current study is that consumption of the beverages (which contain sugars) by healthy subjects for 2 h or for 1 week, did not increase serum glucose levels and did not affect serum lipids or electrolytes (potassium and sodium). Serum PON1 activities (arylesterase and lactonase) were analyzed as an additional marker for oxidative stress. In vitro all the five beverages used significantly increased serum PON1 activities. The mechanism responsible for the PON1 activity increase could be related to the binding of the beverages’ polyphenols to PON1. Such binding may change the enzyme conformation, thus affecting PON1 active site interactions with its substrates. Furthermore, certain polyphenols increase PON1 binding to the HDL, thus stabilizing PON1, as was shown previously upon incubation of serum in vitro with pomegranate juice or its most potent unique polyphenol punicalagin.15,16 Furthermore, 100% Wonderful-variety pomegranate juice consumption over longer periods of time (weeks, months, or years) has been shown to increase PON1 binding to the HDL particles, and as a result, stabilize PON1 and enhance its catalytic Food Funct., 2010, 1, 99–109 | 105

View Online

Table 4 Effect of polyphenol-rich beverages’ consumption by healthy subjects on basal serum oxidation status

Beverage


Acai juice blend (Naked) 100% Concord grape juice (Lakewood) 100% Black currant juice (Knudsen) 100% Wonderful-variety pomegranate juice (POM Wonderful) Red wine (Merlot/Mondavi)

TBARS/nmol/mL before beverage consumption

TBARS/nmol/mL 2 h after beverage consumption

TBARS/nmol/mL after 1 week of beverage consumption

1.50 0.16 1.60 0.07

1.60 0.18 1.70 0.11

1.60 0.07 1.50 0.09

1.60 0.09

1.70 0.11

1.60 0.12

1.50 0.18

1.50 0.12

1.50 0.08

1.60 0.07

1.60 0.08

1.60 0.11

and biological activities.12,13,15,16 We evaluated also serum sulfhydryl (SH) group concentrations, as they have been shown to be inversely related to oxidative stress, and positively correlated with PON1 activity.40 Although all five selected polyphenol-rich juices inhibited AAPH-induced serum lipid peroxidation in vitro, in vivo their consumption for a short period of time (2 h or 1 week) did not significantly affect AAPH-induced serum lipid peroxidation. Serum SH group concentration and PON1 activity however, were modestly, but significantly increased following beverage consumption, with 100% Wonderful-variety pomegranate and 100% black currant juices being the most potent beverages after 1 week of consumption. Nevertheless, this protection by SH groups and PON1 may be insufficient to protect the serum from free radical-induced oxidative stress. PON1 was shown to protect serum from oxidative stress, by its ability to hydrolyze specific oxidized lipids in lipoproteins (such as specific oxidized phospholipids, lipid peroxides, cholesteryl

linoleate hydroperoxides).41–43 Longer periods of beverage consumption (up to months) may be needed to achieve more impressive effects on serum oxidative stress in healthy subjects. Among the in vivo studied beverages, acai juice blend was the least potent, even though it has a similar concentration of polyphenols. This suggests that acai juice blend polyphenols are weak antioxidants, in comparison to the polyphenols in 100% pomegranate juice, 100% black currant juice or 100% Concord grape juice (and also red wine). Similar to the present study, plasma antioxidant capacity increased twelve hours after consumption of acai juice blend,20 or 2 h post-consumption of a mixture of berries, by healthy subjects.21 In a recent study, 100% black currant juice consumption for 1 week, substantially decreased serum lipid peroxidation,19 but this impressive effect is likely related to the high volume of juice consumed (1500 mL). As 100% Wonderful-variety pomegranate juice and 100% black currant juice were the most potent antioxidants in the

Fig. 2 The effect of polyphenol rich beverages consumed by healthy subjects on the concentration of their serum SH groups. Six healthy subjects consumed POM Wonderful, black currant (Knudsen), red wine (Mondavi), grape (Lakewood), and acai (Naked). Blood samples were collected before and after 2 h or 1 week of beverage consumption. Serum SH group concentrations were determined as described under the methods section. (A) 2 h after consumption of beverages. (B) 1 week after of consumption of beverages. Results are expressed as mean SEM. *p 0.10 >0.10 0.003

C. Tissue weight, % BW Heart 0.362 Liver 2.48 Kidney 0.662x Fat 4.94*

0.377 2.75 0.748* 3.75x

0.351 2.73 0.711*x 4.03*x

0.348 2.96 0.726*x 3.80x

0.352 2.62 0.680*x 3.56x

0.012 0.11 0.021 0.24

>0.10 0.06 0.04 0.002

a

HF ¼ High fructose, HF + LC ¼ High fructose + low (3.3 g/kg diet) cranberry powder, HF + MC ¼ HF + medium (6.6 g/kg diet) cranberry powder, HF + HC ¼ High fructose + high (33 g/kg diet) cranberry powder. *x Means without a common superscript are significantly different at the P value indicated in the last column.

Table 3 Calculated average daily consumption of phenolic compounds in rats fed different levels of cranberry powderc

Treatments

PCNa, mg/d

Total phenolics, mg/d

Total ACYb, mg/d

Catechin, mg/d

Epicatechin, mg/d

HF + LC HF + MC HF + HC

3.98 7.75 39.81

6.68 13.0 66.8

106.97 207.92 1069.72

9.72 18.9 97.2

6.03 11.7 60.3

a PCN ¼ procyanidins. b ACY ¼ anthocyanin. c HF ¼ High fructose, HF + LC ¼ High fructose + low (3.3 g/kg diet) cranberry powder, HF + MC ¼ HF + medium (6.6 g/kg diet) cranberry powder, HF + HC ¼ High fructose + high (33 g/kg diet) cranberry powder.

had a significant effect (P < 0.05) on food consumption and cumulative weight gain vs. control (Fig. 2). As a result, animals on control diet were also the heaviest. However, when final and fasted body weight (at the time of sacrifice) and total food intake was analyzed using a randomized complete block design (Table 4), only a tendency (P ¼ 0.06 and 0.07) for the same was observed. Increased body weight, however, did not necessarily result in the higher organ weights (Table 4), except abdominal fat, which was highest in animals fed the control diet. Feeding the high fructose diet decreased abdominal fat accretion, but dietary CP did not significantly (P > 0.1) alter this response. When organ weights were expressed as percent of body weight, high fructose fed animals had the largest kidney weight relative to their body weight compared to animals on control diet, but was not significantly different from other animals on any of the CP diets. A similar trend was observed with liver weights. Cardiac 118 | Food Funct., 2010, 1, 116–123

Fig. 2 Weekly dietary intake (top panel) and cumulative body weight (bottom panel) of rats fed a control low fructose diet, a high fructose diet (HF) and high fructose diets with different levels of cranberry powder (Low, LC; Medium, MC; High, HC).

hypertrophy was not observed in this study as indicated by nonsignificant changes in heart weight as a % of body weight. Both fasting glucose and triglyceride levels were highest in high fructose fed animals compared with the animals on control or CP diets (Table 5). Addition of CP to the diet tended to have positive effects (P ¼ 0.10) in lowering the blood glucose and triglyceride levels. Changes in serum glucose level after the oral glucose load was consistently and significantly (P < 0.05) higher with high This journal is ª The Royal Society of Chemistry 2010

View Online


Table 5 Least square means SEM of fasting glucose, cholesterol, triglycerides, and insulin levels in rats fed a control low fructose diet, a high fructose diet, and high fructose diets with different levels of cranberry powdera

Items

Control HF

HF + HF + HF + LC MC HC SEM P

Glucose, mg/dL Cholesterol, mg/dL Triglycerides, mg/dL b OGTT Insulin, mU/L c HOMA-IR d HOMA-BCF e QUICKI

182.9 83.5 82.4 10457 49.4 22.4*x 148.2* 0.74

196.1 81.3 82.2 9472 31.0 15.2x 84.1x 0.85

213.1 87.3 125.6 14031 54.2 28.5* 130.2*x 0.69

185.3 74.4 81.7 10466 24.8 11.3x 73.1x 0.95

191.0 79.0 90.1 13788 36.3 17.2*x 102.2*x 0.81

11.8 8.2 12.2 1307 6.7 3.1 17.9 0.09

0.10 0.86 0.10 0.15 0.08 0.04 0.05 0.24

a HF ¼ High fructose, HF + LC ¼ High fructose + low (3.3 g/kg diet) cranberry powder, HF + MC ¼ HF + medium (6.6 g/kg diet) cranberry powder, HF + HC ¼ High fructose + high (33 g/kg diet) cranberry powder. b Oral glucose tolerance test area under curve expressed as mg/dL minutes1. c Homeostasis model assessment – Insulin resistance (HOMA-IR) ¼ [Fasting glucose (mg/dL) fasting insulin (mU/L)/405. d Homeostasis model assessment – Beta cell function (HOMA-BCF) ¼ [20 serum insulin (mU/L)]/[plasma glucose (mmol/L)- 3.5]. e Quantitative insulin sensitivity check index (QUICKI) ¼ 1/log HOMA-IR. *x Means without a common superscript are significantly different at the P value indicated in the last column.

Fig. 4 Changes in postprandial serum glucose and insulin levels in rats fed a control low fructose diet, a high fructose diet, and high fructose diets with different levels of cranberry powder (Low, LC; Medium, MC; High, HC).

Fig. 3 Oral glucose tolerance test responses in rats fed a control low fructose diet, a high fructose diet and high fructose diets with different levels of cranberry powder (Low, LC; Medium, MC; High, HC). See Table 3 for AUC.

fructose and high fructose + high CP diets compared to animals in other diets after 60 min of oral glucose load (Fig. 3). The total area under curve after the OGTT, was highest in animals fed the high fructose diet. Addition of CP in the diet, primarily at low and medium levels, lowered the OGTT area under the curve down to control levels (Table 5 and Fig. 3). Serum insulin was low in animals fed diets that contained CP and was highest in animals fed high fructose diet (P ¼ 0.08). No effect of the diet was observed on fasting cholesterol. When the three models of homeostatic assessment scores were calculated in animals fasted overnight, both HOMA-IR and HOMA-BCF were altered by diet, but the QUICKI model of insulin sensitivity was not statistically significant (P > 0.1) among treatments. While insulin resistance was lowest in animals fed medium level of CP in the diet, it was highest in animals fed high This journal is ª The Royal Society of Chemistry 2010

Fig. 5 Changes in postprandial serum cholesterol and triglyceride levels in rats fed a control low fructose diet, a high fructose diet, and high fructose diets with different levels of cranberry powder (Low, LC; Medium, MC; High, HC).

fructose diet. Insulin resistance was reduced by the addition of CP in the diet at all levels (P < 0.04). Similarly, b-cell function was lowest in animals fed medium level of CP in the diet (P 0.05) and highest in animals fed control or high fructose diets. Numerically, QUICKI was lowest in rats fed a high fructose diet and highest in animals fed medium level of CP in the diet. Weekly postprandial blood glucose, cholesterol, and triglycerides were also tested in animals from wk 2 through 7, whereas insulin was tested in animals from wk 5–7. While there were no Food Funct., 2010, 1, 116–123 | 119


View Online

significant effects of diet (P > 0.1) on blood glucose concentration (Fig. 4A), there was a significant treatment week interaction, a situation in which blood glucose level varied from week to week depending on the dietary treatment. Serum insulin (Fig. 4B), on the other hand, was consistently and significantly higher (P < 0.05) in animals fed the control diet compared to animals on high fructose diet; animals on the three CP diets were in between. The concentration of serum triglycerides was consistently higher (P < 0.05) in animals fed high fructose diet (Fig. 5A) even though they had the least amount of abdominal fat as mentioned previously. Inclusion of CP in the diet of rats reduced plasma triglyceride concentrations. Plasma cholesterol concentration increased as the experiment progressed with the increasing age of the animals (Fig. 5B). Although there was a significant treatment week interaction (P < 0.05) on plasma cholesterol concentrations, diet had no significant effect (P > 0.1) on its weekly values.

Discussion Polyphenols are one of the major natural dietary compounds believed to be responsible for promotion of health and protection against many chronic diseases, including metabolic syndrome. Originally known as Syndrome X,14 metabolic syndrome refers to the clustering of cardiometabolic risk factors, including abdominal obesity, hyperglycemia, dyslipidemia, elevated blood pressure, increased body mass index/waist circumference, and a decreased high density lipoprotein cholesterol, that are thought to be linked to insulin resistance.15,16 Although it was believed initially to be associated with increased risk of cardiovascular disease, metabolic syndrome has a stronger association with type 2 diabetes than that previously demonstrated for coronary heart disease.17 In the current study, we investigated whether different levels of CP, a concentrated cranberry product, as a source of polyphenols in the diet were effective in modulating some of the metabolic parameters associated with metabolic syndrome. Dietary CP had positive effects in preventing some of the metabolic profiles associated with metabolic syndrome. Response on two of the parameters, fasting blood glucose and triglycerides were borderline and showed a tendency (P ¼ 0.1) to be affected by CP in the diet. Similarly, OGTT responses were slightly improved and similar to animals on control diet when low or medium, but not when the high level of CP was added to the high fructose diet. However, the dietary effect was more pronounced in HOMA scores with insulin resistance being the least in animals when CP was included in the diet. A lower insulin resistance combined with a tendency for reduced blood glucose suggested that animals fed CP were able to utilize the available glucose even at a reduced concentration of circulating insulin, which was reflected in the reduced HOMA-BCF scores when CP was included in the diet. Whereas a higher concentration of fasting insulin was needed to clear out the available glucose in control and HF animals. Lower concentrations of post-prandial glucose and insulin were in line with some previous reports when high fructose diets were fed.18–20 This may be because fructose produces a smaller postprandial rise in plasma glucose than other common carbohydrates21,22 and reduces circulating insulin.20 In the purified diet used in this study, substituting fructose for the starch in the diet removed 75% of the dietary sources of glucose. 120 | Food Funct., 2010, 1, 116–123

Maltodextrin, which is a short chain of molecularly linked dextrose (glucose) molecules (fewer than 20) manufactured by regulating the hydrolysis of starch, was included in the diet to aid in the pelleting process, which limited the possibility of removing all glucose sources from the high fructose diets. Fructose metabolism is not regulated by insulin and it has a lower glycemic index than foods rich in starch.23,24 However, fructose increases post-prandial serum triglyceride levels19,20 as was observed in this study. Only 0.1% of fructose was converted to fatty acids at 240 min and lower insulin excursion after fructose resulted in less activation of adipose tissue lipoprotein lipase and impaired triglyceride clearance.19 It may be one of the reasons why there was lower amount of abdominal fat accretion in HF group than those in control group. Moreover, it has been shown previously that increased abdominal fat may not always be associated with metabolic syndrome.25 While sustained elevation of plasma triglycerides with high fructose feeding suggested its possible contribution to atherogenesis and cardiovascular disease, its reduction by the concentrated cranberry product may be helpful in minimizing the effect. There is a concern that dietary fructose may stimulate energy intake and promote weight gain and obesity.20 As a result, a definitive link through clinical trials may need to be established between the two.21 We actually observed a tendency for lower body weight in HF fed animals compared to animals fed a control diet with equivalent amounts of starch. This was accompanied by a reduced food intake in animals fed HF diet compared to the control diet. We have observed similar results in other experiments with slightly higher or lower level of fructose in the diet (unpublished data). Given the fact that diets were purified and had all the major nutrients at iso-level in the current study (Table 1), results suggested that high fructose feeding may possibly augment some of the factors associated with metabolic syndrome without stimulating energy intake and/or promoting weight gain and obesity. This may partially explain the higher incidence of diabetes and metabolic syndrome among South Asians at lower body mass index and waist circumference.25 The response to high fructose feeding in growing rats in producing elevated fasting plasma triglycerides, enhanced abdominal fat accretion, insulin resistance, and cardiac hypertrophy were not as marked as predicted from the literature using this model.26,27 High fructose feeding in rats is commonly used to induce a strong response on metabolic parameters associated with the metabolic syndrome, albeit more commonly with adult than with growing rats. However, the authors’ experience with feeding high fructose diet in developing a strong response of metabolic syndrome in growing rats is rather mixed. We have conducted several experiments in this regard, all with purified diet and nutrient concentrations held constant (unpublished data). One of the observations that we have consistently made is a slightly reduced food intake, lower body weight at termination of the experiment, and the complete lack of abdominal obesity even after having elevated levels of postprandial plasma triglycerides. A number of previous studies have used a natural ‘‘chow’’ based diet and added fructose to it without properly balancing all the nutrients in the process. As a result, animals may become marginally deficient or deficient in some other nutrients resulting in confounding of the effects on metabolic parameters and symptomatic responses, including those associated with This journal is ª The Royal Society of Chemistry 2010


View Online

metabolic syndrome. To avoid this, a purified diet was used in the current study with all the other major nutrients held constant across treatment. It is possible that when other nutrients are equally balanced and starch is the only item that is completely (or close to) replaced with fructose, a few of the typical signs of metabolic syndrome may not develop at all, while others, such as postprandial plasma triglycerides or insulin resistance may appear. It was observed that balancing all the nutrients across the treatments in purified diets does not generate appreciable oxidative stress in high fructose fed growing animals over those on control diets (unpublished results) that would otherwise be highly conducive for clear signs of metabolic syndrome. A previous study with Sprague-Dawley rats also showed no difference in fasting plasma glucose, cholesterol, triglycerides, and insulin concentration as well as glucose tolerance curves and weight gain between animals fed control (AIN based diet with 53% corn starch), a high fructose (53%) or high fat (25% soybean oil) diet for 3 months.28 The Wistar may be a better rat model in that it is more sensitive to fructose in the diet. Although it is not possible to determine which of the polyphenols present in CP were responsible for any or all of the observed effects, previous data have suggested that procyanidins may be more responsible than anthocyanins in modulating factors associated with metabolic syndrome.29 Similarly, the effect of total or individual phenolic acids on metabolic syndrome is not clear. Whether and how much of the increased excretion of 4-hydroxycinnamic acid and 3-hydroxyphenylacetic acid and decreased excretion of hippuric acid and 4-hydroxyphenylacetic acid13 have contributed to the observed results is not known. This is the first study detailing the effects of different levels of a commercially available concentrated cranberry product on certain parameters associated with metabolic syndrome in growing animals. The doses provided were calculated based upon previous work using procyanidins on insulin sensitivity and metabolic syndrome.29–31 The high dose of CP was based upon previous data,30 which we predicted would be on the high end of a practical dose. Depending upon the method of extrapolation from the rat to the human, the high dose of CP in the rat (33 g/kg diet) would equate to approximately 54 g of CP for a 70 kg human based upon metabolic weight extrapolation between the rat and human which would provide 3 g of procyanidins. Extrapolating based upon caloric intake, a 70 kg human would consume 21 g of the CP or 1.2 g procyanidins per day. The two lower doses were estimated to be practical levels for the rat and when translated to a human would also be reasonable providing 200–600 mg procyanidins per day. Overall, inclusion of CP had positive effects in some of the parameters investigated. The high (33 g/kg diet) dose did not provide any additional benefit and may not been as strong based upon the HOMA-IR estimate. Consumption of high level of procyanidins may affect other physiological processes, such as binding or interacting with protein or lipids, which procyanidins (also called tannins) from grape, tea, or other sources are associated with.32–34 It should be noted, however, that medium level included in the current study is, by no means, the best or optimal dose since there is a wide gap between medium and high dose used in the current study. Further experiments are needed to confirm the findings as well as determine the optimum level of inclusion in the diet. This journal is ª The Royal Society of Chemistry 2010

In summary, the cranberry powder was effective in improving some, but not all, of the metabolic parameters associated with metabolic syndrome investigated in the current study. Of the three levels of CP included in the diet, the medium level at 6.6 g/ kg diet was the most effective in improving factors associated with metabolic syndrome in the high fructose fed growing rats used in the current study. This highlights the importance of performing dose response studies and that more is not always better. Given the mixed polyphenol content of the cranberry product used, it may be unreasonable to pinpoint the effects observed to one or more specific polyphenols or their constituent compounds.

Experimental Chemicals All chemicals used in the study were HPLC grade or higher and were obtained either from Fisher Scientific (Hampton, NH, USA), SigmaAldrich (St. Louis, MO, USA), or SynerMed (Monterey Park, CA, USA). Animals and diet The protocol was approved by Animal Care and Use Committee of the University of Arkansas for Medical Sciences, Little Rock, AR. Metabolic parameters associated with metabolic syndrome in growing rats were investigated by feeding an American Institute of Nutrition (AIN) based purified diet containing 53% by weight of fructose (0% kcal from starch). Isocaloric and isonitrogenous purified diets were formulated according to Table 1. Purified diets were prepared by Research Diets Inc. (New Brunswick, NJ, USA). Male Sprague-Dawley rats (Charles River Laboratories Intl. Inc., Wilmington, MA; 44 d old, 175.0 8.4 g) were used in a randomized complete block design with initial body weight used as the blocking factor. Animals within block were assigned at random to one of the five treatments, 1) Control (starch based diet); 2) Fructose-rich diet (AIN based diet containing 53% by weight of fructose (HF), 0 kcal from starch); 3) Fructose-rich diet with low, 3.3 g CP per kg diet (HF + LC); 4) Fructose-rich diet with medium, 6.6 g CP per kg diet (HF + MC); or 5) Fructose-rich diet with high, 33 g CP per kg diet (HF + HC). Animals were housed two per cage and provided ad libitum access to food and water. Food consumption and body weight changes were monitored weekly. Cages were changed weekly. Analysis of polyphenols Total procyanidins in CP were determined by the aldehyde condensation of 4-dimethylaminocinnamaldehyde (DMAC) method as described previously.35 The CP was also analyzed for monomeric, oligomeric and polymeric procyanidins using a high performance liquid chromatograph (HPLC) on a diol column, details of which have been described previously.36 This was done to determine the distribution of individual procyanidins based on the proportionate area under the curve in the HPLC chromatogram. Procedures for determining total phenolics have been described recently,13 whereas anthocyanins were determined using diode array detector in an Agilent 1200 series HPLC (Agilent Technologies, Santa Clara, CA, USA) equipped with Food Funct., 2010, 1, 116–123 | 121

View Online

a binary pump. Details about the HPLC conditions, column description, mobile phase, gradient, etc. have been described previously.37

IR using a formula, QUICKI ¼ 1/log HOMA-IR. Insulin values were expressed as SI units (1 mIU/mL ¼ 6.945 pmol/L). Statistical analysis


Sample collection and analysis Weekly post-prandial blood samples were collected from the tail vein using a Microvette capillary tube (Sarstedt AG & Co., N€ umbrecht Germany), while fasting trunk blood was collected at the time of sacrifice. Animals were sacrificed on d 57 and 58 of the experiment after euthanizing in a CO2 chamber and decapitating the head. Organ (kidney, heart, liver, total fat) weights were recorded after the sacrifice. Animals were randomized before blood collection and sacrificed such that treatments were evenly distributed across the time frame or when sacrificed in successive days. Plasma was separated from the blood by centrifugation at 3480 g for 15 min at 4 C. Plasma samples were analyzed using commercially available kits for glucose, cholesterol, and triglycerides (Synermed Intl. Inc., Westfield, IN, USA) in a 96-well plate format using a dual pump FluoStar Galaxy (Durham, NC, USA) microplate reader. Plasma insulin was determined by enzyme-linked immunosorbent assay (ELISA) using commercially available kits (Linco Research Inc., St. Charles, MO, USA) in a Benchmark Plus microplate spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA). All samples were stored at 80 C prior to analyses. Samples were randomized during each analysis such that treatments were evenly distributed across the plates to minimize the variation caused by running multiple plates and generating multiple standard curves. However, it was not possible to include it in the statistical model given the smaller sample size.

Statistical analyses of fasting glucose, cholesterol, triglycerides, insulin, HOMA-IR, HOMA-BCF, QUICKI, final body weight, organ weights, and organ weights as percent of body weight were carried out in SigmaPlot (Systat Software Inc., San Jose, CA, USA). Treatment, block, and their interactions were included in the model as the fixed factors in a randomized complete block design. Statistical analysis of weekly food intake, weight gain, post-prandial glucose, cholesterol, triglycerides, and insulin were carried out in SAS (SAS, Cary, NC, USA) using PROC MIXED. Treatment, week, and their interactions were included in the model with week as the repeated measures on rats. Changes in serum glucose concentration after the oral glucose load was analyzed in PROC MIXED of SAS using treatment, time and their interaction as the fixed factors with time as the repeated measure on the rats. Compound symmetry was used as covariance structure.

Acknowledgements Financial support was provided in part by Decas Botanicals Inc., the Arkansas Biosciences Institute and the U.S. Department of Agriculture, Agriculture Research Service. Mention of a trade name, proprietary product or specific equipment does not constitute a guarantee by the U.S. Department of Agriculture and does not imply its approval to the exclusion of other products that may be suitable.

Oral glucose tolerance test (OGTT)

References

At the end of week 6, an OGTT was performed in six rats/ treatment over a period of three consecutive days. Rats were food deprived for 12 h before the administration of an oral glucose load of 2 g/kg body weight from a 200 g/L glucose solution. Blood samples (150 mL) were collected via tail vein at time 0 (before administration), 30, 60, 90, and 120 min and analyzed for plasma glucose. Animals were randomized before OGTT such that same number of animals per treatment was included in each day.

1 B. Mang, M. Wolters, B. Schmitt, K. Kelb, R. Lichtinghagen, D. O. Stichtenoth and A. B. Hahn, Eur. J. Clin. Invest., 2006, 36, 340–344. 2 C. L. Broadhurst, M. M. Polansky and R. A. Anderson, J. Agric. Food Chem., 2000, 48, 849–852. 3 R. A. Anderson, C. L. Broadhurst, M. M. Polansky, W. F. Schmidt, A. Khan, V. P. Flanagan, N. W. Schoene and D. J. Graves, J. Agric. Food Chem., 2004, 52, 65–70. 4 B. Halliwell, Annu. Rev. Nutr., 1996, 16, 33–50. 5 L. Y. Foo, Y. Lu, A. B. Howell and N. Vorsa, J. Nat. Prod., 2000, 63, 1225–1228. 6 A. B. Howell, Mol. Nutr. Food Res., 2007, 51, 732–737. 7 A. B. Howell, J. D. Reed, C. D. Krueger, R. Winterbottom, D. G. Cunningham and M. Leahy, Phytochemistry, 2005, 66, 2281– 2291. 8 L. Gu, M. A. Kelm, J. F. Hammerstone, G. Beecher, J. Holden, D. Haytowitz, S. Gebhardt and R. L. Prior, J. Nutr., 2004, 134, 613–617. 9 Gu, M. A. Kelm, J. F. Hammerstone, G. Beecher, J. Holden, D. Haytowitz and R. L. Prior, J. Agric. Food Chem., 2003, 51, 7513–7521. 10 J. A. Vinson, X. H. Su, L. Zubik and P. Bose, J. Agric. Food Chem., 2001, 49, 5315–5321. 11 X. Wu, G. Beecher, J. Holden, D. Haytowitz, S. E. Gebhardt and R. L. Prior, J. Agric. Food Chem., 2004, 52, 4026–4037. 12 T. Shoji, S. Masumoto, N. Moriichi, H. Akiyama, T. Kanda, Y. Ohtake and Y. Goda, J. Agric. Food Chem., 2006, 54, 884–892. 13 R. L. Prior, T. J. Rogers, S. E. Wilkes, R. C. Khanal, X. Wu and L. R. Howard, J. Agric. Food Chem., 2010, 58, 3940–3949. 14 G. M. Reaven, Diabetes, 1988, 37, 1595–1607. 15 G. T. Chew, S. K. Gan and G. F. Watts, Med. J. Australia, 2008, 185, 445–449. 16 S. Cowey and R. W. Hardy, Am. J. Physiol., 2006, 169, 1505–1522.

Insulin sensitivity indices The Homeostasis model assessment (HOMA) is a computergenerated model consisting of a number of non-linear empirical equations solved numerically to predict glucose and insulin concentrations in the fasting state for any combination of pancreatic b-cell function (HOMA-BCF) and insulin sensitivity (HOMA-IR). The relative-value of the homeostasis model was calculated as an index of insulin resistance (HOMA-IR)17 using the formula: HOMA-IR ¼ Fasting glucose (mmol/L) fasting insulin (mIU/mL)/22.5. Beta cell function was assessed by the beta cell homeostasis assessment (HOMA-BCF) score: HOMABCF ¼ [20 serum insulin (mU/L)]/[plasma glucose (mmol/L)3.5]. Insulin values were expressed in International Units (1 IU ¼ 0.04167 mg).29,38 Similarly, quantitative insulin-sensitivity check index (QUICKI) was calculated from log-transformed HOMA122 | Food Funct., 2010, 1, 116–123



View Online

17 E. S. Ford, C. Li and N. Sattar, Diabetes Care, 2008, 31, 1898–1904. 18 E. J. Schaefer, J. A. Gleason and M. L. Dansinger, J. Nutr., 2009, 139, 1257S–1262S. 19 M. F. Chong, B. A. Fielding and K. N Frayn, Amer, J. Clin. Nutr., 2007, 85, 1511–1520. 20 K. L. Teff, S. S. Elliott, M. Tsch€ op, T. J. Kieffer, D. Rader, M. Heiman, R. R. Townsend, N. L. Keim, D. D’Alessio and P. J. Havel, J. Clin. Endocrinol. Metab., 2004, 89, 2963–2972. 21 J. P. Bantle, J. Nutr., 2009, 139, 1263S–1268S. 22 J. P. Bantle, D. C. Laine, G. W. Castle, J. W. Thomas, B. J. Hoogwerf and F. C. Goetz, N. Engl. J. Med., 1983, 309, 7–12. 23 R. R. Henry, P. A. Crapo and A. W. Thorburn, Annu. Rev. Nutr., 1991, 11, 21–39. 24 D. J. Jenkins, T. M. Wolever, R. H. Taylor, H. Barker, H. Fielden, J. M. Baldwin, A. C. Bowling, H. C. Newman, A. L. Jenkins and D. V. Goff, Am. J. Clin. Nutr., 1981, 34, 362–366. 25 E. A. Enas, V. Mohan, M. Deepa, S. Farooq, S. Pazhoor and H. Chennikara, J. Cardiometab. Syndrome., 2007, 2, 267–275. 26 S. Delbosc, E. Paizanis, R. Magous, C. Araiz, T. Dimo, J. P. Cristol, G. Cros and J. Azay, Atherosclerosis, 2005, 179, 43–49. 27 M. J. Pagliassotti, P. A. Prach, T. A. Koppenhafer and D. A. Pan, Am. J. Physiol., 1996, 271, R1319–R1326.


28 A. H. Stark, B. Timar and Z. Madar, Eur. J. Nutr., 2000, 39, 229–234. 29 N. A. Al-Awwadi, C. Araiz, A. Bornet, S. Delbosc, J. P. Cristol, N. Linck, J. Azay, P. L. Teissedre and G. Cros, J. Agric. Food Chem., 2005, 53, 151–157. 30 M. Pinent, M. Blay, M. C. Blade, M. J. Salvad o, L. Arola and A. Ardevol, Endocrinology, 2004, 145, 4985–4990. 31 S. H. Kim, S. H. Hyun and S. Y. Choung, J. Ethnopharmacol., 2006, 104, 119–123. 32 R. A. Frazier, E. R. Deaville, R. J. Green, E. Stringano, I. Willoughby, J. Plant and I. Mueller-Harvey, J. Pharm. Biomed. Anal., 2010, 51, 490–495. 33 P. Sarni-Manchado, V. Cheynier and M. Moutounet, J. Agric. Food Chem., 1999, 47, 42–47. 34 Y. S. Tarahovsky, Plant Signal. Behav., 2008, 3, 609–611. 35 R. L. Prior, E. Fan, H. Ji, A. Howell, C. Nio, M. J. Payne and J. Reed, J. Sci. Food Agric., 2010, 90, 1473–1478. 36 R. C. Khanal, L. R. Howard, C. Brownmiller and R. L. Prior, J. Food Sci., 2009, 74, H52–H58. 37 X. Wu, L. Gu, R. L. Prior and S. McKay, J. Agric. Food Chem., 2004, 52, 7846–7856. 38 D. R. Matthews, J. P. Hosker, A. S. Rudenski and B. A. Naylor, Diabetologia, 1985, 28, 412–419.

Food Funct., 2010, 1, 116–123 | 123

View Online

PAPER


Dealcoholized red wine reverse vascular remodeling in an experimental model of metabolic syndrome: role of NAD(P)H oxidase and eNOS activity Marcela Alejandra Vazquez-Prieto,ab Nicol as Federico Renna,ab Carina Lembo,ab Emiliano Raul Diezab and Roberto Miguel Miatello*ab


Received 15th July 2010, Accepted 13th August 2010 DOI: 10.1039/c0fo00077a The present study examines the effect of chronic administration of dealcoholized red wine Malbec (DRW) on vascular remodeling and NAD(P)H oxidase and endothelial nitric oxide synthase activity (eNOS) in an experimental model of metabolic syndrome induced by fructose administration. Thirtyday old male Wistar rats were fed a normal rat diet (control) or the same diet plus 10% fructose in drinking water (FFR). During the last 4 weeks of a 10-week period of the corresponding diet, a subgroup of control and FFR (n ¼ 8 each) received DRW in their drinking water. Systolic blood pressure (SBP), a homeostasis model assessment of insulin resistance (HOMA-IR), aortic NAD(P)H oxidase and eNOS activity in the heart and vascular tissue were evaluated. Vascular remodeling was evaluated in the left carotid artery (CA) and interlobar, arcuate and interlobular renal arteries (RA) through lumen to media (L/M) ratio determination. At the end of the study FFR increased the SBP (p < 0.001), HOMA-IR (p < 0.001), and aortic NAD(P)H oxidase activity (p < 0,05) but reduced cardiac and vascular eNOS activity (p < 0.01), L/M ratio in CA (p < 0.001) and RA (p < 0.01) compared with the C group. DRW reduced SBP (p < 0.05), aortic NAD(P)H oxidase (p < 0.05), and recovered eNOS activity (p < 0.001) and L/M in CA (p < 0.001) and RA (p < 0.001) compared with FFR. This study provides new data about the beneficial effect of DRW on oxidative stress and vascular remodeling in the experimental model of metabolic syndrome. Data suggest the participation of mechanisms involving oxidative stress in FFR alterations and the usefulness of natural antioxidant substances present in red wine in the reversion of these changes.

Introduction Metabolic syndrome (MS), characterized by insulin resistance, dyslipidemia and hypertension, is an important risk factor for cardiovascular diseases.1 Rats chronically receiving fructose (FFR) provide a useful experimental model for the study of the interaction between factors clustered in MS.2 Endothelial dysfunction is associated with this experimental model.3 We previously reported a decrease of the endothelial isoform of nitric oxide synthase activity (eNOS) at cardiovascular level and an increase in vascular smooth muscle cell proliferation in primary culture, showing also evidence involving the renin angiotensin system (RAS) in the pathophysiology of these injuries.4,5 Furthermore, it has been demonstrated that angiotensin, acting on AT1 receptors, could induce oxidative stress, through activation of nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase, the most important source of intracellular reactive oxygen species (ROS) in vascular cells.6 ROS play a physiological role in the vessel wall and participate as second messengers in endothelium dependent function, in smooth muscle cell and endothelial cell growth and survival, and in remodeling of the vessel wall.7,8 The major vascular ROS is superoxide anion ($O2), which inactivates nitric oxide (NOc), a Institute of Experimental Medicine and Biology of Cuyo (IMBECU), National Council of Research (CONICET), Mendoza, Argentina b Department of Pathology, School of Medicine, National University of Cuyo, Av. Libertador 80, 5500 Mendoza, Argentina. E-mail: rmiatell@ fcm.uncu.edu.ar; Fax: +54 261 4135242; Tel: +54 261 41305000 ext 2697

124 | Food Funct., 2010, 1, 124–129

the main vascular relaxing factor.9 The relationship between oxidative stress and vascular remodeling had been previously reported in human and animal experimental studies,7 including fructose-fed rats.10,11 The study of the beneficial effect on human health of consumption of natural antioxidants, present in vegetables, fruits and beverages such as red wine, has recently increased in significance. Epidemiological studies suggest that moderate red wine consumption could decrease the risk of cardiovascular mortality,12 mainly attributable to the polyphenol content but also attributable to the alcohol content.13 Polyphenols could favor endothelium-dependent vasodilatation in aorta and human coronary arteries, inhibit vascular smooth muscle cell proliferation.14–16 We previously reported that resveratrol was able to increase the eNOS activity and reduce the systolic blood pressure (SBP) in this model of MS.17 In order to establish the beneficial effects of non-alcoholic constituents of red wine on vascular remodeling, the aim of this study was to determine the effect of chronic administration of dealcoholized red wine (DRW) in fructose-fed rats upon the possible participation of changes in ROS and NOc generation in the development of structural and functional alterations at cardiovascular and metabolic levels. Specifically, ROS production by the NAD(P)H oxidase system, and NOc generation by eNOS were examined in order to establish whether these systems are involved as pathogenic mechanisms in metabolic and structural cardiovascular changes associated with this experimental model. This journal is ª The Royal Society of Chemistry 2010

View Online


Results No differences were observed in food and drink intake between groups throughout the experimental period. Table 1 shows body weight, metabolic variables and SBP. The body weight did not vary among groups. At the end of the study fructose-fed rats developed insulin resistance, increased significantly the triglyceride levels and reduced the HDL cholesterol compared with control groups. Chronic administration of DRW significantly reduced the insulin resistance state and increased the HDL cholesterol. Systolic blood pressure was gradually increasing throughout the experimental period in FFR and reached a significant difference compared to controls. DRW administration to FFR during the last four weeks was able to reduce SBP in a slight but significantly way, without effect on control rats. The NAD(P)H oxidase activity in aortic tissue was higher in FFR, compared with the C group. Administration of DRW significantly reduced the NAD(P)H oxidase activity (Fig. 1). Fig. 2 shows eNOS activity levels, measured in a mesenteric vascular bed (panel A) and heart tissue from left ventricle homogenates (panel B). The eNOS activity was significantly diminished in the FFR group, compared to control rats. DRW chronic administration to FFR was able to return NOc production to control levels in both mesenteric vascular and heart tissue, while DRW to control rats increased significantly the eNOS activity in mesenteric vascular tissue. Arterial wall modifications were detected by structural analysis performed by histological methods, which allow us to observe changes in arteries from different localizations and calibers. Fig. 3 shows lumen : media (L/M) ratios and representative microphotographs observed in arteries from different localizations: left carotid (A), renal interlobar (B), renal arcuate (C), and renal interlobular (D) arteries in each group. The carotid lumen to media ratio in the FFR group was significantly

Table 1 Body weight, SBP, and metabolic parameters from C, C + DRW, FFR, and F + DRW rats. Groups

Body weight/g Plasma glycemia/ mmol L1 Plasma insulin (pmol/L) HOMA-IR Plasma triglycerides/ mmol L1 Plasma HDL/ mmol L1 Plasma total cholesterol/ mmol L1 SBP (mmHg)1 Baseline Week 6 Week 10

C

C + DRW

FFR

FFR + DRW

340 7 4.0 0.2b

324 9 4.0 0.2b

349 7 6.3 0.4a

325 7 5.6 0.2a

72 6c

75 8c

152 7a

118 6b

1.8 0.4c 1.9 0.5c 6.1 0.8a 4.2 0.6b 0.81 0.02b 0.72 0.07b 1.23 0.08a 1.08 0.08a 0.92 0.04a 0.95 0.04a 0.80 0.02b 0.92 0.01a 1.48 0.04 1.40 0.06 1.46 0.08 1.41 0.08

100 1 106 1b 115 1c

102 1 107 1b 116 1c

103 1 130 1a 136 1a

100 1 129 1a 125 1b

Values are expressed as mean SEM, n ¼ 8; means without a common letter differ, P < 0.05.


Fig. 1 NAD(P)H oxidase aorta activity from C, C + DRW, FFR, and F + DRW rats. Values are mean SEM (n ¼ 8). Bars without a common letter differ, P < 0.05.

Fig. 2 eNOS activity in mesenteric vascular bed homogenates (A) and heart tissue homogenates from the left ventricle (B), from C, C + DRW, FFR, and F + DRW rats. Values are mean SEM (n ¼ 4). Bars without a common letter differ, P < 0.05.

reduced, compared to control rats. Chronic administration of DRW to FFR increased the L/M ratio to control levels. A similar structural pattern was found in interlobar renal arteries (caliber between 120 to 180 mm), in smaller caliber arteries (50 a 120 mm) such as arcuate renal arteries and in very small arteries (10 a 50 mm) such as interlobular renal arteries.

Discussion In the present study we demonstrate that DRW was able to reverse vascular remodeling in fructose-fed rats, an experimental model of MS, associated with an increased eNOS activity and a reduced aortic NAD(P)H oxidase activity. These results suggest that non-alcoholic constituents of red wine reverse the structural and functional changes by mechanisms related to oxidative stress enhanced in this model. We have previously demonstrated the development of endothelial dysfunction in this experimental model, supported by a diminished NOc generation capability and changes in vascular smooth muscle cell proliferative behavior in primary culture.4 These changes could be attributed to a significant increase in ROS production, evaluated through an increased activity of NAD(P)H oxidase, the most quantitatively important source of Food Funct., 2010, 1, 124–129 | 125


View Online

Fig. 3 Lumen to media ratio observed in arteries from different localizations: left carotid (A), renal interlobar (B), renal arcuate (C), renal interlobular (D) arteries described by representative microphotographs and analyzed in the bar graph from C, C + DRW, FFR, and F + DRW rats. Values are mean SEM (n ¼ 8). Bars without a common letter differ, P < 0.05. Arrows indicate the location of the arteries.

superoxide at vascular level.10,11,18 ROS produced by vascular wall cells can directly inactivate other biologically active free radicals, thereby disturbing vascular homeostasis. One of the main targets of ROS, particularly superoxide anion is NOc, decreasing its bioavailability and favoring the formation of peroxynitrite, a potent vasoconstrictor.19 In this study, we found a decreased eNOS activity in both heart and mesenteric vascular tissue in FFR. DRW administered to FFR was able to restore the activity of this enzyme, suggesting that red wine polyphenols could be responsible for these beneficial effects. The effects of some polyphenols in these variables had been achieved. Quercetin increased the activity of eNOS and downregulates the activity and expression of NAD(P)H oxidase in an experimental model of hypertension.20 Others studies have shown that metabolites of flavonoids inhibit the activity of NAD(P)H oxidase.21,22 In this study, DRW administered to FFR induced a slight but significant decrease in systolic blood pressure, reduced the index of insulin resistance and increased HDL cholesterol. Furthermore, chronic administration of DRW was able to revert the vascular remodeling in FFR in both distribution and resistance arteries. The structural changes in FFR could be associated to vascular smooth muscle cell proliferative behavior previously observed in vitro in this model.4 Red wine administration could protect the NOc inactivation process by ROS and also increased the NOc generating system activity. The final result could be the inhibition of vascular remodeling associated with this experimental model. The beneficial effects of moderate red wine consumption have been demonstrated in several studies. Some mechanisms involved in those effects have pointed to the action of antioxidant properties of different polyphenols present in red wine.23 These substances could induce endothelium-dependent vasodilatation in human aorta and coronary arteries, inhibit vascular smooth muscle cell proliferation and protect ischemic 126 | Food Funct., 2010, 1, 124–129

myocardium.15,16,24,25 In vivo, flavonoids such as quercetin prevent endothelial dysfunction and reduce blood pressure, oxidative stress and end-organ damage in hypertensive animals.26 Quercetin and theaflavin significantly attenuated the atherosclerotic lesion size in aorta arteries in ApoE deficient mice by alleviating inflammation, improving NOc bioavailability, and inducing heme oxygenase-1.27 The prevention of angiotensin II-induced hypertension and endothelial dysfunction by red wine polyphenol extract administration, with a normalization of vascular superoxide anion production and NAD(P)H oxidase expression, has also been described.28 It is important to note that the administration of DRW to the control rats had no positive effects on almost of all variables studied, suggesting that under normal conditions DRW adds no further benefit. Our results are in agreement with epidemiological and experimental evidence demonstrating the beneficial effects of moderated red wine consumption on cardiovascular pathology and contribute to support the hypothesis that the non-alcoholic fraction of wine, represented mainly by phenolic compounds with antioxidant properties, may be the primary factor responsible for this protective effect. Further studies are needed to clarify the molecular mechanism of DRW on vascular alterations.

Experimental Animals and experimental design All procedures were performed according to institutional guidelines for animal experimentation and were approved by the Technical and Science Secretary from the School of Medicine of National University of Cuyo, Mendoza, Argentina. Thirty-dayold male Wistar rats, weighting 90–130 g were housed during the experimental period of 10 weeks in a room under conditions of controlled temperature (21 2 C), humidity and a 12 h This journal is ª The Royal Society of Chemistry 2010


View Online

light/dark cycle. At the beginning of the study, 32 rats were randomly distributed into two groups: one control group (C) (n ¼ 16) and one experimental group (FFR) (n ¼ 16). After six weeks of treatment, the half of C and experimental groups were assigned to receive 10 mL/Kg daily of DRW for four more weeks. The names of each group were assigned as follows: Control (C); C + DRW; FFR: 10% (w/v) fructose solution administration in the drinking water during all the experimental protocol; and F + DRW. All groups were fed the same standard rat diet (GepsaFeeds, Buenos Aires, Argentina) and tap water ad libitum. Administration of 10% fructose (Saporiti Labs., Buenos Aires, Argentina) solution in drinking water was used to achieve the pathological model. The red wine (Malbec grape variety) was provided by the School of Agricultural Sciences, National University of Cuyo. The phenolic characterization of RW Malbec was evaluated by high performance liquid chromatography as previously described.29 One litre of red wine contained 2.9 g of total phenols expressed as gallic acid. The main phenolic content was (expressed as mg L1): non-flavonoids: 18.2 gallic acid; 2 caffeic acid; 4.2 cis-caftaric acid, trans-resveratrol: 1.1, flavonoids: 24.1 catechin; 14.2 epicatechin; procyanidin (11.3 B1; 3.1 B3), flavonols: 4.9 quercetin, and anthocyanins (344 malvidin-3-glucoside; 16.2 peonidin-3-glucoside; 60.3 delphinidin-3-glucoside). Red wine was dealcoholized by rotary evaporation at low pressure and temperature, and then the volume of alcohol evaporated was reconstituted with water, in order to conserve phenolic composition. DRW (10 mL/Kg) was administered in drinking water. The weight of each animal was measured weekly and the energy intake was recorded twice per week during the experimental period in all groups. At the end of the experimental period, and after an overnight fast, the rats were weighed, anesthetized with ketamine (50 mg kg1) and acepromazine (1 mg kg1). Blood was collected from the abdominal aorta into heparinized tubes. Plasma obtained after centrifugation was frozen at 70 C until assayed. Arteries and organs were excised aseptically for the measurement of various parameters described below.

mesenteric resistance arteries and left ventricular cardiac tissue by the conversion of L-[3H]arginine to L-[3H]citrulline, as previously described.4 Mesenteric vessels were homogenized on ice for four 15 s intervals with a Politron homogenizer and then sonicated in a buffer (pH 7.4, 37 C) containing 50 mmol L1 Tris, 20 mmol l1 HEPES, 250 mmol L1 sucrose, 1 mmol L1 dithiothreitol, 10 mg mL1 leupeptin, 10 mg mL1 soybean trypsin inhibitor, 5 mg mL1 aprotinin and 0.1 mmol L1 phenyl methyl sulfonyl fluoride. Heart tissue from left ventricle myocardium was also homogenized on ice for four 15 s intervals with a polytron homogenizer and then sonicated in the same buffer. After centrifugation of the homogenates (100 g, 5 min, 4 C) and determination of the protein content (Bradford method), aliquots of 50 mL were added to 100 mL of a cocktail reaction buffer containing 50 mmol L1 Tris, 20 mmol L1 HEPES, 1 mmol L1 dithiothreitol, 1 mmol L1 NADPH, 0.1 mmol L1 tetrahydrobiopterin, 50 mmol L1 FAD, 50 mmol L1 FMN, and 10 mCi/ml L-[2,3-3H]-arginine (New England Nuclear, Boston MA), and incubated for 30 min at 37 C in a shaking bath in the presence of 10 mg ml1 calmodulin and 3 mmol l1 CaCl2 or with 3 mmol L1 EGTA in the absence of Ca2+/calmodulin. The reaction was stopped by adding 1 mL cold distilled water and the mixture applied to an anion-exchange chromatography column containing Dowex AG 50W-X8 (200–400 Mesh) resin previously saturated with 50 mL of 100 mmol L1 L-citrullin and 2 mL of 50 mmol L1 Tris, 20 mmol L1 HEPES buffer (pH 7.4) and eluted with 2 mL of distilled water. Specifically eluted L-[3H]citrulline concentration was determined by liquid scintillation counting. The calcium-dependent NOS activity was calculated as the difference between activity in the presence and absence of Ca2+/calmodulin. Values were corrected to the amount of protein present in the homogenates and the incubation time (dpm/mg protein/min). Each rat mesenteric vascular bed and heart tissue was processed and eNOS activity measured independently.

Plasma glucose, triglycerides, HDL-cholesterol and total cholesterol concentrations were determined using commercial kits by enzymatic colorimetric methods (Wiener Lab, Rosario, Argentina). Insulin was measured by RIA (Coat-A-Count, Siemens, CA, USA), and insulin resistance was assessed using the homeostasis model assessment (HOMA-IR) described by Mathew et al.30 HOMA-IR was calculated using the following formula: HOMA-IR (mmol L1 mU/mL) ¼ fasting glucose (mmol L1) fasting insulin (mU/mL)/22.5.

Measurement of vascular NAD(P)H oxidase activity. The lucigenin-derived chemiluminescence assay was used to determine NAD(P)H oxidase activity in the aorta as previously described.18 A 2 cm length segment of thoracic aorta was cut, cleaned, washed, transferred to a tube with 2 mL of Jude’s Krebs buffer (JKB) containing (in mmol L1) 2 HEPES, 11.9 NaCl, 0.46 KCl, 0.1 MgSO4$7H2O, 0.015 Na2HPO4, 0.04 KH2PO4, 0.5 NaHCO3, 1.2 CaCl2, 5.5 glucose; pH 7.40; and equilibrated at 37 C during 30 min. Then the aortic segment was transferred to a tube containing 1 mL JKB and 5 mmol L1 lucigenin and left in darkness at room temperature for 10 min. This concentration of lucigenin does not appear to be involved in redox cycling and specifically detects superoxide anion. To assess NAD(P)H oxidase activity, 500 mmol L1 bNAD(P)H was added and chemiluminescence was immediately measured in a liquid scintillation counter (LKB Wallac Model 1219 Rack-Beta Scintillation Counter, Finland) set in the out-of coincidence mode. Time-adjusted and normalized to tissue weight scintillation counts were used for calculations. Measurements were repeated in the absence and presence of diphenylene iodinium (DPI) (106 mol L1), which inhibits flavincontaining enzymes, including NAD(P)H oxidase.

Measurements of eNOS activity. Ca2+/calmodulin-dependent nitric oxide synthase activity was measured in homogenates from

Tissue preservation. Tissue samples for histopathology were processed as previously reported.10 Samples from all rats were

Systolic blood pressure (SBP). Systolic blood pressure was monitored indirectly in conscious, pre-warmed (32 C) slightly restrained rats by the tail-cuff method and recorded on a Grass Model 7 polygraph (Grass Instruments Co., Quincy, MA, USA). Biochemical determinations


Food Funct., 2010, 1, 124–129 | 127

View Online


used in these observations. The kidneys were in vivo perfused with PBS (pH 7.40, 4 C) through the renal artery over 5 min. For histological studies, left kidneys were then perfused with 4% paraformaldehyde solution for 10 min, then additionally fixed by immersion in the same solution for 48 h, introduced to a 30% sucrose solution and kept at 70 C. Five mm thick tissue slices were transversely cut through the entire kidney on a cryostat (Microm HM 505E, Germany) at 26 C and processed for histological studies. Common left carotid arteries were fixed and processed as described above for kidneys. Histopathology and morphometry. Lumen to media ratio in kidney arteries transversal slices from common left carotid artery and left kidney were placed on microscope slides and stained with Masson’s trichrome solution and examined under a light microscope (Nikon Optiphot-2, Kanagawa, Japan). Images were digitalized with a digital camera (GP-KR222 color CCD, Panasonic, Osaka, Japan) and processed with an analysis system Scion Image 4.01 (Scion, Bethesda, MD, USA). To evaluate the renal arterial wall thickening, images from three different artery types were studied in each kidney: interlobar, arcuate and interlobular arteries. The lumen-to-wall media ratio (the internal diameter to the medial thickness) was then calculated. Forty slices from each kidney were processed and 5 to 10 arteries of each type in each slice were analyzed, in order to obtain an average value for each rat. The average values were then used for final analysis. Common left carotid arteries were sectioned transversely. L/M was then calculated in 10 slices from each artery, in order to obtain an average value for each rat and then used for final analysis. Reagents Unless otherwise noted, reagents were purchased from Sigma Chemical Co, MO USA. All other chemicals were of molecular biology or reagent grade. Statistical and data analysis Results were expressed as mean and their deviation errors. The statistical significance was assessed by one-way ANOVA followed by Student-Newman-Keuls post-test using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, California USA. Differences were considered significant at p < 0.05. In the figures and tables, data shown without a common letter differ at a p < 0.05 significance level.

Conclusions The non-alcoholic constituents of red wine increased the eNOS activity, reduced the activity of the enzyme NAD(P)H oxidase and reversed vascular remodeling. The antioxidant properties of polyphenols could be responsible for the beneficial effects of DRW.

Acknowledgements We thank Susana Gonzalez and Cristina Lama for their technical assistance. This work was supported by grants from Program 06/ P01 SECTyP Universidad Nacional de Cuyo, and PIP-5192 CONICET. 128 | Food Funct., 2010, 1, 124–129

References 1 J. E. Tooke and M. M. Hannemann, Adverse endothelial function and the insulin resistance syndrome, J. Intern. Med., 2000, 247, 425–31. 2 I. S. Hwang, H. Ho, B. B. Hoffman and G. M. Reaven, Fructoseinduced insulin resistance and hypertension in rats, Hypertension., 1987, 10, 512–516. 3 X. Wang, Y. Hattori, H. Satoh, C. Iwata, N. Banba, T. Monden, K. Uchida, Y. Kamikawa and K. Kasai, Tetrahydrobiopterin prevents endothelial dysfunction and restores adiponectin levels in rats, Eur. J. Pharmacol., 2007, 555, 48–53. 4 R. M. Miatello, N. R. Risler, C. M. Castro, E. S. Gonzalez, M. E. R€ uttler and M. C. Cruzado, Aortic smooth muscle cell proliferation and endothelial nitric oxide synthase activity in fructose-fed rats, Am. J. Hypertens., 2001, 14, 1135–1141. 5 R. M. Miatello, N. R. Risler, C. M. Castro, M. E. R€ uttler and M. C. Cruzado, Effects of Enalapril on the Vascular Wall in an Experimental Model of Syndrome X, Am. J. Hypertens., 2002, 15, 872–878. 6 R. M. Touyz and E. L. Schiffrin, Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells, Pharmacol. Rev., 2000, 52, 639–672. 7 A. Fortu~ no, G. San Jose, M. U. Moreno, J. Dıez and G. Zalba, Oxidative stress and vascular remodelling, Exp. Physiol., 2005, 90, 457–62. 8 X. Chen, R. Touyz, J. B. Park and E. Schiffrin, Antioxidant effects of Vitamin C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR, Hypertension, 2001, 38, 606–611. 9 G. Kojda and D. Harrison, Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure, Cardiovasc. Res., 1999, 43, 562–571. 10 N. F. Renna, M. A. Vazquez, M. C. Lama, S. Gonzalez and R. Miatello, Effect of chronic aspirin administration on an experimental model of metabolic syndrome, Clin. Exp. Pharmacol. Physiol., 2009, 36, 162–168. 11 M. A. Vazquez-Prieto, R. E. Gonzalez, N. F. Renna, C. R. Galmarini and R. M. Miatello, Aqueous Garlic Extracts Prevents Oxidative Stress and Vascular Remodeling in an Experimental Model of Metabolic Syndrome, J. Agric. Food Chem., 2010, 58, 6630–6635. 12 S. Renaud and M. de Lorgeril, Wine, alcohol, platelets and the French paradox for coronary artery disease, Lancet, 1992, 339, 1523–6. 13 J. Belleville, The French Paradox: Possible involvement of ethanol in the protective effect against cardiovascular diseases, Nutrition, 2002, 18, 173–177. 14 J. C. Stoclet, T. Chataigneau, M. Ndiaye, M. H. Oak, J. El Bedoui, M. Chataigneau and V. B. Schini-Kerth, Vascular protection by dietary polyphenols, Eur. J. Pharmacol., 2004, 500, 299–313. 15 F. Leighton, A. Cuevas and V. Guasch, Plasma polyphenols and antioxidants oxidative DNA damage and endothelial function in a diet and wine intervention study in humans, Drugs. Exp. Clin. Res., 1999, 25, 133–141. 16 K. Iijima, M. Yoshizumi, M. Hashimoto, S. Kim, M. Eto, J. Ako, Y. Q. Liang, N. Sudoh, K. Hosoda, K. Nakahara, K. Toba and Y. Ouchi, Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gene, Circulation, 2000, 101, 805–811. 17 R. M. Miatello, M. A. Vazquez, N. F. Renna, M. C. Cruzado, A. Z. Ponce Zumino and N. R. Risler, Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructosefed rats, Am. J. Hypertens., 2005, 18, 864–870. 18 M. Cruzado, N. Risler, R. Miatello, G. Yao, E. Schiffrin and R. Touyz, Vascular smooth muscle cell NAD(P)H oxidase activity during the development of hypertension: effect of angiotensin II and role of insulin-like growth factor-1 receptor transactivation, Am. J. Hypertens., 2005, 18, 81–7. 19 J. S. Beckman and W. H. Koppenol, Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly, Am. J. Physiol., 1996, 271, 1424–1437. 20 M. Sanchez, M. Galisteo, R. Vera, I. C. Villar, A. Zarzuelo, J. Tamargo, F. Perez-Vizcaino and J. Duarte, Quercetin downregulates NAPDH oxidase, increases eNOS activity and prevents endotelial dysfunction in spontaneously hypertensive rats, J. Hypertens., 2006, 24, 75–84.



View Online

21 Y. Steffen, C. Gruber, T. Schewe and H. Sies, Mono-O-methylated flavonols and other flavonoids as inhibitors of endothelial NADPH oxidase, Arch. Biochem. Biophys., 2008, 469, 209–219. 22 Y. Steffen, T. Schewe and H. Sies, (-)-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase, Biochem. Biophys. Res. Commun., 2007, 359, 828–833. 23 C. G. Fraga, Plant polyphenols: how to translate their in vitro antioxidant actions to in vivo conditions, IUBMB Life, 2007, 59, 308–315. 24 S. M. Mosca and H. E. Cingolani, Cardioprotection from ischemia/ reperfusion induced by red wine extract is mediated by K(ATP) channels, J. Cardiovasc. Pharmacol., 2002, 40, 429–437. 25 J. C. Fantinelli, G. Schinella, H. E. Cingolani and S. M. Mosca, Effects of different fractions of a red wine non-alcoholic extract on ischemia-reperfusion injury, Life Sci., 2005, 76, 2721–2733. 26 F. Perez-Vizcaino, J. Duarte and R. Andriantsitohaina, Endothelial function and cardiovascular disease: effects of quercetin and wine polyphenols, Free Radical Res., 2006, 40, 1054–1065.


27 W. M. Loke, J. M. Proudfoot, J. M. Hodgson, A. J. McKinley, N. Hime, M. Magat, R. Stocker and K. D. Croft, Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction, Arterioscler., Thromb., Vasc. Biol., 2010, 30, 749–757. 28 M. Sarr, M. Chataigneau, S. Martins, C. Schott, J. El Bedoui, M. H. Oak, B. Muller, T. Chataigneau and V. B. Schini-Kerth, Red wine polyphenols prevent angiotensin II induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase, Cardiovasc. Res., 2006, 71, 794–802. 29 M. Fanzone, A. Pe~ na-Neira, V. Jofre, M. Assof and F. Zamora, Phenolic characterization of malbec wines from mendoza province (Argentina), J. Agric. Food Chem., 2010, 58, 2388–2397. 30 D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher and R. C. Turner, Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, 1985, 28, 412–419.

Food Funct., 2010, 1, 124–129 | 129

Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10.1039/C0FO90004D

Top Quality Analytical Science Journals Analyst - interdisciplinary detection science giving an analytical perspective on the leading topics in the chemical, biological and physical sciences. www.rsc.org/analyst

JAAS - Journal of Analytical Atomic Spectrometry, the leading journal for fundamentals in elemental analysis and isotope ratio determinations within all fields of application. www.rsc.org/jaas

Analytical Abstracts - the database for analytical science information with over 400,000 records from 1980 to the present. www.rsc.org/aa

New Journal Analytical Methods - highlighting new and improved methods for the practical application of analytical science. www.rsc.org/methods

Take a look today! www.rsc.org/journals Registered Charity Number 207890

011044

View Online

View Online

w al Ne rn u Jo

Food & Function Linking the chemistry and physics of food with health and nutrition

Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10.1039/C0FO90005B

www.rsc.org/foodfunction

Volume 1 | Number 1 | 2010 | Pages 1–100

ISSN 2042-6496

Food & Function Linking the chemistry and physics of food with health and nutrition Food science and nutrition is a highly multidisciplinary area. We know it can be difficult to keep abreast of each other’s work, especially when there is not enough time in the day and the pile of work keeps growing. Wouldn’t it be great if there was a journal which pulled together high impact chemical and physical research linking to human health and nutrition? Just one platform to find what you need in the field, and reach exactly the right audience when you publish your work. Food & Function provides a dedicated venue for physicists, chemists, biochemists, nutritionists and other health scientists focusing on work related to the interaction of food components with the human body.

Go to the website now to submit your research and register for free access!

www.rsc.org/foodfunction Registered Charity Number 207890

View Online

superior science

powerful impact

responsive leading publisher

Downloaded on 21 October 2010 Published on 06 October 2010 on http://pubs.rsc.org | doi:10.1039/C0FO90005B

less clicking

leading technology

dynamic integrated

simple

accurate

filter

journals

discover

chemical sciences

fast

publishing innovation

connections

semantic

intuitive

browse

ebooks

interactive articles

intelligent

global community

The new RSC Publishing platform allows you to spend more time on your research and less time trying to find it. • One simple search to access all RSC journals, books and databases • Find the right content fast through filtered searching • Discover related research through article linking • Share & recommend research using your favourite bookmarking tools • Store searches and receive search results as alerts with your personal account

search faster

navigate smarter

connect more

www.rsc.org/publishing Registered Charity Number 207890

Food & Function. Vol 01, No 01, October 2010

Food & Function. Vol 01, No 03, December 2010

Food & Function, Vol 01, No 02, November 2010

Food & Function, Vol 02, No 02, February 2011

01! 01! 01!

The South Pole Vol 01&2

Opera Philosophica Vol. 01

Grantville Gazette Vol 01

Selected Writings Vol 01

Opera Philosophica Vol. 01

Erotiek Omnibus Vol. 01

Opera Theologica Vol. 01

Erotiek Omnibus Vol. 01

Kevin's Stories vol 01

Legendwar Vol 01

Виль Липатов. 01! 01! 01!

Science Magazine 2010-01-29

Авиация и космонавтика 2010 01

Witch & Wizard 01

Авиация и время 2010 01

Witch & Wizard #01

Авиация и время 2010 01

Scandals & Seductions 01

Техника и вооружение 2010 01

Science Magazine 2010-01-08

Harvard Theological Review 2010-01

01

01

Breathe Deep Fear vol 01

The Early Asimov Vol 01

A Family Saga, Vol 01

Food & Function. Vol 01, No 01, October 2010

Food & Function. Vol 01, No 03, December 2010

Food & Function, Vol 01, No 02, November 2010

Food & Function, Vol 02, No 02, February 2011

01! 01! 01!

The South Pole Vol 01&2

Opera Philosophica Vol. 01

Grantville Gazette Vol 01

Selected Writings Vol 01

Opera Philosophica Vol. 01

Erotiek Omnibus Vol. 01

Opera Theologica Vol. 01

Erotiek Omnibus Vol. 01

Kevin's Stories vol 01

Legendwar Vol 01

Виль Липатов. 01! 01! 01!

Science Magazine 2010-01-29

Авиация и космонавтика 2010 01

Witch & Wizard 01

Авиация и время 2010 01

Witch & Wizard #01

Авиация и время 2010 01

Scandals & Seductions 01

Техника и вооружение 2010 01

Science Magazine 2010-01-08

Harvard Theological Review 2010-01

01

01

Breathe Deep Fear vol 01

The Early Asimov Vol 01

A Family Saga, Vol 01

Recommend Documents